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Chapter 1 10 
GENERAL  INTRODUCT ION  
OESOPHAGEAL CANCER AND GASTRIC CANCER  
In the Netherlands, the incidence of oesophageal cancer increased during the 
past decades, while the incidence of gastric cancer has been stable.1  
In 2018, the incidence of oesophageal cancer was approximately 2.500 and the 
incidence of gastric cancer was 1.300.  
The percentage of oesophageal cancer patients with potentially curable disease 
at diagnosis is around 60%.2 However, the percentage of patients that 
underwent a curative treatment increased in the past years. Between 2005-
2009, 57% of patients underwent curative treatment versus 68% of patients in 
the period 2011-2013.2  
The percentage of gastric cancer patients with potentially curable disease 
according to tumour stage at diagnosis was around 50%.3 In contrast to 
oesophageal cancer, the percentage of patients that underwent a curative 
treatment has decreased. Between 2005-2009, 73% of patients underwent 
curative treatment versus 65% of patients in the period 2010-2013.3  
Despite significant improvements in both diagnosis and (multimodality) 
treatment, prognosis of patients with oesophagogastric cancer remains dismal 
with 5-year survival rates of 24% and 23%.1  
 
MULTIMODALITY TREATMENT OF OESOPHAGEAL CANCER  
Multimodality treatment has become the standard of care for locally advanced 
oesophageal and junctional cancer. The CROSS (Chemo Radiotherapy for 
Oesophageal cancer followed by Surgery Study) trial showed improved disease-
free and overall survival for patients treated with the combination of 
neoadjuvant chemoradiotherapy and surgery versus surgery alone.4 The median 
overall survival was 24.0 months in patients that underwent surgery only and 
49.4 months for patients treated with neoadjuvant chemoradiotherapy and 
surgery. Nowadays, almost 90% of patients receive neoadjuvant 
chemoradiotherapy followed by oesophagectomy in the Netherlands.5  
In the past years, also non-surgical treatments have been introduced as an 
alternative to surgery. Endoscopic resection was introduced for early-stage 
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tumours and definitive chemoradiotherapy for locally advanced cancer 
(especially squamous cell cancers) are widely applied now.6-8 
The most recent development in the treatment of oesophageal cancer is the 
potential application of active surveillance after neoadjuvant 
chemoradiotherapy. In the phase-III-multi-centre SANO (Surgery As Needed 
approach in Oesophageal cancer patients) trial, the (cost-) effectiveness of active 
surveillance versus standard oesophagectomy after neoadjuvant 
chemoradiotherapy is assessed.9 When active surveillance with surgery as 
needed leads to non-inferior overall survival compared to standard 
oesophagectomy, this organ-sparing approach may be implemented as a novel 
treatment strategy. 
 
MULTIMODALITY TREATMENT OF GASTRIC CANCER  
Perioperative chemotherapy is nowadays recommended for patients with non-
metastasized resectable gastric cancer (excluding stage I). A significant survival 
benefit of perioperative treatment compared to surgery alone was shown in 
both the MAGIC trial and the French FNCLCC/FFCD trial.10, 11 In the perioperative 
chemotherapy group, the 5-year survival rate was 36%, versus 23% in the 
surgery only group. Also, a decrease in tumour size, tumour stage, and curative 
resection rate were seen in the perioperative chemotherapy group. Since the 
publication of these trials, the administration of perioperative treatment in the 
Netherlands increased over time. In 2006, 3% of patients received perioperative 
chemotherapy and in 2014 this percentage increased to 26% of patients.12 The 
most recent study for perioperative chemotherapy was the FLOT trial.13 This trial 
showed that in locally advanced, resectable gastric or gastro-oesophageal 
junction adenocarcinoma, perioperative FLOT improved overall survival 
compared with perioperative ECF/ECX (median survival 50 months versus 35 
months).  
 
SURGICAL MANAGEMENT  
Although the treatment of oesophagogastric cancer requires a multimodality 
approach, surgical resection remains the cornerstone of curative treatment for 
the majority of patients. The main goals of surgery are a pathologically complete 
1
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tumour resection with an adequate lymphadenectomy and reliable 
reconstruction of the gastrointestinal tract.   
 
ORGANISATION OF OESOPHAGOGASTRIC CANCER CARE IN THE 
NETHERLANDS 
Oesophagectomy and gastrectomy are complex procedures associated with 
considerable postoperative morbidity and mortality.14 To minimize morbidity 
and mortality, several multimodal aspects are essential. Careful patient selection 
is a requisite which demands accurate staging and risk assessment. 
Postoperatively, early recognition and timely management of potentially serious 
complications are needed.15 Exemplary, skilled surgeons, an experienced 
multidisciplinary team, excellent hospital facilities, appropriate consultative and 
critical care staff, experienced nursing staff, and structured perioperative clinical 
pathways are needed. 
To increase the experience and expertise of surgical teams, minimum volume 
standards for oesophagectomy and gastrectomy were introduced by the 
Association of Surgeons in the Netherlands.14 From 2011 onwards, a minimum 
of 20 resections per hospital is required. For other medical disciplines involved 
with oesophageal and gastric cancer, no minimum volume standards have been 
set.16 In 2016, oesophagogastric surgery was performed in 25 hospitals, this 
number decreased to 20 in 2018.17 
 
DUTCH UPPER GASTROINTESTINAL CANCER AUDIT 
Nationwide clinical audits are used to evaluate the quality of care between 
hospitals. The Dutch Institute for Clinical Auditing (DICA) was founded to 
facilitate and organise the initiation of nationwide audits in a uniform format.18 
In 2011, the Dutch Upper gastrointestinal Cancer Group initiated the Dutch 
Upper gastrointestinal Cancer Audit (DUCA).14 All hospitals need to enter data 
on all patients undergoing surgery with the intention of resection for 
oesophageal or gastric cancer. Outcomes are collected and analysed by DICA and 
on a weekly basis case-mix corrected and benchmarked outcome data are 
reported to the participating hospitals.  
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HISTORY OF CLINICAL AUDITING AND THE CLINICAL AUDIT CYCLE 
One of the first clinical audits was undertaken by Florence Nightingale during the 
Crimean War of 1853-1855. Nightingale was appalled by the high mortality rates 
among injured or ill soldiers. By applying sanitary routines and standards of 
hygiene to the hospital, the mortality rates fell from 40% to 2%.19 Her methodical 
approach is recognised as one of the earliest programmes of outcomes 
management.20 Another famous advocate of clinical audits was the surgeon 
Ernest Amory Codman (1869-1940). He was recognised as the first medical 
auditor following his work on monitoring outcomes of surgery.21 
 
For control and continuous improvement of processes, the clinical audit cycle 
has been described (Figure 1).22 This cycle is related to change management 
methodology and uses the technique of the Plan-Do-Check-Act method.23 
Within this clinical audit cycle there are stages that follow a systematic process: 
identify an audit topic, set a standard, collect and analyse data, and if needed: 
act to improve outcomes. Repeating the cycle can be necessary to sustain 
continuous improvement. By going through this audit cycle, each cycle aspires 
to a higher level of quality. 
 
QUALITY INDICATORS IN THE DUCA 
In the DUCA, the scientific committee determined several audit topics and 
quality indicators are set. These quality indicators contain results regarding the 
process of care, pathological outcomes, and postoperative outcomes until 30 
days after surgery. The results on these quality indicators are used not only by 
health care professionals themselves but also by policy makers, health care 
insurance companies and patient federations.  
Therefore, the main focus of this thesis was to determine the reliability, validity 
and value of these currently used quality indicators.  
 
1
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Figure 1. The clinical audit cycle 
 
THESIS  OUTLINE   
PART I. NATIONAL OUTCOMES ON POSTOPERATIVE MORBIDITY QUALITY 
INDICATORS 
It is known that postoperative complications can affect patient’s quality of life, 
are associated with higher costs, and may affect long term outcomes.24, 25 
Therefore, postoperative morbidity is one of the main topics in the DUCA.  
To compare the prevalence of complications between hospitals or countries, it 
is essential that everyone uses the same definitions. To facilitate these 
comparisons, an international standardized outcomes set was implemented in 
the DUCA. The Dutch results on these outcomes are reported in Chapter 2.26 In 
most audits and clinical trials, complications are graded using the Clavien Dindo 
classification. Often, the most severe complication is only recorded. The total 
number of complications is not taken into account whilst in oesophagogastric 
cancer surgery, it is common that patients suffer from more than one 
complication. The Comprehensive Complication Index (CCI) was recently 
launched as a novel measure to evaluate the total burden of complications for 
 
Chapter 1 15 
patients. In Chapter 3, the added value of this CCI measure in a national audit is 
assessed.27  
 
In the new era where active surveillance for oesophageal cancer may gain 
popularity, postponed surgery is expected to take place more often. While some 
patients do not need surgery at all due to a complete clinical response to 
neoadjuvant chemoradiation, delayed surgery (>12 weeks after 
chemoradiation) may be associated with more complications e.g. due to 
radiation-induced mediastinal fibrosis. The association between delayed surgery 
and postoperative complications in oesophageal cancer is evaluated in Chapter 
4.28 Also, additional organ resections are suggested to be associated with higher 
morbidity. For advanced gastric cancer, segmental pancreatic or colonic 
resections or splenectomy may be indicated to achieve a complete tumour 
resection. In Chapter 5, the postoperative outcomes of gastrectomy including 
partial resection of the pancreas are analyzed.29  
When using data for comparison, it is essential that the data are robust and 
reliable. DICA uses a standardized data verification process; this process is 
described in Chapter 6.30 
 
PART II. QUALITY INDICATORS AS A PROXY FOR LONG-TERM OUTCOMES  
In addition to quality indicators for postoperative morbidity, quality indicators 
on short-term outcomes potentially associated with long-term outcomes are 
included in the DUCA. In Chapter 7, the association of ‘complete tumour 
resection’, ‘textbook outcome’, and ‘a complicated postoperative course’ with 
long-term survival is evaluated.31 Other examples of short-term indicators that 
may be associated with long-term outcomes are the number of lymph nodes and 
the percentage of patients with a complete tumour resection.  
 
LYMPH NODES 
An extensive lymph node dissection is an integral part of surgery for 
oesophagogastric cancer. It is felt that a lymph node dissection improves 
locoregional tumour control. Also, a lymphadenectomy leads to more accurate 
staging. In Chapter 8, differences in surgical approach and lymph node dissection 
1
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for the transhiatal and transthoracic technique of oesophagectomy are 
discussed. Since 2013, the number of retrieved lymph nodes is used as a quality 
indicator in the DUCA. In Chapter 9, data on the number of retrieved lymph 
nodes in the first years after the introduction of this quality indicator and the 
association with hospital volume are evaluated.32 In Chapter 10, the association 
of the quality indicator ‘retrieval of at least 15 lymph nodes’ with overall survival 
and accuracy of pathological staging is assessed.33, 34  
 
COMPLETE TUMOUR RESECTION 
The percentage of patients with a complete tumour resection is another quality 
indicator because an incomplete tumour resection is associated with worse 
survival. For gastric cancer, the percentage of patients with an incomplete 
tumour resection is relatively high (8-11%).5 In Chapter 11, risk factors associated 
with an incomplete tumour resection are identified.35 Another aim of this study 
is to evaluate whether low hospital volume is associated with incomplete 
tumour resection.  
 
In Chapter 12, a national improvement project using data of the DUCA is 
described. 
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ABSTRACT  
OBJECTIVE  
This nation-wide population-based study aimed to report postoperative morbidity and 
mortality after oesophagectomy and gastrectomy in the Netherlands according to the 
definitions of the Esophagectomy Complications Consensus Group (ECCG).  
BACKGROUND 
To standardize international outcome reporting in oesophageal surgery, the ECCG developed 
a standardized outcomes set.  
METHODS 
For this national cohort study, all patients undergoing oesophagectomy or gastrectomy for 
cancer between 2016-2017 were selected from the Dutch Upper gastrointestinal Cancer Audit 
(DUCA). In a random sample of hospitals, data completeness and accuracy were validated by 
re-abstraction of the data. The investigated outcomes in the present study were 
postoperative complications, major complications (Clavien-Dindo grade ³III), and 30-day 
mortality, according to definitions of the ECCG.  
RESULTS 
A total of 2545 patients from 22 hospitals were included. The completeness of the DUCA was 
estimated at 99.8%. Data accuracy on different items was 94-100%. After oesophagectomy, 
1046 of 1617 patients (65%) had a postoperative complication including 468 patients (29%) 
with a major complication. Most common complications were pneumonia (21%), oesophago-
enteric leak from anastomosis, staple line or localized conduit necrosis (19%), and atrial 
dysrhythmia (15%). The 30-day mortality was 1.7%. After gastrectomy, 397 of 928 patients 
(42%) had a postoperative complication including 180 patients (19%) with a major 
complication. Most common complications were pneumonia (12%), oesophago-enteric leak 
from anastomosis, staple line or localized conduit necrosis (9%), and acute delirium (5%). The 
30-day mortality was 4.4%. 
CONCLUSIONS 
Reporting complications according to the ECCG platform is feasible in the Netherlands and 
facilitates international benchmarking.  
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INTRODUCTION 
For resectable non-metastatic oesophageal and gastric cancer, resection is as 
yet the cornerstone of treatment. Both oesophagectomy and gastrectomy are 
associated with high postoperative morbidity rates. To evaluate quality of care, 
in several European countries clinical audits are used.1-3 Feedback of audit data 
to the specialist may improve outcomes by stimulating best practices and the 
initiation of improvement programs for health care pathways. For a reliable 
comparison of outcomes between hospitals on a national level and to compare 
patterns of care and outcomes between countries, it is important to use uniform 
definitions. 
To standardize outcome reporting in oesophageal surgery, the Esophagectomy 
Complications Consensus Group (ECCG) developed a standardized outcomes-
set.4 In 2017, in 24 hospitals in different countries the outcomes after 
oesophagectomy were collected according to the definitions of the ECCG.5 
 
In January 2016, the definitions of the ECCG were introduced in the Dutch Upper 
gastrointestinal Cancer Audit (DUCA).1 The outcomes including postoperative 
complications, re-admission and 30-day mortality were registered according to 
the definitions of the ECCG platform for both oesophagectomy and gastrectomy. 
At that time, an international standardized outcomes-set for gastrectomy was 
lacking. Hence, the ECCG outcomes-set was applied for patients that underwent 
oesophagectomy and gastrectomy also because the type and severity of 
complications that occur after both procedures is somewhat comparable. 
 
The primary aim of this study was to report postoperative morbidity and 
mortality after oesophagectomy and gastrectomy in the Netherlands according 
to the ECCG definitions and to report the completeness and accuracy of the 
DUCA data. Secondly, the outcomes after oesophagectomy in the DUCA were 
compared with the reported outcomes of the initial ECCG dataset.5 
 
2
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METHODS  
STUDY DESIGN 
For this national cohort study, patient data were retrieved from the DUCA 
database. Dutch hospitals are mandated to register all oesophageal (including 
gastro-oesophageal junction) or gastric cancer patients undergoing surgery with 
the intent of a resection.  
DATA VERIFICATION 
Before evaluation of the DUCA data, it is important to test whether the 
outcomes are valid. The reliability of data of the data was verified in 2016. 
Participation of hospitals in this data verification process was voluntary. 
Outcomes of this data verification were the completeness and accuracy of 
registered data. A random sample of 15 participating hospitals was visited by an 
external data verification employee and a random sample of operated patients 
with oesophageal or gastric cancer was checked for inclusion in the DUCA 
database. Per hospital, 30 patients operated in 2016 were selected.  If less than 
30 patients were operated, all available patients were selected. Re-abstraction 
of data from the electronic patient dossier took place for all selected patients. 
The original data was compared to data registered in the DUCA.6 In the present 
study, the accuracy with regard to registration of postoperative complications, 
30-day mortality, reinterventions, readmissions, number of lymph nodes, 
resections margin and ASA score (the physical status classification according to 
the American Society of Anesthesiologists) was tested. The accuracy was 
estimated by the number of discrepancies found against the total number of 
patients in the sample.  
PATIENTS 
All patients undergoing an oesophagectomy of gastrectomy in the Netherlands 
between January 2016 and December 2017 for oesophageal or gastric cancer 
were included in this study. Patients with a palliative bypass procedure were 
excluded. Also, patients with missing data regarding complications or other 
essential elements of the registration including date of birth, survival status at 
30 days after surgery or date of discharge (in case of a hospital stay of >30 days) 
were excluded.  
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OUTCOMES 
The primary outcome was frequency of postoperative complications. The 
severity of the complications was defined according to Clavien-Dindo.7 
Complications grade IIIa or higher were defined as major complications. The 
secondary outcomes were hospital stay, duration of stay at the Intensive Care 
Unit (ICU), the frequency of reinterventions, 30-day and/or in-hospital mortality, 
readmissions, the number of retrieved lymph nodes, surgical resection margins 
and the ASA score. For all patients who underwent an oesophagectomy, the 
outcomes were compared to the outcomes of the ECCG as recently reported.5  
STATISTICAL METHODS 
Patient and tumour characteristics of all included patients were reported 
according to the type of resection (oesophagectomy or gastrectomy) using 
frequencies and percentages. Also, all postoperative outcomes were described 
using frequencies and percentages. The outcomes after oesophagectomy in the 
DUCA were compared with the reported outcomes of the ECCG dataset5 using 
χ2 analyses. Statistical analyses of the present study were performed using 
Microsoft Excelâ for Mac (version 15.41). Statistical significance was defined as 
P<0.05. 
 
RESULTS  
DATA VERIFICATION 
The completeness of the DUCA was estimated at 99.8% (Table 1). In a sample of 
408 patients, one patient who should have been registered according to the 
inclusion criteria of the DUCA was not registered. Complications were accurately 
registered in 382 of 407 patients (94%). In 25 patients (6%) no complication was 
registered in the DUCA, whereas in the electronical patient file a complication 
was reported. Thirty-day and/or in-hospital mortality was accurately registered 
in 406 of 407 patients (98.8%).  In 13 of 407 patients (3%), a complicated 
postoperative course (defined as a complication leading to prolonged hospital 
stay (>21 days), reintervention or death) was not registered in the DUCA 
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database but was extracted from the electronic patient files. All verified 
variables are shown in Table 1.  
 
Table 1. Results of external data verification 
Completeness of data           
Sample size: 408 Registered 
Wrongly not 
registered   Completeness    
  n n   %   
Included in DUCA 407 1   99.8%   
            
Accuracy of data           
Sample size: 407 
Correctly 
registered 
Wrongly 
registered Missing Accuracy  
  n n n %   
Complications 382 25 0 94%   
30-day/in-hospital mortality 406 1 0 99.8%   
Reinterventions 394 13 0 97%   
Complications leading to prolonged 
hospital stay (>21 days), 
reintervention or death 394 13 0 97%  
Readmission 390 12 5 97%   
Number of lymph nodes 394 13 0 97%   
Resection margins 394 11 2 97%   
ASA score 379 28 0 93%   
 
PATIENTS 
From January 2016 to December 2017, a total of 1617 patients undergoing an 
oesophagectomy and 928 patients undergoing a gastrectomy were registered in 
the DUCA. Eight patients were excluded due to missing data. Patient, disease 
and treatment characteristics are summarized in Table 2 and Table 3. Minimally 
invasive techniques were used in 86% of patients undergoing an 
oesophagectomy and in 58% of patients undergoing a gastrectomy. Fifty-two 
percent of oesophagectomies was performed via a transthoracic approach. In 
43% percent of all gastrectomies, a total gastrectomy was performed.   
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Table 2. Patient-, and disease characteristics. 
    
ECCG   
Oesophagectomy5 
DUCA  
Oesophagect
omy 
DUCA  
Gastrectomy 
    n  % n % n % 
Total    2704   1617   928   
Sex Male 2096 78% 1228 76% 561 61% 
  Female 607 22% 388 24% 367 40% 
  Unknown   1 0% 0 0% 
Age (in years) 40 or less 66 2% 6 0% 25 3% 
  41-50 217 8% 76 5% 53 6% 
  51-60 721 27% 316 20% 129 14% 
  61-70 1100 41% 739 46% 227 25% 
  71-80 532 20% 451 28% 355 38% 
  more than 80 67 3% 29 2% 139 15% 
Body Mass Index <18.5 184 7% 47 3% 34 4% 
  18.5-25 1085 40% 657 41% 420 45% 
  25-30 908 34% 642 40% 329 36% 
  30+ 526 20% 265 16% 136 15% 
  Unknown     6 0% 9 1% 
ASA score I 412 15% 255 16% 113 12% 
  II 1249 46% 1012 63% 526 57% 
  III 992 37% 340 21% 273 29% 
  IV 49 2% 7 0% 15 2% 
  V 1 0% 0 0% 0 0% 
  Unknown     3 0% 1 0% 
Charlson Comorbidity 
score 0     754 47% 411 44% 
  1     385 24% 191 21% 
  2+     478 30% 326 35% 
Comorbidities Myocardial infarction 146 5% 86 5% 66 7% 
  Congestive heart failure 124 5% 12 1% 19 2% 
  
Chronic Pulmonary 
Disease 285 11% 326 20% 155 17% 
  
Peripheral Vascular 
Disease 185 7% 73 5% 53 6% 
  
Diabetes Mellitus 
(uncomplicated) 348 13% 221 14% 160 17% 
  
Diabetes Mellitus (end-
organ damage) 16 1% 13 6% 5 3% 
  
Moderate to Severe 
Renal Disease 35 1% 21 1% 29 3% 
Pathology (indication 
for surgery) Benign 97 4%         
  Malignant 2585 96%         
  
Other, including 
perforations 21 1%         
Location (ECCG) At the GE junction 762 28%         
  
Proximal 1/2 of 
oesophagus 304 11%         
  Distal 1/2 of oesophagus 1519 56%         
Location (DUCA) Cervical (C15.0)     1 0% 0 0% 
  Proximal (C15.3)     14 1% 0 0% 
  Mid (C15.4)     226 14% 0 0% 
  Distal (C15.5)     1087 67% 3 0% 
  Gastro-oesophageal junction(C16.0) 261 16% 32 3% 
  Fundus (C16.1)     18 1% 69 7% 
  Corpus (C16.2)     1 0% 281 30% 
  Antrum (C16.3)     0 0% 365 39% 
  Pylorus (C16.4)     0 0% 80 9% 
  Total stomach     0 0% 44 5% 
  Rest stomach / anastomosis   0 0% 34 4% 
  Unknown (stomach)     6 0% 1 0% 
  Missing     3 0% 19 2% 
  Unknown     2 0% 2 0% 
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Table 3. Pathological- and treatment characteristics, according to type or resection: 
oesophagectomy (for ECCG5 and DUCA) and gastrectomy are shown. 
    
ECCG  
Oesophagectomy5 
DUCA  
Oesophagectomy 
DUCA  
Gastrectomy 
    n  % n % n % 
Total    2704   1617   928   
Pathological Tumour 
stage  pT0-2  1242 65% 966 60% 341 37% 
  pT3 1075 42% 592 37% 327 35% 
  pT4 78 3% 21 1% 236 25% 
  Missing  0 0%  38 2% 24 3% 
Pathological Node 
stage pN-  1477 57%  957 59% 421 45% 
  pN+  1101 42%  622 39% 485 52% 
  pNx  7 0%  4 0% 7 1% 
  Missing     34 2% 15 2% 
Pathological 
Metastases stage pM- 
2170 84% 
1528 95% 796 86% 
  pM+ 46 2% 23 1% 61 7% 
  Not applicable  0  0% 48 3% 54 6% 
  pMx 369 14% 18 1% 17 2% 
Timing of surgery Elective 2680 99% 1610 100% 895 96% 
  Urgent     3 0% 25 3% 
  Emergency 23 1% 3 0% 8 1% 
  Unknown     1 0% 0 0% 
Neoadjuvant therapy No 545 21% 105 7% 379 42% 
  Chemotherapy 763 30% 86 5% 502 55% 
  Chemoradiotherapy 1192 46% 1417 88% 28 3% 
  Radiotherapy 5 0% 6 0% 0 0% 
  Unknown     0 0% 1 0% 
  
Definitive 
chemoradiotherapy 80 3%         
Surgical approach Open 1407 52% 229 14% 394 43% 
  MI 1296 48% 1388 86% 534 58% 
Esophagectomy (open) Transhiatal 283 20% 109 48%     
  Transthoracic 1124 80% 120 52%     
Esophagectomy (MI) Abdomen only 521 40% 222 16%     
  Chest only 144 11% 60 4%     
  Abdomen and chest 631 49% 1106 80%     
Gastrectomy (open 
and MI) Total           402 43% 
  Partial         526 57% 
Site of anastomosis Chest   1641 61% 876 54% 65 7% 
  Neck 1025 38% 696 43% 2 0% 
  Abdomen     7 0% 807 87% 
  Other/none 37 1% 38 2% 54 6% 
Conduit/reconstruction Stomach 2564 95%  1567 99% 4 0% 
  Colon 34 1% 4 0% 1 0% 
  Small bowel 72 3% 0 0% 2 0% 
  
Oesophagojejunostomy  
(Roux-Y) 5 0% 394 44% 
  
Gastroenterostomy  
(BII or Roux-Y) 0 0% 483 54% 
  Other/none 33 1% 9 1% 12 1% 
Resection margins R0 Microscopic radical 2414 93% 1532 95% 820 89% 
  
R1 Microscopic 
irradical 157 6% 65 4% 83 9% 
  
R2 Locoregional 
residual tumour 14 1% 1 0% 4 0% 
  Not applicable     8 1% 8 1% 
  Unknown     2 0% 2 0% 
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OUTCOMES AFTER OESOPHAGECTOMY 
Sixty-five percent of patients who underwent an oesophagectomy had a 
postoperative complication (Table 4). Clavien Dindo grade III or higher 
complications occurred in 29% of all patients (Table 5). Most common 
complications were pneumonia (21%), leak from the anastomosis, staple line or 
localized conduit necrosis (19%), and atrial dysrhythmia (15%). All complications 
are presented in Supplementary Table 1. The median stay at the intensive care 
unit was 2 days (interquartile range: 1-4), and median hospital stay was 11 days 
(interquartile range: 9-18). The 30-day mortality rate was 1.7% and the 30-
day/in-hospital mortality rate was 2.4%.  
In comparison with the reported outcomes of the ECCG5, the overall 
complication rate was significantly higher in the DUCA (65% versus 59%, 
p<0.001). Also, pneumonia and leak from anastomosis, staple line or localized 
conduit necrosis, occurred more often (respectively, 21% versus 15%, p<0.001 
and 19% versus 11%, p<0.001) (Figure 1). Hospital readmission within 30 days 
after discharge occurred in 15% of patients, significantly more often compared 
to the ECCG cohort (11%, p<0.001). The 30-day mortality rate was 1.7% versus 
2.4% in the ECCG cohort (p=0.10).  
 
 
Figure 1. Comparison of outcomes after oesophagectomies, DUCA versus ECCG. 
 
 
0% 10% 20% 30% 40% 50% 60% 70%
All complications
Esophago-enteric leak from anastomosis, 
staple line or localized conduit necrosis
Pneumonia 
Dysrhytmia atrial requiring treatment
Readmission
30-day mortality
* significant, p<0.05ECCG DUCA
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Table 4. Outcomes of the DUCA according to type of resection 
Complications DUCA 
Oesophagectomy  
DUCA 
Gastrectomy 
Total (n=) 1617   928 
 
  Median  [IQR] Median  [IQR] 
Hospital stay (days) 11 [9-18] 8 [6-13] 
ICU stay (days) 2 [1-4] 0 [0-1] 
  n % n % 
Intra-operative complication 89 5.5% 34 3.7% 
Postoperative complication 1046 65% 397 43% 
Reintervention 420 26% 186 20% 
Radiological 170  51  
Endoscopic 187  54  
Re-operation 208  121  
In-hospital/30-day mortality 38 2.4% 49 5.3% 
30-day mortality 27 1.7% 41 4.4% 
Readmission 233 15% 123 14% 
Postoperative complication Clavien Dindo 
grade III or more 468 29% 180 19% 
ICU: intensive Care Unit 
 
OUTCOMES AFTER GASTRECTOMY 
Forty-three percent of patients who underwent a gastrectomy experienced a 
postoperative complication (Table 4). Clavien Dindo grade III or higher 
complications occurred in 19% of patients (Table 5). Most common 
complications were pneumonia (12%), oesophago-enteric leak from 
anastomosis, staple line or localized conduit necrosis (9%), and acute delirium 
(5%). All complications are presented in Supplementary Table 1. The severity of 
four outcome measures according to the ECCG4 are presented in Supplementary 
table 2.  The median stay at the intensive care unit stay was 0 days (interquartile 
range: 0-1), and median hospital stay was 8 days (interquartile range: 6-13). 
Hospital readmission within 30 days after discharge occurred in 14% of patients. 
The 30-day mortality rate was 4.4%, and the 30-day/in-hospital mortality was 
5.3%.  
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Table 5. Severity of complications in the DUCA according to type of resection 
Complication Severity Esophagectomy Gastrectomy 
  n % 95% CI  n %      95% CI  
No complications 605 37% 35% 40% 562 61% 57% 64% 
Grade I 150 9% 8% 11% 39 4% 3% 6% 
Grade II 379 23% 21% 26% 130 14% 12% 16% 
Grade IIIa 192 12% 10% 14% 51 6% 4% 7% 
Grade IIIb 128 8% 7% 9% 66 7% 6% 9% 
Grade IVa 110 7% 6% 8% 23 3% 2% 4% 
Grade IVb 11 1% 0% 1% 5 1% 0% 1% 
Grade V 27 2% 1% 2% 35 4% 3% 5% 
Grade unknown 15 1% 1% 2% 17 2% 1% 3% 
 
DISCUSS ION 
This study with DUCA data shows that reporting complications according to the 
ECCG definitions can be achieved on a national level. Data verification showed 
that the completeness and accuracy of data in the DUCA were high. Overall, 
complications after oesophagectomy and gastrectomy occurred in 65% and 43% 
of patients, respectively. Major complications (Clavien Dindo grade III or higher) 
occurred in 29% and 19% of patients, respectively. The most common 
complications after oesophagectomy were pneumonia, oesophago-enteric leak, 
and dysrhythmia atrial. After gastrectomy, pneumonia, oesophago-enteric leak, 
and acute delirium were the most common complications.  
 
Recently, the outcomes of 24 high volume hospitals participating in the ECCG 
were published5. Compared to these data, overall complication rates, 
pneumonia rates, and oesophago-enteric leakage rates were significantly higher 
in the DUCA. Different explanations may exist for these discrepancies.  
First, differences in patient and treatment characteristics exist between the 
ECCG cohort and DUCA cohort which might have influenced the occurrence of 
complications. From previous studies with DUCA data, it is known that higher 
age, ASA score, body mass index, N+ status, proximal-mid oesophageal tumour-
location, and open transthoracic procedures are associated with an increased 
risk for postoperative complications.8,9 Some of these factors were more 
frequently present in the DUCA, e.g., 30% of patients were older than 70 years 
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old (versus 23% in the ECCG cohort). However, in the ECCG cohort, patients with 
ASA III or higher were more frequently present then in the DUCA (39% versus 
21%).  
The second difference was the percentage of patients that was treated with 
neoadjuvant chemoradiotherapy. In the DUCA, 88% of patients was treated with 
neoadjuvant chemoradiotherapy, versus 46% in the ECCG cohort. In the 
literature, some studies regarding neoadjuvant chemoradiotherapy have 
reported no significant differences in complication rates between neoadjuvant 
chemoradiotherapy and neoadjuvant chemotherapy alone or no neoadjuvant 
therapy.10-12 However, Klevebro et al. reported a higher frequency of severe 
complications after neoadjuvant chemoradiotherapy in comparison with 
neoadjuvant chemotherapy alone.12 It has been suggested that radiotherapy 
affects the lung tissue and may increase pulmonary complications.13 The 
difference in type and frequency of neoadjuvant therapy could be an 
explanation of the higher pneumonia rate in the DUCA versus the ECCG cohort. 
A study with combined datasets and correction for differences in case-mix could 
potentially answer this issue.  
Another difference between both cohorts was the type of oesophagectomy. In 
the DUCA 86% of patients underwent a minimally invasive oesophagectomy 
versus 48% in the ECCG. The TIME trial, a randomized trial evaluating minimally 
invasive versus open transthoracic oesophagectomy, showed that in-hospital 
pulmonary infections occurred significantly less frequent after minimally 
invasive oesophagectomy (12% versus 34%).14 A previous Dutch study showed 
that during the implementation of minimally invasive oesophagectomies in the 
Netherlands there was no differences in pulmonary complications and 30-
day/in-hospital mortality between minimally invasive versus open gastrectomy. 
However, the same study showed higher anastomotic leakage rates and 
reintervention rates after minimally invasive gastrectomy.15 The introduction of 
minimally invasive surgery and the associated learning curve that goes with it16, 
might have influenced the complication rate. Nonetheless, in 2015, 84% of the 
registered oesophagectomies in the DUCA was performed with minimally 
invasive techniques and, since the current study only reports data of 2016 and 
2017, it could be that most surgeons might already have completed their 
learning curve in this period. However, it is important to keep in mind that that 
learning curve until proficiency might be much longer that initially was 
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expected.16 Future studies are needed to evaluate the ‘real’ length of the 
learning curve.  
Also, the approach of oesophagectomy differed between the DUCA and ECCG 
cohorts. The transhiatal approach was more favourite in the DUCA cohort than 
in the ECCG cohort: 48% versus 20%, respectively. As reported in a meta-analysis 
of Hulscher et al., the transhiatal approach and cervical anastomosis is 
associated with a higher frequency of anastomotic leakage and vocal cord 
paralysis.17 In the transthoracic group in this meta-analysis, there was more 
perioperative blood loss, pulmonary complications, chyle leak, and wound 
infections. Thus, the difference in favoured approaches between the DUCA and 
ECCG might explain the higher anastomotic leakage rate in the DUCA database. 
Nonetheless, the higher pneumonia rate in the DUCA could not be explained by 
the differences in surgical approach.  
The annual hospital volume of the participating hospitals in the ECCG has been 
described as all ‘high volume’. In the DUCA, in 2016, the annual hospital volume 
varied each year. In 2016, 9 of 22 hospitals performed 40 or more resections and 
5 hospitals performed less than 20 resections.18 Differences in annual hospital 
volume may influence outcomes. However, further studies are needed to 
evaluate whether these differences can explain the variation in outcomes 
between the cohorts.  
 
Due to the use of a standardized outcomes set, the DUCA outcomes after 
oesophagectomies could be compared with the ECCG outcomes fairly. For 
outcomes after gastrectomies, at the time of the implementation of the ECCG 
outcomes, there was no standardized international consensus set and the ECCG 
outcomes were also incorporated for patients after gastrectomy. To our 
knowledge, the ECCG outcomes set has not been used for reporting outcomes 
after gastrectomy in other cohorts. Recently, a specific standardized outcomes 
set for gastric cancer surgery was published with the intent to facilitate 
international comparison.19 The intent is to implement this standardized set of 
definitions in the DUCA because it potentially facilitates international 
comparison.  
An international comparison of Dutch results after oesophagectomy and 
gastrectomy has been done previously. The results of the DUCA were compared 
to the results of the Swedish NREV (Nationellt Kvalitetsregister matstrups- och 
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magsäckscancer).20 However, the results of the registries at that time were not 
standardized, which makes comparison not really reliable.  
 
The 30-day mortality in the DUCA database was 1.7% after oesophagectomy and 
4.4% after gastrectomy. In comparison with the outcomes of the ECCG cohort, 
the mortality after oesophagectomies was not significantly different. The 30-day 
mortality after gastrectomy and oesophagectomy was also reported in the 
annual report of the British ‘National Oesophago Gastric Cancer Audit (NOGCA)’. 
Between 2007-2009 and between 2013-2015, the 30-day mortality after 
oesophagectomies was 3.8% (95% confidence interval: 3.1%-4.7%) and 1.6% 
(95% confidence interval: 1.2%-2.1%), respectively. After gastrectomy it was 
4.5% (95% confidence interval: 3.4%-5.7%) and 1.9% (95% confidence interval 
1.3%-2.7%), respectively. In the annual report of the NOGCA, no clarification was 
given for this improvement in 30-day mortality after oesophagectomy and 
gastrectomy. It would be interesting to evaluate the underlying processes; in 
order to direct a strategy to also improve 30-day mortality after gastrectomy in 
the Netherlands.  
 
In conclusion, evaluation of quality of care is important, especially for high 
complex, low-volume procedures such as oesophagectomy and gastrectomy. 
Reporting outcomes using standardized definitions is an essential step towards 
reliable results. Furthermore, it enables international comparisons that could 
help to reveal significant differences in outcomes and to identify factors which 
could be improved. A more widespread adoption of the ECCG platform could be 
recommended to improve international benchmarking in oesophageal surgery. 
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Supplementary table 1. Complications according to type of resection of the DUCA and 
comparison with the ECCG5 
Complications 
ECCG  
oesophagectomy 
DUCA 
oesophagectomy  
DUCA 
gastrectomy 
 n % n % n % 
Total  2704   1617   928   
All complications  1595 59% 1046 65% 397 43% 
Pulmonary 752 28% 529 33% 154 17% 
Pneumonia* 396 15% 341 21% 111 12% 
Pleura effusion requiring additional                                    
drainage procedure 267 10% 124 8% 28 3% 
Pneumothorax requiring treatment 91 3% 68 4% 7 1% 
Atelectasis mucous plugging requiring  
bronchoscopy 85 3% 18 1% 5 1% 
Respiratory failure requiring reintubation 189 7% 84 5% 23 3% 
Acute aspiration 50 2% 25 2% 15 2% 
Acute respiratory distress syndrome ** 27 1% 24 2% 3 0% 
Tracheobronchial injury 11 0% 11 1% 1 0% 
Chest tube maintenance for air leak for  
>10 days postoperatively 13 1% 11 1% 1 0% 
Cardiac 455 17% 276 17% 46 5% 
Myocardial infarction*** 28 1% 5 0% 5 1% 
Dysrhythmia atrial requiring treatment 393 15% 224 14% 25 3% 
Dysrhythmia ventricular requiring  
treatment 15 1% 23 1% 8 1% 
Congestion heart failure requiring  
treatment 25 1% 17 1% 9 1% 
Pericarditis requiring treatment 12 0% 3 0% 1 0% 
Cardiac arrest requiring CPR 2 0% 9 1% 4 0% 
Gastrointestinal 606 22% 392 24% 171 18% 
Oesophagoenteric leak from  
anastomosis, staple line or localized  
conduit necrosis 307 11% 307 19% 85 9% 
Conduit necrosis/failure 34 1% 13 1% 1 0% 
Ileus defined as small bowel dysfunction  
preventing or delaying enteral feeding 46 2% 12 1% 42 5% 
Small bowel obstruction 12 0% 4 0% 10 1% 
Feeding J-tube complication 27 1% 55 3% 12 1% 
Pyloromyotomy/pyloroplasty  
complication 5 0% 6 0% 0 0% 
Clostridium difficile Infection 23 1% 2 0% 2 0% 
Gastrointestinal bleeding requiring  
intervention or transfusion 21 1% 1 0% 24 3% 
Delayed conduit emptying requiring  
intervention or delaying discharge or  
requiring maintenance of NG drainage  
>7days postoperatively 180 7% 27 2% 7 1% 
Pancreatitis 8 0% 3 0% 6 1% 
Liver dysfunction 6 0% 5 0% 2 0% 
Urologic 224 8% 66 4% 46 5% 
Acute renal insufficiency (defined as  
doubling of baseline creatinine) 39 1% 11 1% 10 1% 
Acute renal failure requiring dialysis 24 1% 5 0% 3 0% 
Urinary tract infection 68 3% 20 1% 16 2% 
Urinary retention requiring reinsertion of  
urinary catheter, delaying discharge, or  
discharge with urinary catheter 104 4% 32 2% 16 2% 
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Supplementary table 1. (continued) 
      
 
Complications 
ECCG 
oesophagectomy 
DUCA 
oesophagectomy 
DUCA 
gastrectomy 
 n % n % n % 
Thromboembolic 141 5% 45 3% 18 2% 
Deep venous thrombosis 25 1% 4 0% 6 1% 
Pulmonary embolus 33 1% 35 2% 10 1% 
Stroke (CVA) 4 0% 1 0% 1 0% 
Peripheral thrombophlebitis 79 3% 4 0% 1 0% 
Neurologic/psychiatric 254 9% 172 11% 53 6% 
Recurrent nerve injury 114 4% 70 4% 0 0% 
Other neurologic injury 33 2% 10 1% 8 1% 
Acute delirium **** 105 4% 97 6% 46 5% 
Delirium tremens 16 1% 2 0% 1 0% 
Infection 383 14% 120 7% 87 9% 
Wound infection requiring opening  
wound or antibiotics 20 1% 37 2% 20 2% 
Central IV-line infection requiring  
removal or antibiotics 55 2% 10 1% 5 1% 
Intrathoracic/intra-abdominal abscess 65 2% 37 2% 34 4% 
Generalized sepsis ***** 52 2% 17 1% 20 2% 
Other infections requiring antibiotics 227 8% 20 1% 21 2% 
Wound/diaphragm 78 3% 30 2% 21 2% 
Wound dehiscence 40 2% 16 1% 8 1% 
Fasciedehiscence/Platzbauch/hernia  
(acute) 33 1% 7 0% 12 1% 
Hernia diafragmatica (acute) 8 0% 7 0% 0 0% 
Chyle leak 128 5% 139 9% 15 2% 
Other     138 9% 70 8% 
Reoperation for reasons other than  
bleeding, anastomotic leak or conduit  
necrosis 39 1% 17 1% 7 1% 
Multiple organ dysfunction  
syndrome****** 27 1% 2 0% 5 1% 
Postoperative bleeding requiring  
transfusion or reoperation     7 0% 7 1% 
Complications of epidural catheter     4 0% 3 0% 
* Definition Thoracic Society and Infectious Diseases Society of 
America       
** Berlin definition             
*** Definition World Health Organization             
**** Definition Diagnostic and Statistical Manual of Mental 
Disorders, 5th       
***** Definition CDC             
****** Definition American college of chest physicians/society of critical care medicine consensus 
conference committee 
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Supplementary Table 2. Severity of complications in the DUCA in comparison with the 
ECCG5 
    
ECCG 
oesophagectomy 
DUCA 
oesophagectomy 
    n % n % 
Anastomotic leak No Leak 2403 88.9% 1310 81.0% 
 Type I 90 3.3% 92 5.7% 
 Type II 131 4.8% 131 8.1% 
 Type III 80 3.0% 83 5.1% 
 Unknown   1 0.1% 
Conduit necrosis/failure No conduit necrosis 2672 98.8% 1604 99.2% 
 Type I 2 0.1% 1 0.1% 
 Type II 7 0.3% 3 0.2% 
 Type III 23 0.9% 9 0.6% 
Recurrent laryngeal nerve 
injury involvement 
No recurrent laryngeal 
nerve injury 2595 96.0% 1547 95.7% 
 Type Ia 81 3.0% 55 3.4% 
 Type Ib 6 0.2% 6 0.4% 
 Type Iia 12 0.4% 4 0.2% 
 Type Iib 4 0.1% 1 0.1% 
 Type IIIa 2 0.1% 0 0.0% 
 Type IIIb 4 0.1% 1 0.1% 
 Unknown   3 0.2% 
Chyle leak  No Chyle leak 2578 95.3% 1478 91.4% 
 Type Ia 67 2.5% 68 4.2% 
 Type Ib 10 0.4% 3 0.2% 
 Type Iia 11 0.4% 14 0.9% 
 Type Iib 6 0.2% 8 0.5% 
 Type IIIa 12 0.4% 2 0.1% 
  Type IIIb 20 0.7% 19 1.2% 
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ABSTRACT  
OBJECTIVE 
Assessment of postoperative morbidity is crucial to monitor the quality of surgery and 
perioperative care. The Comprehensive Complication Index (CCI) is a novel composite 
measure for the total burden of postoperative morbidity. This study aimed to calculate the 
CCI for hospitals participating in a nationwide audit and to compare the CCI with existing 
quality indicators.  
DESIGN, SETTING, PARTICIPANTS 
For this nationwide observational study, data was retrieved from the Dutch Upper 
Gastrointestinal Cancer Audit (DUCA). Patients with oesophagogastric cancer who underwent 
an oesophagectomy or gastrectomy between 2016 and 2018 were included.  
MAIN OUTCOMES 
The main outcome was the median CCI per hospital and the percentage of patients per 
hospital (1) within the 75th percentile of CCI, (2) with a complicated postoperative course 
(defined as any complication in combination with a hospital stay >21 days, reintervention or 
in-hospital/30-day mortality, and (3) with a Clavien Dindo Classification grade >II 
complication, all adjusted for differences in case-mix.  
RESULTS 
In total, 2396 patients who underwent oesophagectomy and 1373 patients who underwent 
gastrectomy were included. In the oesophagectomy group, the median CCI was 20.9 
(interquartile range: 0.0-33.5) with at least one postoperative complication occurring in 1578 
of 2396 patients (66%). In the gastrectomy group, the median CCI was 0.0 (interquartile range: 
0.0-20.9) and at least one postoperative complication occurring in 573 of 1373 patients (42%). 
On hospital level, the percentage of patients within the 75th percentile of CCI was strongly 
correlated with a complicated postoperative course for both oesophagectomies and 
gastrectomies but was not correlated with a Clavien Dindo Classification grade >II 
complication. 
CONCLUSION AND RELEVANCE 
The CCI can be applied in a national clinical audit to report outcomes. Hospital outcomes on 
the CCI are strongly correlated with a complicated postoperative course.  
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ABSTRACT  
INTRODUCTION 
The optimal time between end of neoadjuvant chemoradiotherapy (nCRT) and 
oesophagectomy is unknown. The aim of this study was to assess the association between 
this interval and pathologic complete response rate (pCR), morbidity, and 30-day/in-hospital 
mortality.  
METHODS 
Patients with oesophageal cancer treated with nCRT and surgery between 2011 and 2016 
were selected from a national database. The interval between end of nCRT and surgery was 
divided into six periods: 0-5 weeks(n=157;A), 6-7 weeks(n=878;B), 8-9 weeks(n=972;C), 10-12 
weeks(n=720;D), 13-14 weeks(n=195;E) and 15 or more weeks(n=180;F). The association 
between these interval groups and outcomes was investigated using univariable and 
multivariable analysis with group C (8-9 weeks) as reference. 
RESULTS 
In total 3102 patients were included. The pCR rate for the groups A to F was 31%, 28%, 26%, 
31%, 40%, and 37%, respectively. A longer interval was associated with a higher probability of 
pCR (≥10 weeks for adenocarcinoma: odds ratio[confidence interval]: 1.35[1.00-1.83], 
1.95[1.24-3.07], 1.64[0.99-2.71] and ≥13 weeks for squamous cell carcinoma: 2.86[1.23-6.65], 
2.67[1.29-5.55]. Patients operated ≥10 weeks after nCRT had the same probability for 
intraoperative/postoperative complications. Patients from groups D and F had a higher 30-
day/in-hospital mortality (1.80[1.08-3.00], 3.19[1.66-6.14]).  
CONCLUSION 
An interval of ≥10 weeks for adenocarcinoma and ≥13 weeks for squamous cell carcinoma 
between nCRT and oesophagectomy was associated with a higher probability of having a pCR. 
Longer intervals were not associated with intraoperative/postoperative complications. The 
30-day/in-hospital mortality was higher in patients with extended intervals (10-12 and ≥15 
weeks), however this might have been due to residual confounding.  
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INTRODUCTION 
Oesophageal cancer is the eighth most common cancer in the world and the 
incidence is increasing.1 Randomized clinical trials have shown that neoadjuvant 
chemoradiotherapy (nCRT) or chemotherapy improves survival after 
oesophagectomy. Multimodality treatment for resectable oesophageal cancer 
has now become standard in the Netherlands.2 NCRT induces tumour regression 
and a pathological complete response (pCR) is observed in 25-30% of patients.3 
A pCR is associated with an improved survival compared to patients who have 
an incomplete pathological response.3,4  
A longer interval between nCRT and surgery has been suggested to increase the 
probability of a pCR.5 In pancreatic and rectal cancer, there is some evidence 
that a longer interval between end of neoadjuvant treatment and surgery is 
associated with higher pCR rates and also improved (disease-free) survival.6-8 
However, extended intervals might also lead to residual tumour growth or 
increased radiation fibrosis resulting in technically more challenging operations 
with higher postoperative complication rates, resulting in a worse survival. For 
oesophageal cancer, conflicting data have been published. Most studies 
modelled the time interval as a dichotomous variable or included only a small 
number of patients.9-12 
 
The aim of this population-based study was to assess the association between 
the time after nCRT and pCR, complications and postoperative mortality in a 
large national cohort. It was hypothesized that a longer time interval is 
associated with a higher pCR, but also with a higher complication rate.  
METHODS  
STUDY DESIGN  
We conducted a retrospective study using data from the Dutch Upper 
Gastrointestinal Cancer Audit (DUCA), a large prospective national audit 
facilitated by the Dutch Institute for Clinical Auditing (DICA). All patients 
undergoing surgery for gastric or oesophageal cancer in the Netherlands are 
4
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registered in this database.13 Patient-, tumour-, treatment characteristics, 
pathological information and postoperative outcome (until 30 days 
postoperative) were extracted from this database.  
 
PATIENT SELECTION 
Patients who underwent an elective oesophagectomy with curative intent for 
oesophageal or junctional cancer after nCRT between 2011 and 2016 were 
included. Criteria for exclusion were: cervical oesophageal tumours, non-
completion of the nCRT regimen, cT1N0 tumours (according to the 7th edition of 
the Union for International Cancer Control-American Joint Committee on Cancer 
(UICC-AJCC) tumour, node, metastasis (TNM) staging system 14), unknown date 
of birth, unknown curability status of resection (curative/palliative), or unknown 
30-day/in-hospital survival status.  
 
Since 2010, nCRT followed by surgery has been the standard treatment 
according to the Dutch guideline for oesophageal carcinoma (with the exception 
for T1N0 tumours). Furthermore, in 2014, the guideline specified the nCRT 
regimen based on the CROSS trial15: Carboplatin (AUC 2 mg/ml/min) and 
paclitaxel (50 mg/m2) is administered on days 1, 8, 15, 22 and 29. Concurrent 
radiotherapy 41.4 Gray is administered in 23 fractions, 5 days a week starting on 
the day of first chemotherapy administration.15,16 Although the exact regimen 
used was not specified in the database, it was assumed that all patients in this 
study were treated with this regimen.  
TIME INTERVAL  
In the DUCA the start of nCRT and the date of surgery are registered. The date 
of the end of nCRT is not registered. To estimate the interval between the end 
of nCRT and surgery, 30 days (duration of CROSS schedule) were subtracted from 
the calculated interval between start of nCRT and operation. In this manuscript 
‘interval’ always refers to the time interval between the end of nCRT and 
resection. 
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OUTCOMES 
The primary outcome was pCR, defined as no vital tumour cells at the location 
of the primary tumour and in the lymph nodes. Secondary endpoints were the 
number of resected lymph nodes, intraoperative complications, postoperative 
complications (within 30 days postoperative), severe postoperative 
complications and 30-day/in-hospital mortality. Severe complications were 
defined as postoperative complications leading to a prolonged hospital stay (>21 
days), (surgical, endoscopic or radiological) re-intervention or death. From 2016, 
the severity of complications was scored according to Clavien Dindo17.  
Patients were grouped in six interval categories: group A: 0-5 weeks, B: 6-7 
weeks, C: 8-9 weeks, D: 10-12 weeks, E: 13-14 weeks and F: 15 or more weeks. 
The upper and lower boundaries of the second and third group were chosen to 
analyse differences between the most common intervals and the other groups.  
 
POTENTIAL DELAY-RELATED CONFOUNDERS 
To adjust for the possibility that variations in interval were not only caused by 
structure and process difficulties, but also by patient-related characteristics (i.e. 
intentionally extended interval in e.g. less fit patients), the effects of the interval 
on the outcomes were adjusted for confounders. These factors were the 
Charlson comorbidity index (calculated using the registered information 
regarding comorbidities in the DUCA, the current oesophageal tumour was not 
included as malignancy)18, American Society of Anesthesiologists (ASA) score, 
body mass index (BMI, kg/m2) at the time of diagnosis, gender, and age. Also, 
the tumour specific characteristics: tumour location, T-, N- and M- category and 
histological tumour type were used. Finally, treatment characteristics including 
type of surgical approach, annual hospital volume and year of surgery were 
used. 13,19  
 
In this study, informed consent or ethical approval were not required under 
Dutch law.  
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STATISTICAL ANALYSIS 
To compare characteristics and outcome parameters between the different 
interval groups, χ2 tests were used. To identify associated factors for pCR and 
the secondary outcomes, univariable logistic regression analysis was performed. 
Multivariable logistic regression analysis was used to test the association of 
interval with the outcomes, adjusted for factors identified with univariable 
analysis. The median time interval was used as reference. For all multivariable 
logistic regression models, variables were added to the model if the P-value in 
univariable analysis was ≤0.10. In all other analyses, statistical significance was 
defined as P≤0.05. SPSS® version 24 was used for statistical analysis (IBM, 
Armonk, New York, USA).    
RESULTS  
Some 3 091 patients underwent oesophagectomy for cT1N1 or T2-3N0-1 
oesophageal or junctional cancer. All patients received and completed nCRT and 
there were no missing data (Figure 1). The median time interval was 8 
[interquartile range (IQR): 7-10] weeks (Figure 2). The median time interval 
increased from 8 weeks (years 2011-2013) to 9 weeks (years 2014-2016).  
 
 
PRIMARY OUTCOME 
Overall, 906 of 3091 of patients (29%) had a pCR. The pCR rate for 
adenocarcinoma and squamous cell carcinoma is shown in Figure 3. The 
percentage of patients with a pCR increased with length of time interval and was 
31%, 28%, 26%, 31%, 40%, and 37% for group A to F was respectively (Table 2). 
This difference across the groups was statistically significant (p<0.01). For 
adenocarcinomas, the interval, cT category and year of resection were 
associated with pathological response. An interval of 10 or more weeks was 
independently associated with a higher probability of a pCR (reference group: 8-
9 weeks): odds ratios(ORs) for group D, E and F [95% confidence interval (CI)]: 
1.35[1.00-1.83], 1.95[1.24-3.07] and 1.64[0.99-2.71] (Table 3).  
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For squamous cell carcinomas both increased interval and cN category were 
associated with pathological response. Intervals of 13 or more weeks were 
independently associated with a higher probability of a pCR (reference group: 8-
9 weeks): ORs [95%CI] for group E and F: 2.86[1.23-6.65], 2.67[1.29-5.55] (Table 
3). 
 
 
 
Figure 1. Flowchart included patients 
 
 
 
DEMOGRAPHICS AND SURGICAL OUTCOMES 
The median age of the study population was 65 [IQR: 59-61] years, and 690 of 
3091 patients were female (22%). Patient-, tumour- and treatment 
characteristics, according to time interval are shown in Table 1.  
4
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Figure 2. Number of patients treated in different time intervals between neoadjuvant 
chemo radiotherapy. 
 
 
 
 
Figure 3a and 3b. Percentage pathological complete response in patients with an 
adenocarcinoma (a) and a squamous cell carcinoma (b) for the time interval subgroups. 
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Table 1. Patient, tumour, and treatment characteristics for six groups based on the time 
interval between the end of neoadjuvant chemo radiotherapy and surgery. 
  A B C D E F   
  0-5 weeks 6-7 weeks 8-9 weeks 
10-12 
weeks 
13-14 
weeks ≥15 weeks 
P 
value 
Patient 
characteristics n=157 n=878 n=972 n=720 n=195 n=180   
Age (in years)                         0.84 
0-64 80 51% 405 46% 428 44% 328 46% 87 45% 75 42%     
65-74  59 38% 364 42% 416 43% 288 40% 83 43% 83 46%     
75+  18 12% 108 12% 126 13% 99 14% 23 12% 21 12%     
Female 31 20% 202 23% 219 23% 153 21% 43 22% 42 23% 0.92 
Underweight 
(BMI<20) 9 6% 61 7% 55 6% 49 7% 15 8% 15 8% 0.69 
ASA score                         <0.001 
ASA I-II 126 80% 707 81% 782 81% 548 77% 142 73% 127 71%     
ASA III+ 31 20% 169 19% 184 19% 165 23% 52 27% 53 29%     
Charlson score                         0.09 
0 91 58% 464 53% 498 51% 342 48% 102 52% 75 42%     
1 37 24% 212 24% 248 26% 186 26% 44 23% 50 28%     
2+ 29 19% 202 23% 226 23% 192 27% 49 25% 55 31%     
  A B C D E F   
  0-5 weeks 6-7 weeks 8-9 weeks 
10-12 
weeks 
13-14 
weeks ≥15 weeks 
P 
value 
Tumour 
characteristics n=157 n=878 n=972 n=720 n=195 n=180   
Clinical T category                          0.07 
cT0-2 42 27% 196 22% 184 19% 143 20% 35 18% 33 18%     
cT3 109 69% 634 72% 722 74% 532 74% 146 75% 127 71%     
cT4 3 2% 19 2% 31 3% 24 3% 9 5% 15 8%     
Unknown 3 2% 29 3% 35 4% 21 3% 5 3% 5 3%     
Clinical N category                          0.78 
cN0 51 33% 285 33% 318 33% 237 33% 58 30% 54 30%     
cN1 63 40% 371 42% 427 44% 312 43% 80 41% 69 38%     
cN2 34 22% 171 20% 174 18% 131 18% 41 21% 46 26%     
Unknown 9 6% 51 6% 53 6% 40 6% 16 8% 11 6%     
Clinical M 
category                          0.17 
cM0 153 98% 860 98% 952 98% 695 97% 190 97% 171 95%     
cM1 1 1% 2 0% 8 1% 4 1% 1 1% 3 2%     
Unknown 3 2% 16 2% 12 1% 21 3% 4 2% 6 3%     
Tumour location                         0.04 
Proximal-mid 
oesophagus 22 14% 114 13% 139 14% 101 14% 27 14% 39 22%     
Distal 
oesophagus 102 65% 618 70% 622 64% 474 66% 131 67% 109 61%     
Gastro-
oesophageal 
junction 33 21% 146 17% 211 22% 145 20% 37 19% 32 18%     
Histologic tumour 
type                         0.29 
Adenocarcinoma 104 67% 612 71% 684 70% 498 69% 136 70% 114 63%     
Squamous cell 
carcinoma 31 20% 155 18% 175 18% 132 18% 28 14% 43 24%     
Other 0 0% 23 3% 21 2% 13 2% 2 1% 3 2%     
Not applicable 17 11% 64 7% 70 7% 59 8% 20 10% 18 10%     
Unknown 3 2% 13 2% 21 2% 16 2% 9 5% 2 1%   
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Table 1. Continued 
 
      
  0-5 weeks 6-7 weeks 8-9 weeks 
10-12 
weeks 
13-14 
weeks ≥15 weeks 
P 
value 
Treatment 
characteristics n=157 n=878 n=972 n=720 n=195 n=180   
Curability of 
procedure                         n.a. 
Curative 
resection 156 99% 876 100% 972 100% 718 100% 195 100% 180 100%     
Palliative 
resection (tumour 
left behind or no 
resection) 1 1% 1 0% 0 0% 2 0% 0 0% 0 0%     
Surgical approach                         <0.001 
TTO thoracic 
part open 38 24% 191 22% 165 17% 72 10% 23 12% 31 17%     
TTO thoracic 
part MI  42 27% 384 44% 539 56% 488 68% 130 67% 95 53%     
THO open 71 45% 253 29% 174 18% 97 14% 28 14% 34 19%     
THO MI 6 4% 50 6% 90 9% 60 8% 13 7% 19 11%     
Unknown 0 0% 0 0% 4 0% 3 0% 1 1% 1 1%     
Additional 
resection(s)  3 2% 18 2% 24 3% 15 2% 1 1% 4 2% 0.68 
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, TTO = 
Transthoracic oesophagectomy, MI = Minimally invasive 
SECONDARY OUTCOMES  
The median number of retrieved lymph nodes was significantly different 
between the groups; the longer the interval, the higher the number of lymph 
nodes retrieved (Table 2; p<0.01). In a multivariable logistic regression model, 
there was no association between the lymph node retrieval and the interval 
(Table 3). The percentage of patients with an intraoperative complication was 
not statistically significant different between the groups. The postoperative 
complication rate was higher for longer intervals: A-F: 52%, 56%, 60%, 62%, 69%, 
70%, (p<0.01). In a multivariable logistic regression model however, extended 
intervals were not associated with postoperative complications (reference: 8-9 
weeks) (Table 3). The occurrence of severe postoperative complications (defined 
as postoperative complications that lead to a prolonged hospital stay (>21 days), 
re-intervention or death) was also not significantly different between the groups 
(28%, 27%, 28%, 33%, 30% and 34% for respectively group A-F, p=0.13). The 30-
day/in-hospital mortality was significantly different between the groups (Table 
2). In the multivariable analysis, intervals of 10-12 weeks and 15 or more weeks 
were associated with a significantly higher 30-day/in-hospital mortality (Table 3). 
The results of all univariable and multivariable analyses are shown in 
Supplementary Tables 1-6.  
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Table 2. Outcome characteristics for six groups based on the time interval between 
the end of neoadjuvant chemo radiotherapy and surgery. 
 A B C D E F   
 0-5  
weeks 
6-7  
weeks 
8-9  
weeks 
10-12 
weeks 
13-14 
weeks 
≥15  
weeks 
P 
value 
Outcome characteristics n=157 n=878 n=972 n=720 n=195 n=180   
Pathologic yT stage                         0.16 
   ypT0 (incl. T0N0-2M0) 42 27% 223 25% 213 22% 179 25% 54 28% 53 29%   
   ypT1 20 13% 125 14% 155 16% 123 17% 24 12% 34 19%   
   ypT2 32 20% 190 22% 207 21% 127 18% 34 17% 32 18%   
   ypT3 53 34% 301 34% 357 37% 253 35% 71 36% 56 31%   
   ypT4 2 1% 1 0% 8 1% 2 0% 1 1% 1 1%   
   Unknown 8 5% 38 4% 32 3% 36 5% 11 6% 4 2%     
Pathologic yN stage                         0.3 
   pN0 90 57% 519 59% 586 60% 444 62% 127 65% 121 67% 
     pN1 38 24% 190 22% 199 21% 138 19% 35 18% 39 22% 
   pN2 13 8% 95 11% 113 12% 68 9% 18 9% 11 6% 
   Unknown 16 10% 74 8% 74 8% 70 10% 15 8% 9 5%     
Pathologic yM stage                         0.63 
   pM0 154 98% 851 97% 943 97% 685 95% 192 99% 174 97%      pM1 1 1% 9 1% 9 1% 10 1% 0 0% 2 1% 
   Unknown 2 1% 18 2% 20 2% 25 4% 3 2% 4 2%     
Pathological response                         <0.01 
   No response 14 9% 56 6% 74 8% 65 9% 16 8% 14 8% 
     Complete response 49 31% 244 28% 249 26% 220 31% 77 40% 67 37% 
   Partial response 87 55% 526 60% 619 64% 417 58% 95 49% 87 48% 
   Unknown 7 5% 52 6% 30 3% 18 3% 7 4% 12 7%     
Resection margins                         0.36 
   Not free of tumour cells  11 7% 29 3% 42 4% 31 4% 8 4% 6 3%      Free of tumour cells  143 93% 842 97% 922 96% 681 96% 186 96% 174 97% 
   Unknown 1 1% 1 0% 3 0% 2 0% 0 0% 0 0%     
Number of LNs                         <0.01 
   Median [IQR] 16 [11-20] 18 [13-23] 18 [13-25] 19 [14-26] 20 [14-29] 20 [14-26]   
   ≥ 15 LNs 92 59% 599 68% 680 70% 526 73% 143 73% 134 74% <0.01 
 A B C D E F   
 0-5  
weeks 
6-7  
weeks 
8-9  
weeks 
10-12 
weeks 
13-14 
weeks 
≥15  
weeks 
P 
value 
Outcome characteristics n=157 n=878 n=972 n=720 n=195 n=180   
Intraoperative 
complications 8 5% 48 6% 48 5% 34 5% 8 4% 10 6% 0.97 
Postoperative 
complications (within 30 
days) 
81 52% 486 56% 582 60% 442 62% 134 69% 126 70% <0.01 
Clavien-Dindo classification 
complications*                       0.34 
   No complication 6 40% 60 43% 73 38% 74 41% 24 36% 9 20% 
     Clavien-Dindo I-II 5 33% 33 23% 65 34% 54 30% 22 33% 17 38%    Clavien-Dindo III+ 4 27% 46 33% 51 26% 48 27% 20 30% 16 36% 
   Classification unknown 0 0% 2 1% 4 2% 4 2% 1 2% 3 7% 
Anastomotic 
leakage/leakage due to 
necrosis 
18 12% 90 10% 92 10% 97 14% 17 9% 27 15% 0.05 
Severe complications** 44 28% 241 27% 274 28% 238 33% 59 30% 61 34% 0.13 
Mortality (30-day/in-
hospital) 5 3% 17 2% 27 3% 35 5% 7 4% 15 8% <0.01 
Length of hospital stay 
(days)                             
   Median [IQR] 12 [9-12] 12 [9-18] 12 [9-21] 12 [9-21] 12 [9-18] 15 [10-22.5] 0.16 
Length of IC stay (days)                             
   Median [IQR] 2 [1-4] 2 [1-5] 2 [1-4] 2 [1-4] 1 [1-3] 2 [1-5] 0.98 
LNs = lymph nodes IQR = inter quartal range * Only information of 2016  ** Postoperative complications leading to 
reintervention, prolonged hospital stay (>21 days) or dead 
 
4
 
Chapter 4 80 
Table 3. Multivariable logistic analyses for several outcomes.  
 
Outcomes   Multivariable analyses  
n=1982 
Interval nCRT - resection 
(in weeks) 
n OR 95% CI P-value 
Pathological Complete Response (pCR) Adenocarcinoma         0.003 
Adjusted for: cT category year 
of resection ^ 
0-5 97 1.41 0.84 2.37 0.20 
6-7 557 0.90 0.66 1.22 0.50 
8-9 633 ref       
10-12 466 1.35 1.00 1.83 0.05 
13-14 126 1.95 1.24 3.07 0.004 
15 and more 103 1.64 0.99 2.71 0.05 
Pathological Complete Response (pCR) Squamous cell carcinoma       0.006 
Adjusted for: cN category ^ 0-5 29 0.45 0.17 1.17 0.10 
6-7 143 1.33 0.84 2.11 0.23 
8-9 169 ref       
10-12 126 1.22 0.75 1.98 0.43 
13-14 27 2.86 1.23 6.65 0.014 
15 and more 38 2.67 1.29 5.55 0.01 
Intraoperative complications           1.00 
Adjusted for: ASA score, 
Charlson score, histological type 
of tumour, surgical approach, 
year of resection ^ 
0-5 151 ref       
6-7 849 0.94 0.42 2.08 0.87 
8-9 934 1.08 0.70 1.66 0.72 
10-12 686 1.00 0.62 1.60 0.99 
13-14 182 0.92 0.42 2.02 0.84 
15 and more 176 1.03 0.50 2.11 0.94 
Retrieval of ≥15 LNs           0.93 
Adjusted for: age, ASA score, 
Charlson score, cN category, cT 
category, location tumour, 
surgical approach, annual 
hospital volume, year of 
resection ^ 
0-5 154 1.04 0.70 1.55 0.83 
6-7 845 1.07 0.85 1.33 0.58 
8-9 917 ref       
10-12 677 1.01 0.79 1.29 0.94 
13-14 186 0.96 0.65 1.44 0.85 
15 and more 171 1.23 0.82 1.87 0.32 
Postoperative complications           0.05 
Adjusted for: age, Charlson 
score, ASA score, BMI, cN 
category, histological type of 
tumour, surgical approach, 
annual hospital volume ^ 
0-5 149 0.78 0.54 1.12 0.18 
6-7 839 0.85 0.70 1.04 0.11 
8-9 919 ref       
10-12 670 0.98 0.79 1.21 0.83 
13-14 180 1.30 0.92 1.84 0.14 
15 and more 172 1.31 0.91 1.87 0.14 
Severe postoperative complications* 
  
        0.74 
Adjusted for: age, Charlson 
score, ASA score, BMI, 
histological type of tumour,  
surgical approach, annual 
hospital volume  
0-5 149 1.32 0.88 1.97 0.18 
6-7 835 1.07 0.87 1.33 0.52 
8-9 919 ref       
10-12 669 1.12 0.90 1.40 0.32 
13-14 180 0.97 0.68 1.40 0.89 
15 and more 172 1.14 0.80 1.64 0.47 
30-day/in-hospital mortality           0.01 
Adjusted for:  age, Charlson 
score, ASA score, BMI, cT 
category, cN category, 
histological type of tumour 
0-5 148 1.42 0.53 3.85 0.49 
6-7 814 0.75 0.39 1.43 0.38 
8-9 900 ref       
10-12 660 1.87 1.08 3.23 0.03 
13-14 176 1.32 0.55 3.18 0.54 
15 and more 170 2.45 1.20 4.97 0.01 
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists *Postoperative complications leading to 
reintervention, prolonged hospital stay (>21 days) or dead, ^Based on univariable logistic regression analysis, 
variables with p≤0.10 are added to the multivariable logistic regression model 
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DISCUSS ION 
This study shows that an interval of ≥10 weeks (adenocarcinoma) and ≥13 weeks 
(squamous cell carcinoma) is associated with a higher probability of pCR. The 
percentage of a retrieval of more than 15 lymph nodes, intraoperative and 
postoperative complications is comparable between the intervals. However, an 
interval of 10-12 and 15 or more weeks is associated with a higher 30-day/in-
hospital mortality. 
 
Some studies also observed a trend towards a higher pCR in patients with longer 
time intervals5,12,20-23, while other studies did not find such an association.10,24 
Most studies used a modelled dichotomous variable for interval and used 6-8 
weeks as a cut-off point. Because of the rather small sample size in most studies, 
the interval beyond 10 weeks was not divided into subgroups. Haisley et al. 9 
included six time intervals (0-42, 43-56, 57-70, 71-84, 85-98, and 99 or more 
days). They showed an increased probability of pCR for the group 85-98 days 
compared with other groups (OR: 5.46 [95% CI: 1.16-25.68]). These results are 
in line with the results of the present study. 
 
Previous studies also reported conflicting results on complications for the 
extended interval groups: some showed higher complication rates 12, but other 
did not.9,10,21 The higher 30-day/in-hospital mortality rates for patients operated 
after 10-12 and 15 or more weeks in the present study have not been reported 
before. The observed higher complication rate and 30-day/in-hospital mortality 
may be due to selection bias, since more frail patients (higher ASA score and 
Charlson comorbidity score of 2 or higher) were represented in the extended 
interval groups. This may reflect that logistic reasons (patient planning) played a 
role but the delay of the resection may also be due to the time taken to recover 
from the toxicity of nCRT before undergoing surgery. Despite a longer recovery 
period after nCRT these patients are still at higher risk for postoperative 
mortality. In a single-centre Dutch study, an increased risk for postoperative 
complications in patients treated with extended intervals was reported (OR: 1.20 
per additional week). However, after adjustment for potential delay-related 
confounders and surgical approach this effect was reduced (OR 1.10 per 
4
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additional week) and became statistically nonsignificant. Covariates in the 
multivariate model were Charlson comorbidity index at diagnosis, Karnofsky 
performance score during the last week of nCRT, and weight loss during nCRT.12  
In our study, we adjusted only for Charlson comorbidity score at diagnosis. When 
adjusting for the available factors, there was no association of the extended 
intervals with postoperative complications. However, the association of the 
extended intervals with 30-day/in-hospital mortality was still present. We 
assume that there was residual confounding because of missing potential delay-
related factors like performance score in the last week of nCRT and weight loss 
during nCRT. Besides more frail patients in the extended interval group (>15 
weeks), there were also more patients with a proximal or mid-oesophageal 
tumour. Theoretically, these patients may have been enrolled in a wait-and-see 
strategy with definitive CRT (50 Gray, versus 41.4 Gray as used in the nCRT 
regimen) to avoid a resection. However, when these patients eventually 
undergo (salvage) oesophagectomy there may be an increased risk for 
complications and mortality. Unfortunately, because the CRT dose was not 
registered in the audit, it was not possible to distinguish between patients 
treated with definitive CRT and ‘salvage’ resections, and patients treated with 
extended intervals after nCRT. When there is indeed residual confounding in the 
patient- and treatment characteristics as mentioned, we might underestimate 
the potential benefit of longer waiting time.  
 
Our study has an important strength. Because of the large patient cohort, it was 
possible to compare small interval groups and to adjust for potential delay 
related factors. The national and prospective set-up of the audit reduced 
selection bias and the national pathological guidelines led to uniform 
registration of pCR.  
A limitation is however that we are not informed on the exact reason why 
surgery was delayed. Furthermore, the exact details of nCRT are not registered 
in the database (to distinguish between definitive CRT from nCRT). From 2018 
onwards, details on the type of nCRT will be registered in the audit. Lastly, 
previous studies showed a comparable survival for different intervals. This might 
be due to the small sample size of these studies. Unfortunately, because 
mortality beyond 30 days/after hospital discharge is not registered in the DUCA, 
 
Chapter 4 83 
more accurate analysis of survival of the extended interval groups was not 
possible in this study.  
In conclusion, this study showed that an interval of more than 12 weeks between 
end of neoadjuvant chemoradiotherapy and oesophagectomy for cancer is 
associated with higher pathological complete response rate, but not with 
increased intraoperative and postoperative complications. Higher 30-day/in-
hospital mortality was observed for intervals of 10-12 and 15 or more weeks but 
this might be due to selection bias. 
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Supplementary table 1. Univariable and multivariable logistic regression analysis on 
factors associated with pathological complete response, stratified for adenocarcinoma 
and squamous cell carcinoma  
Pathological Complete 
Response (pCR) 
Adenocarcinoma 
Univariable analysis  
Total Study population 
n=2139 
Multivariable analysis  
n=1982 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - 
resection (in weeks)         0.03         0.003 
   0-5 99 1.51 0.92 2.50 0.11 97 1.41 0.84 2.37 0.20 
6-7 574 0.94 0.70 1.26 0.67 557 0.90 0.66 1.22 0.50 
8-9 658 ref       633 ref       
10-12 481 1.27 0.94 1.71 0.11 466 1.35 1.00 1.83 0.05 
13-14 128 1.71 1.10 2.65 0.02 126 1.95 1.24 3.07 0.004 
15 and more 106 1.46 0.89 2.38 0.13 103 1.64 0.99 2.71 0.05 
Gender         1.00           
  Male 1718 ref                 
  Female 327 1.00 0.74 1.35             
Age (in years)         0.40           
0-64 932 ref                   
65-74  842 1.18 0.93 1.49 0.18           
75+  272 1.07 0.76 1.51 0.71           
Clinical T category          0.10         0.08 
cT0-2 397 ref       397 ref       
cT3 1531 1.05 0.79 1.38 0.75 1531 1.04 0.78 1.38 0.79 
cT4 54 0.34 0.12 0.96 0.04 54 0.32 0.11 0.91 0.03 
Clinical N category         0.78           
cN0 668 ref                 
cN1 862 0.93 0.72 1.20 0.55           
cN2 402 1.06 0.78 1.44 0.73           
Unknown 114 0.86 0.51 1.45 0.58           
Clinical M category          0.23           
cM0 2003 ref                 
cM1 12 2.10 0.63 6.99             
Tumour location         0.24           
Proximal-mid 
oesophagus 88 ref                 
Distal oesophagus 1469 1.11 0.63 1.97 0.72           
Gastro-oesophageal 
junction 489 1.36 0.75 2.47 0.31           
Charlson score         0.98           
0 1054 ref                 
1 528 1.00 0.77 1.30 0.99           
2 276 1.07 0.77 1.50 0.67           
3+ 188 1.00 0.67 1.48 1.00           
ASA score         0.69           
I/II 1628 ref                 
III+ 407 0.95 0.72 1.25             
BMI          0.62           
<20 72 ref                 
20-24 725 0.87 0.46 1.67 0.68           
25-29 858 1.14 0.89 1.47 0.29           
>30 366 1.00 0.72 1.38 0.99           
Year of resection         0.02         0.003 
2011 222 ref       219 ref       
2012 261 1.19 0.75 1.87 0.46 253 1.23 0.78 1.96 0.37 
2013 317 1.41 0.92 2.17 0.12 306 1.43 0.93 2.21 0.11 
2014 387 1.20 0.79 1.84 0.39 372 1.15 0.75 1.77 0.52 
2015 441 1.13 0.75 1.72 0.55 425 1.06 0.69 1.62 0.79 
2016 418 0.72 0.46 1.12 0.14 407 0.64 0.41 1.01 0.06 
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Pathological Complete 
Response (pCR) 
Squamous Cell 
Carcinoma 
Univariable analysis  
Total Study population 
n= 562 
Multivariable analysis  
n= 532 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - 
resection (in weeks)         0.01         0.006 
   0-5 29 0.46 0.18 1.20 0.11 29 0.45 0.17 1.17 0.10 
6-7 143 1.28 0.81 2.02 0.29 143 1.33 0.84 2.11 0.23 
8-9 169 ref       169 ref       
10-12 126 1.09 0.68 1.76 0.73 126 1.22 0.75 1.98 0.43 
13-14 27 2.58 1.12 5.90 0.03 27 2.86 1.23 6.65 0.014 
15 and more 38 2.43 1.19 4.98 0.02 38 2.67 1.29 5.55 0.01 
Gender         0.28           
  Male 285                   
  Female 247 1.21 0.86 1.72             
Age (in years)         0.26           
0-64 228 ref                 
65-74  237 0.83 0.57 1.20 0.31           
75+  67 0.64 0.36 1.13 0.12           
Charlson score         0.88           
0 243 ref                 
1 121 1.20 0.77 1.86 0.43           
2 106 1.08 0.68 1.72 0.74           
3+ 62 1.00 0.57 1.78 1.00           
ASA score         0.72           
I/II 389 ref                  
III+ 139 0.93 0.63 1.38             
BMI          0.21           
<20 89 1.33 0.81 2.17 0.26           
20-24 250 ref                   
25-29 149 1.53 1.02 2.32 0.04           
>30 40 1.07 0.54 2.13 0.86           
Clinical T category          0.10           
cT0-2 106 ref                 
cT3 366 0.66 0.42 1.01 0.06           
cT4 38 1.01 0.48 2.12 0.98           
Clinical N category         0.01         0.004 
cN0 163 ref         163 ref       
cN1 228 0.51 0.34 0.77 0.001 228 0.49 0.32 0.74 0.001 
cN2 106 0.56 0.34 0.93 0.02 106 0.50 0.30 0.83 0.01 
Unknown 35 0.50 0.24 1.08 0.08 35 0.45 0.21 0.98 0.04 
Clinical M category          n.a.           
cM0 517                   
cM1 3                   
Tumour location         0.14           
Proximal-mid 
oesophagus 261 ref                 
Distal oesophagus 240 0.98 0.69 1.40 0.90           
Gastro-oesophageal 
junction 31 0.41 0.17 0.99 0.05           
Year of resection         0.55           
2011 53 ref                   
2012 72 0.83 0.39 1.73 0.61           
2013 81 0.97 0.48 1.99 0.94           
2014 91 1.03 0.51 2.07 0.93           
2015 130 1.41 0.74 2.72 0.30           
2016 105 1.19 0.61 2.34 0.61           
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, 
THO = Transthoracic oesophagectomy, MI = Minimally invasive, nCRT = neoadjuvant Chemo radio Therapy 
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Supplementary table 2. Univariable and multivariable logistic regression analysis on 
factors associated with intraoperative complications 
Intraoperative 
complications 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
 n=2978 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - resection (in 
weeks)       0.96         1.00 
   0-5 156 1.03 0.48 2.23 0.93 151 ref       
   6-7 875 1.11 0.74 1.67 0.62 849 0.94 0.42 2.08 0.87 
   8-9 966 ref       934 1.08 0.70 1.66 0.72 
   10-12 714 0.93 0.59 1.46 0.74 686 1.00 0.62 1.60 0.99 
   13-14 193 0.83 0.39 1.78 0.63 182 0.92 0.42 2.02 0.84 
   15 and more 179 1.13 0.56 2.28 0.73 176 1.03 0.50 2.11 0.94 
Gender         0.62           
  Male 2396 ref                 
  Female 686 1.10 0.75 1.61             
Age (in years)         1.00           
   0-64 1397 ref                 
   65-74  1292 1.00 0.71 1.42 0.98           
   75+  394 1.01 0.61 1.69 0.96           
Charlson score         0.02         0.09 
   0 1562 ref       1502 ref       
   1 773 1.15 0.77 1.72 0.50 755 1.03 0.68 1.58 0.88 
   2 451 1.06 0.64 1.74 0.83 437 0.91 0.54 1.53 0.71 
   3+ 297 2.08 1.30 3.32 0.002 284 1.80 1.08 3.00 0.02 
ASA score         0.002           
   I/II 2416 ref       2343 ref       
   III+ 651 1.75 1.23 2.49 0.15 635 1.56 1.06 2.30   
BMI                     
   <20 204 1.91 1.08 3.36 0.03           
   20-24 1164 ref                 
   25-29 1199 1.10 0.76 1.61 0.61           
   >30 482 1.00 0.60 1.67 0.99           
Clinical T category          0.27           
   cT0-2 629 ref                 
   cT3 2256 1.21 0.79 1.84 0.38           
   cT4 101 0.43 0.10 1.85 0.26           
Clinical N category         0.23           
   cN0 999 ref                 
   cN1 1314 1.02 0.69 1.50 0.92           
   cN2 593 1.43 0.92 2.21 0.11           
   Unknown 177 0.71 0.30 1.69 0.44           
Clinical M category          0.93           
   cM0 3002 ref                 
   cM1 19 1.10 0.15 8.32             
Tumour location         0.26           
   Proximal-mid 
oesophagus 439 ref                 
   Distal 
oesophagus 2043 0.71 0.46 1.09 0.12           
   Gastro-
oesophageal 
junction 601 0.69 0.41 1.18 0.18           
Histological type         0.002         0.01 
   Adenocarcinoma 2134 ref       2116 ref       
   Squamous cell 
carcinoma 559 2.01 1.39 2.91 <0.001 555 1.91 1.30 2.80 0.001 
   Other 62 1.55 0.55 4.36 0.41 61 1.69 0.59 4.82 0.33 
   Not applicable 248 0.94 0.48 1.84 0.86 246 1.02 0.51 2.00 0.97 
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Supplementary table 2. Continued  
 
Intraoperative 
complications 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
 n=2978 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Surgical approach         0.01         0.13 
  TTO thoracic part 
open 515 ref       504 ref       
  TTO thoracic part 
MI  1669 0.54 0.36 0.81 0.003 1617 0.66 0.42 1.03 0.07 
  THO open 654 0.73 0.46 1.17 0.19 625 0.89 0.55 1.47 0.66 
  THO MI 236 0.43 0.20 0.93 0.03 232 0.48 0.21 1.06 0.07 
Location of 
anastomosis         0.95           
   Neck 1957 ref                   
   Intrathoracic 1091 0.99 0.70 1.40             
Annual hospital 
volume         0.36           
   0-25 390 ref                 
   26-50 1767 1.45 0.83 2.53 0.19           
   50+ 908 1.24 0.68 2.27 0.48           
Year of resection         0.09         0.19 
   2011 343 ref       330 ref       
   2012 438 0.65 0.36 1.16 0.14 420 0.66 0.36 1.21 0.18 
   2013 456 0.65 0.36 1.16 0.14 432 0.65 0.35 1.20 0.17 
   2014 545 0.37 0.20 0.70 0.002 540 0.42 0.22 0.82 0.01 
   2015 660 0.70 0.42 1.19 0.19 634 0.78 0.44 1.37 0.38 
   2016 641 0.64 0.38 1.09 0.10 622 0.76 0.43 1.37 0.36 
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, 
TTO = Transthoracic oesophagectomy, MI = Minimally invasive, nCRT = neoadjuvant Chemo radio Therapy 
 
 
 
Supplementary table 3. Univariable and multivariable logistic regression analysis on 
factors associated with postoperative complications  
Postoperative 
complications 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
n=2929 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - resection (in 
weeks)       <0.001         0.05 
   0-5 155 0.73 0.52 1.03 0.08 149 0.78 0.54 1.12 0.18 
6-7 874 0.84 0.70 1.01 0.07 839 0.85 0.70 1.04 0.11 
8-9 969 ref       919 ref         
10-12 714 1.06 0.87 1.30 0.54 670 0.98 0.79 1.21 0.83 
13-14 193 1.49 1.07 2.07 0.02 180 1.30 0.92 1.84 0.14 
15 and more 179 1.55 1.10 2.19 0.01 172 1.31 0.91 1.87 0.14 
Gender         0.25           
  Male 2397 ref                 
  Female 686 1.11 0.93 1.32             
Age (in years)         <0.001         0.001 
0-64 1400 ref         1328 ref         
65-74  1290 1.30 1.12 1.52 0.001 1229 1.27 1.08 1.50 0.01 
75+  394 1.58 1.25 1.99 <0.001 372 1.55 1.20 2.01 0.001 
Charlson score         <0.001         <0.001 
0 1560 ref       1470 ref         
1 774 1.14 0.96 1.35 0.15 744 0.99 0.82 1.19 0.88 
2 453 1.54 1.24 1.92 <0.001 434 1.34 1.06 1.70 0.02 
3+ 297 2.19 1.66 2.88 <0.001 281 1.72 1.27 2.32 <0.001 
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Supplementary table 3. Continued 
 
Postoperative 
complications 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
n=2929 
Variables n OR 95%CI P-value n OR 95%CI P-value 
ASA score         <0.001         <0.001 
I/II 2416 ref         ref         
III+ 652 1.90 1.57 2.29     1.61 1.31 1.98   
BMI          0.001         0.003 
<20 203 1.52 1.12 2.08 0.01 195 1.43 1.03 2.00 0.04 
20-24 1166 ref       1117 ref         
25-29 1200 1.35 1.15 1.59 <0.001 1154 1.37 1.15 1.63 <0.001 
>30 481 1.25 1.01 1.55 0.04 463 1.19 0.95 1.50 0.14 
Clinical T category          0.47           
cT0-2 630 ref                   
cT3 2255 1.03 0.86 1.24 0.72           
cT4 101 1.32 0.85 2.04 0.22           
Clinical N category         0.04         0.04 
cN0 999 ref         940 ref         
cN1 1315 0.86 0.73 1.01 0.07 1245 0.90 0.75 1.07 0.22 
cN2 592 1.12 0.91 1.38 0.31 575 1.21 0.97 1.51 0.09 
Unknown 178 1.07 0.77 1.49 0.69 169 1.02 0.72 1.45 0.90 
Clinical M category          0.53           
cM0 3003 ref                   
cM1 19 0.75 0.30 1.85             
Tumour location         0.001         0.04 
Proximal-mid 
oesophagus 440 ref         425 ref         
Distal oesophagus 2047 0.76 0.62 0.95 0.01 1934 0.79 0.61 1.03 0.08 
Gastro-oesophageal 
junction 597 0.62 0.48 0.80 <0.001 570 0.67 0.49 0.91 0.01 
Histological type         0.05         0.74 
Adenocarcinoma 2134 ref         2078 ref         
Squamous cell 
carcinoma 562 1.31 1.08 1.59 0.01 552 1.07 0.85 1.36 0.56 
Other 61 0.95 0.57 1.58 0.83 59 0.95 0.55 1.62 0.84 
Not applicable 248 0.99 0.76 1.29 0.94 240 0.89 0.67 1.18 0.42 
Surgical approach         <0.001         0.003 
TTO thoracic part 
open 520 ref         505 ref         
TTO thoracic part MI  1668 0.89 0.73 1.10 0.28 1598 0.90 0.72 1.13 0.38 
THO open 649 0.59 0.46 0.75 <0.001 603 0.64 0.49 0.83 0.001 
THO MI 238 0.92 0.67 1.27 0.62 223 0.87 0.61 1.24 0.45 
Location of anastomosis         0.09           
Neck 1953                   
Intrathoracic 1090 0.88 0.76 1.02             
Annual hospital volume         <0.001         0.001 
0-25 390 ref         363 ref         
26-50 1767 1.03 0.83 1.30 0.78 1712 0.93 0.72 1.19 0.55 
50+ 909 0.74 0.58 0.94 0.01 854 0.68 0.52 0.89 0.01 
Year of resection         0.27           
2011 342 ref                   
2012 436 1.25 0.94 1.67 0.13           
2013 461 1.15 0.87 1.53 0.32           
2014 546 1.30 0.99 1.71 0.06           
2015 658 1.32 1.01 1.72 0.04           
2016 641 1.35 1.03 1.76 0.03           
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, TTO = 
Transthoracic oesophagectomy, MI = Minimally invasive, nCRT = neoadjuvant Chemo radio Therapy 
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Supplementary table 4. Univariable and multivariable logistic regression analysis on 
factors associated with severe postoperative complications* 
Severe postoperative 
complications* 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
n=2924 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - resection (in 
weeks)       0.12         0.74 
   0-5 155 1.01 0.69 1.47 0.96 149 1.32 0.88 1.97 0.18 
6-7 870 0.98 0.80 1.20 0.81 835 1.07 0.87 1.33 0.52 
8-9 968 ref       919 ref       
10-12 713 1.28 1.04 1.57 0.02 669 1.12 0.90 1.40 0.32 
13-14 193 1.09 0.78 1.53 0.60 180 0.97 0.68 1.40 0.89 
15 and more 179 1.28 0.91 1.80 0.15 172 1.14 0.80 1.64 0.47 
Gender         0.34           
  Male 2393 ref                 
  Female 684 1.09 0.91 1.32             
Age (in years)         0.01         0.02 
0-64 1396 ref       1324 ref       
65-74  1290 1.14 0.97 1.35 0.12 1230 1.14 0.95 1.36 0.17 
75+  392 1.43 1.12 1.81 0.003 370 1.45 1.12 1.88 0.01 
Charlson score         <0.001         0.003 
0 1559 ref       1469 ref       
1 773 1.13 0.94 1.37 0.21 744 1.01 0.82 1.25 0.91 
2 451 1.33 1.06 1.67 0.01 432 1.18 0.93 1.51 0.18 
3+ 295 2.08 1.61 2.69 <0.001 279 1.68 1.26 2.23 <0.001 
ASA score         <0.001         <0.001 
I/II 2411 ref       2304 ref       
III+ 651 2.10 1.76 2.52   620 1.98 1.62 2.43   
BMI          0.06         0.09 
<20 203 1.49 1.09 2.04 0.01 195 1.41 1.01 1.97 0.05 
20-24 1167 ref       1118 ref       
25-29 1196 1.11 0.93 1.33 0.23 1151 1.15 0.95 1.38 0.15 
>30 478 0.99 0.78 1.26 0.95 460 0.95 0.74 1.22 0.68 
Clinical T category          0.28           
cT0-2 627 ref                 
cT3 2253 1.03 0.85 1.25 0.75           
cT4 101 1.43 0.92 2.21 0.12           
Clinical N category         0.46           
cN0 996 ref                 
cN1 1312 0.99 0.83 1.19 0.91           
cN2 593 1.01 0.81 1.27 0.91           
Unknown 177 1.29 0.92 1.81 0.14           
Clinical M category          0.20           
cM0 2997 ref                 
cM1 19 0.44 0.13 1.53             
Tumour location         0.002         0.18 
Proximal-mid oesophagus 437 ref       423 ref       
Distal oesophagus 2044 0.69 0.56 0.86 0.001 1931 0.80 0.61 1.04 0.10 
Gastro-oesophageal 
junction 597 0.66 0.50 0.85 0.002 570 0.89 0.64 1.23 0.48 
Histological type         0.005         0.43 
Adenocarcinoma 2131 ref       2075 ref       
Squamous cell carcinoma 560 1.42 1.17 1.73 <0.001 551 1.12 0.88 1.43 0.373 
Other 61 1.23 0.71 2.11 0.46 59 1.20 0.68 2.13 0.52 
Not applicable 247 1.00 0.74 1.33 0.97 239 0.85 0.62 1.16 0.30 
Surgical approach         <0.001         <0.001 
TTO thoracic part open 517 ref       502 ref       
TTO thoracic part MI  1664 1.07 0.87 1.32 0.53 1595 1.11 0.88 1.40 0.38 
THO open 650 0.48 0.37 0.63 <0.001 604 0.46 0.34 0.62 <0.001 
THO MI 238 0.79 0.57 1.12 0.18 223 0.68 0.47 0.98 0.04 
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Supplementary table 4. Continued 
 
Severe postoperative 
complications* 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
n=2924 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Location of anastomosis         0.19           
Neck 1949 ref                   
Intrathoracic 1088 1.11 0.95 1.31             
Annual hospital volume         0.01         0.24 
0-25 390 ref         363 ref       
26-50 1765 1.31 1.03 1.68 0.03 1710 1.05 0.80 1.38 0.74 
50+ 906 1.05 0.80 1.38 0.71 851 0.89 0.66 1.20 0.44 
Year of resection         0.46           
2011 340 ref                  
2012 434 0.96 0.70 1.31 0.80           
2013 460 0.88 0.64 1.20 0.41           
2014 545 1.16 0.87 1.56 0.311           
2015 658 1.00 0.75 1.34 0.98           
2016 641 1.05 0.79 1.40 0.74           
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, TTO = 
Transthoracic oesophagectomy, MI = Minimally invasive, nCRT = neoadjuvant Chemo radio Therapy 
*Postoperative complications leading to reintervention, prolonged 
hospital stay (>21 days) or dead           
 
 
Supplementary table 5. Univariable and multivariable logistic regression analysis on 
factors associated with 30-day and in-hospital mortality   
30-day and in-hospital mortality 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
n=2868 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - resection (in weeks)     <0.001         0.01 
   0-5 157 1.15 0.44 3.03 0.78 148 1.42 0.53 3.85 0.49 
6-7 877 0.69 0.37 1.28 0.24 814 0.75 0.39 1.43 0.38 
8-9 970 ref       900 ref       
10-12 715 1.80 1.08 3.00 0.03 660 1.87 1.08 3.23 0.03 
13-14 193 1.31 0.56 3.06 0.53 176 1.32 0.55 3.18 0.54 
15 and more 179 3.19 1.66 6.14 <0.001 170 2.45 1.20 4.97 0.01 
Gender         0.30           
  Male 2402 ref                 
  Female 688 1.26 0.81 1.96             
Age (in years)         0.01         0.01 
0-64 1403 ref       1303 ref       
65-74  1293 2.01 1.30 3.12 0.002 1207 2.07 1.29 3.34 0.00 
75+  395 1.81 0.98 3.33 0.06 358 1.65 0.83 3.27 0.15 
Charlson score         <0.001         0.16 
0 1565 ref       1449         
1 775 1.32 0.80 2.19 0.27 721 0.83 0.48 1.44 0.50 
2 454 1.48 0.83 2.64 0.18 426 0.99 0.53 1.83 0.96 
3+ 297 3.20 1.89 5.43 <0.001 272 1.70 0.92 3.14 0.09 
ASA score         <0.001         <0.001 
I/II 2422 ref       2280 ref       
III+ 653 2.96 1.99 4.41   588 2.61 1.65 4.12   
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Supplementary table 5. Continued 
 
30-day and in-hospital mortality 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
n=2868 
Variables n OR 95% CI P-value n OR 95% CI P-value 
BMI          0.01         0.06 
<20 204 2.43 1.31 4.51 0.01 189 2.16 1.07 4.36 0.03 
20-24 1168 ref       1091 ref       
25-29 1202 1.13 0.73 1.77 0.58 1136 1.16 0.72 1.87 0.53 
>30 483 0.71 0.36 1.41 0.33 452 0.65 0.31 1.36 0.25 
Clinical T category          0.01         0.11 
cT0-2 631 ref       601 ref       
cT3 2261 1.03 0.63 1.71 0.90 2167 0.88 0.52 1.50 0.64 
cT4 101 2.99 1.32 6.76 0.01 100 2.02 0.83 4.91 0.12 
Clinical N category         0.06         0.10 
cN0 1001 ref       915 ref       
cN1 1317 1.16 0.71 1.90 0.56 1242 1.21 0.71 2.04 0.49 
cN2 594 1.79 1.04 3.06 0.04 568 1.93 1.07 3.49 0.03 
Unknown 179 2.14 1.02 4.49 0.05 143 2.03 0.86 4.80 0.11 
Clinical M category          0.67           
cM0 3010 ref                 
cM1 19 1.55 0.21 11.74             
Tumour location         0.07         0.50 
Proximal-mid oesophagus 441 ref       410 ref       
Distal oesophagus 2048 0.67 0.41 1.10 0.12 1894 0.79 0.42 1.46 0.44 
Gastro-oesophageal junction 602 0.45 0.23 0.90 0.02 564 0.62 0.28 1.38 0.24 
Histological type         0.04         0.37 
Adenocarcinoma 2139 ref       2037         
Squamous cell carcinoma 562 1.82 1.16 2.86 0.01 531 1.06 0.58 1.91 0.86 
Other 62 2.31 0.81 6.56 0.12 61 2.67 0.90 7.90 0.08 
Not applicable 248 1.26 0.62 2.57 0.52 239 1.01 0.46 2.21 0.99 
Surgical approach         0.15           
TTO thoracic part open 520 ref                 
TTO thoracic part MI  1670 0.87 0.53 1.43 0.59           
THO open 654 0.64 0.34 1.21 0.17           
THO MI 238 0.29 0.09 0.98 0.05           
Location of anastomosis         0.25           
Neck 1959 ref                 
Intrathoracic 1091 0.78 0.51 1.19             
Annual hospital volume         0.69           
0-25 391 ref                 
26-50 1773 0.89 0.49 1.62 0.71           
50+ 909 1.08 0.57 2.03 0.82           
Year of resection         0.12           
2011 343 ref                 
2012 439 1.79 0.77 4.17 0.18           
2013 462 1.80 0.78 4.15 0.17           
2014 546 1.26 0.54 2.99 0.59           
2015 660 2.06 0.94 4.54 0.07           
2016 641 0.94 0.39 2.25 0.88           
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, TTO = 
Transthoracic oesophagectomy, MI = Minimally invasive, nCRT = neoadjuvant Chemo radio Therapy 
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Supplementary table 6. Univariable and multivariable logistic regression analysis on 
factors associated with retrieval of ≥15 LNs 
Retrieval of ≥15 LNs 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
 n=2950 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Interval nCRT - resection (in weeks)       0.01         0.93 
   0-5 157 0.61 0.43 0.86 0.01 154 1.04 0.70 1.55 0.83 
6-7 877 0.92 0.75 1.12 0.40 845 1.07 0.85 1.33 0.58 
8-9 970 ref       917 ref       
10-12 715 1.17 0.94 1.45 0.16 677 1.01 0.79 1.29 0.94 
13-14 193 1.19 0.84 1.69 0.32 186 0.96 0.65 1.44 0.85 
15 and more 179 1.24 0.86 1.78 0.25 171 1.23 0.82 1.87 0.32 
Gender         0.47           
  Male 2402 ref                 
  Female 688 1.07 0.89 1.29             
Age (in years)         <0.001         0.29 
0-64 1403 ref       1344 ref       
65-74  1293 0.96 0.81 1.13 0.59 1234 1.01 0.84 1.22 0.91 
75+  395 0.65 0.52 0.82 <0.001 372 0.82 0.62 1.08 0.15 
Charlson score         0.06         0.24 
0 1565 ref       1493 ref       
1 775 0.95 0.78 1.15 0.58 739 1.01 0.81 1.26 0.94 
2+ 751 0.80 0.66 0.96 0.02 718 0.84 0.67 1.05 0.12 
ASA score         0.002         0.32 
I/II 2416 ref       2335 ref       
III+ 651 1.75 1.23 2.49   615 0.89 0.72 1.12   
BMI          0.75           
<20 204 ref                
20-24 1168 0.99 0.72 1.38 0.97           
25-29 1202 1.01 0.73 1.39 0.97           
>30 483 0.89 0.62 1.27 0.52           
Clinical T category          0.05         0.52 
cT0-2 631 ref       619 ref       
cT3 2261 1.25 1.03 1.50 0.02 2231 1.14 0.91 1.41 0.25 
cT4 101 1.45 0.90 2.33 0.13 100 1.12 0.65 1.91 0.68 
Clinical N category         0.01         0.62 
cN0 1001 ref       950 ref       
cN1 1317 1.20 1.00 1.43 0.05 1275 1.10 0.89 1.35 0.37 
cN2 594 1.40 1.12 1.75 <0.001 579 1.18 0.91 1.53 0.22 
Unknown 179 0.87 0.63 1.22 0.42 146 1.17 0.76 1.79 0.48 
Clinical M category          0.86           
cM0 3010 ref                 
cM1 19 0.92 0.35 2.42             
Tumour location         <0.001         0.82 
Proximal-mid oesophagus 441 ref       421 ref       
Distal oesophagus 2048 0.67 0.53 0.85 <0.001 1956 0.96 0.72 1.26 0.74 
Gastro-oesophageal junction 602 0.55 0.42 0.73 <0.001 573 1.02 0.74 1.42 0.90 
Histological type         0.26           
Adenocarcinoma 2139 ref                 
Squamous cell carcinoma 562 1.26 1.02 1.56 0.03           
Other 62 0.93 0.54 1.60 0.789           
Not applicable 248 1.00 0.75 1.33 0.99           
Unknown 64 1.22 0.70 2.15 0.48           
Surgical approach         <0.001         <0.001 
TTO thoracic part open 520 ref       503 ref       
TTO thoracic part MI  1670 1.69 1.34 2.13 <0.001 1611 1.21 0.93 1.57 0.16 
THO open 654 0.29 0.22 0.37 <0.001 623 0.27 0.20 0.36 <0.001 
THO MI 238 0.43 0.31 0.59 <0.001 213 0.40 0.28 0.58 <0.001 
Annual hospital volume         <0.001         <0.001 
0-25 391 ref       362 ref       
26-50 1773 2.97 2.38 3.72 <0.001 1713 2.24 1.72 2.92 <0.001 
50+ 909 4.59 3.55 5.93 <0.001 875 3.637 2.717 4.87 <0.001 
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Supplementary table 6. Continued 
 
Retrieval of ≥15 LNs 
Univariable analysis  
Total Study population 
n=3091 
Multivariable analysis  
 n=2950 
Variables n OR 95% CI P-value n OR 95% CI P-value 
Year of resection         <0.001         <0.001 
2011 343 ref       321 ref       
2012 439 1.61 1.21 2.14 <0.001 413 1.538 1.11 2.13 0.01 
2013 462 1.74 1.31 2.32 <0.001 431 1.50 1.08 2.07 0.01 
2014 546 2.70 2.03 3.59 <0.001 526 2.17 1.57 2.99 <0.001 
2015 660 2.92 2.21 3.85 <0.001 633 2.24 1.63 3.08 <0.001 
2016 641 3.84 2.88 5.12 <0.001 626 2.52 1.81 3.50 <0.001 
BMI = Body Mass Index, ASA = American Society of Anaesthesiologists, THO = Transhiatal oesophagectomy, TTO = 
Transthoracic oesophagectomy, MI = Minimally invasive, nCRT = neoadjuvant Chemo radio Therapy 
 
 
Supplementary figure 1a and 1b: Percentage of postoperative complications (a) and 
severe postoperative complications (b) for subgroups based on the time interval 
between neoadjuvant chemo radiotherapy and surgery  
*Postoperative complications leading to reintervention, prolonged hospital stay (>21 
days) or dead 
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ABSTRACT  
BACKGROUND 
Radical gastrectomy is the cornerstone of the treatment of gastric cancer. For tumours 
invading the pancreas, en-bloc partial pancreatectomy may be needed for a radical resection. 
The aim of this study was to evaluate the outcome of gastrectomies with partial 
pancreatectomy for gastric cancer.  
METHODS 
Patients who underwent gastrectomy with or without partial pancreatectomy for gastric or 
gastro-oesophageal junction cancer between 2011-2015 were selected from the Dutch Upper 
GI Cancer Audit (DUCA). Outcomes were resection margin (pR0) and Clavien Dindo grade ³III 
postoperative complications and survival. The association between partial pancreatectomy 
and postoperative complications was analysed with multivariable logistic regression. Overall 
survival of patients with partial pancreatectomy was estimated using the Kaplan Meier 
method. 
RESULTS  
Of 1966 patients that underwent gastrectomy, 55 patients (2.8%) underwent en-bloc partial 
pancreatectomy. A pR0-resection was achieved in 45 of 55 patients (82% versus 85% in the 
group without additional resection, p=0.82). Clavien Dindo grade ³III complications occurred 
in 21 of 55 patients (38% versus 17%, P<0.001). Median overall survival [95% confidence 
interval] was 15 [6.8-23.2] months. For patients with and without perioperative systemic 
therapy, median survival was 20 [12.3-27.7] and 10 [5.7-14.3] months, and for patients with 
pR0 and pR1 resection it was 20 [11.8-28.3] and 5 [2.4-7.6] months, respectively. 
CONCLUSIONS 
Gastrectomy with partial pancreatectomy is associated with a pR0-resection rate of 82% but 
also with increased postoperative morbidity. It should only be performed if a pR0-resection is 
feasible. 
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INTRODUCTION 
The mainstay of curative treatment in gastric cancer is surgery. For patients with 
resectable gastric cancer of stage II or higher, neoadjuvant or adjuvant 
chemotherapy is recommended.1 A radical resection with tumour-negative 
resection margins (pR0 resection) is the most powerful predictor of survival.2,3  
In patients with advanced gastric cancer, en-bloc partial pancreatectomy may be 
needed to obtain a pR0 resection. However, the benefits of en-bloc partial 
pancreatectomy should be critically evaluated given the potential for increased 
morbidity. Routine splenectomy in patients who underwent a D2 gastrectomy 
did not lead to increased survival.4-6 In the past, a gastrectomy with 
pancreatosplenectomy was regarded as the standard of care for gastric cancer 
because it was believed that this would increase lymph node yield and thereby 
improve oncological outcomes. Since two large trials demonstrated that a D2 
lymphadenectomy with pancreatosplenectomy increases postoperative 
morbidity and mortality without any additional beneficial effects on survival,7-9 
current guidelines recommend a D2 resection without pancreatosplenectomy1. 
Nowadays, an en-bloc partial pancreatectomy is only indicated for tumours that 
invade the pancreas.1 
The aim of this study was to evaluate patient characteristics and outcomes of 
en-bloc partial pancreatectomies in patients undergoing gastrectomy for gastric 
cancer in the Netherlands between 2011 and 2015. 
 
METHODS  
STUDY POPULATION 
For this study, the database of the Dutch Upper Gastrointestinal Cancer Audit 
(DUCA) was used. Participation in this national audit registry is mandatory for all 
Dutch hospitals that perform oncological upper gastrointestinal surgery. All 
patients with gastric or oesophageal cancer who are scheduled to undergo 
resection are included.10 In this audit, patient, disease, and treatment 
characteristics are prospectively collected. Outcomes are registered until 30 
5
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days postoperatively or during hospitalisation. The completeness of cases 
registered in the DUCA approached 100% of patients registered in 2013.10 
Patients who underwent gastrectomy between 2011 and 2015 were selected 
from the DUCA (Figure 1). Patients with missing 30-day mortality status (n=27), 
date of birth (n=3) or type of procedure (n=4) were excluded. When a partial 
pancreatectomy was registered as an additional surgical procedure, details of 
patient, treatment and (long-term) outcome characteristics were provided by 
participating centres. Patients in whom the partial pancreatectomy was 
erroneously registered were excluded. For the comparison of patients with and 
without partial pancreatectomy, patients with other additional resections than 
pancreatectomy (e.g. splenectomy) were excluded. A separate analysis was 
executed to compare the occurrence of complications, in patients with partial 
pancreatectomy compared to patients with other additional (non-pancreas) 
resections. Another subgroup analysis was executed for patients with a pT4 
tumour, the occurrence of complications in patients with partial 
pancreatectomy was compared to the occurrence of complications in patients 
without a partial pancreatectomy. 
OUTCOMES 
The prevalence of partial pancreatectomy for gastric cancer was analysed for all 
individual hospitals. Characteristics and short-term outcomes of patients with a 
partial pancreatectomy were evaluated and compared with patients with no 
additional resection. Also, short-term outcomes were described for both groups: 
duration of hospital stay, Intensive Care Unit stay (ICU), resection margins 
(tumour negative: pR0, microscopically positive: pR1, macroscopically positive: 
pR2), postoperative complications, postoperative complications Clavien Dindo 
grade ³III (defined as a complication in combination with a reintervention, 
readmission to the intensive care unit/medium care unit or death), and 30-
day/in-hospital mortality.  
Disease-free and overall survival for patients with partial pancreatectomy were 
evaluated. The following subgroups within the partial pancreatectomy-group 
were compared: pR0 versus pR1 resections and perioperative systemic therapy 
versus no perioperative systemic therapy.  
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STATISTICAL ANALYSIS 
Characteristics and short-term outcomes of patients who underwent 
gastrectomy with and without partial pancreatectomy were compared using 
Mann-Whitney U test and Chi-square test, when appropriate. The association 
between partial pancreatectomy and complications was tested with univariable 
and multivariable logistic regression analysis. In the multivariable analysis, 
clinically relevant variables were added to the model, as well as the variables 
that were associated with complications (p-value <0.10 in univariable analyses). 
The association was tested for sex, age, Charlson comorbidity score11, American 
Society of Anaestesiologists (ASA) score, tumour location, cT category, and cN 
category. Overall survival was estimated using the Kaplan Meier method, and 
subgroups were compared with log-rank analysis. All analyses were performed 
using SPSS® version 24 (IBM, Armonk, NY, USA). 
 
RESULTS  
PATIENTS 
Between 2011 and 2015, 2 192 patients who underwent a gastrectomy for 
gastric cancer were registered in the DUCA database. Additional resections were 
performed in 177 of 2 192 patients (8.1%). An additional partial pancreatectomy 
was performed in 70 of 2 192 patients (3.2%) (Figure 1). The percentage 
gastrectomies with additional partial pancreatectomy varied between 0% and 
10% for the individual hospitals.  
Some 55 of 70 patients who underwent additional partial pancreatectomy were 
included in the analysis because all data could be retrieved from the patient 
charts. After exclusion of patients with incomplete data, 1 911 patients without 
additional resections served as the control group. 
Patient demographics are shown in Table 1. In 12 of 55 patients who underwent 
a partial pancreatectomy, the tumour was staged preoperatively as cT4. In all 55 
patients a preoperative CT scan was performed. In 15/55 (27%) patients 
preoperatively EUS was performed. 
In the additional pancreatectomy group, total gastrectomy was performed in 31 
patients (56%), and 34 patients received perioperative systemic therapy (62%) 
5
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(Table 2). Additional resections of adjacent organs/structures were performed in 
31 of 55 patients, including the spleen (n=25), mesocolon (n=7), liver (n=4), 
diaphragm (n=1) and other (n=10). Five of 27 patients with a distal 
pancreatectomy did not undergo a splenectomy. The remaining patients who 
underwent a splenectomy, n=3, underwent a wedge resection/pancreatic head 
resection. Upon pathological examination, 34 (62%) tumours were staged as pT4 
(Table 2).  
 
 
Figure 1. Patients who underwent gastrectomy between 2011 and 2015  
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Table 1. Patient- and disease characteristics of patients undergoing gastrectomy with 
no additional resection and with additional partial pancreatectomy 
        
  
Gastrectomy alone 
Gastrectomy plus 
partial  
pancreatectomy P value 
 n=1911 (97%) n=55 (2.8%)   
  n  % n  %     
Gender         0.53 
Man 1207 63% 37 67%   
Women 704 37% 18 33%   
Age (in years, median, IQR) 70 [62-77] 66 [57-73]     
Age (in groups)         0.04 
<65 years 605 32% 22 40%   
65-74 years 645 34% 23 42%   
>75 years 661 35% 10 18%   
Charlson score         <0.001 
0 835 44% 39 71%     
1 458 24% 7 13%     
2+ 618 32% 9 16%     
ASA score         0.71 
I-II 1293 68% 39 71%   
III+ 600 31% 16 29%     
Unknown 18 0.9% 0 0.0%   
Location of tumour         0.05 
Oesophageal-Gastric junction  69 3.6% 1 1.8%     
Fundus  134 7.0% 8 15%     
Corpus 556 29% 16 29%     
Antrum 771 40% 13 24%     
Pylorus 153 8.0% 9 16%     
Entire stomach 95 5.0% 3 5.5%     
Pouch 59 3.1% 3 5.5%   
Unknown 74 3.9% 2 3.6%     
cT-category          <0.001 
cT0-2 571 30% 2 3.6%   
cT3 763 40% 27 49%   
cT4 78 4.1% 12 22%     
cTx 457 24% 14 26%     
Missing 42 2.2% 0 0.0%   
cN-category          0.002 
cN-0 976 51% 15 27%   
cN+ 661 35% 28 51%     
cNx 231 12% 12 22%     
Missing 43 2.3% 0 0.0%   
cM-category          0.001 
cM-0 1774 93% 49 89%   
cM+ 24 1.3% 4 7.3%   
cMx 113 5.9% 2 3.6%   
TNM stage         n.a. 
Stage 0 33 1.8% 0 0.0%   
Stage I 392 21% 1 1.8%   
Stage II 637 35% 17 31%     
Stage III 138 8% 8 15%     
Stage IV 24 1.3% 3 5.5%   
Stage unknown 687 36% 26 47%   
IQR: interquartile range, ASA: American Society Anaesthesiologists, n.a.: not available 
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Table 2. Treatment characteristics of patients undergoing gastrectomy with no 
additional resection and with additional partial pancreatectomy 
        
  Gastrectomy alone 
Gastrectomy plus 
partial pancreatectomy P value 
 n=1911 (97%) n=55 (2.8%)   
  n  % n  %     
(Neo)adjuvant therapy         0.28 
None 779 42% 21 38%   
Neoadjuvant and adjuvant 688 37% 17 31%   
Adjuvant 44 2% 3 6%     
Neoadjuvant  358 19% 14 26%   
Urgency of surgery         0.01 
Elective 1833 96% 49 89%   
Urgent /Emergency 75 4% 6 11%   
  Unknown 3 0% 0 0%     
Curative/Palliative         n.a. 
Palliative  52 3% 3 6%     
Curative  1835 96% 51 93%   
  Prophylactic resection 13 1% 0 0%   
Unknown 11 1% 1 2%     
Type of resection         0.03 
Total gastrectomy 803 42% 31 56%   
Partial gastrectomy 1108 58% 24 44%     
Procedure         n.a. 
Open 1331 70% 44 80%     
MI abdomen  489 26% 5 9%     
MI abdomen converted 56 2.9% 6 11%     
MI thorax  1 0.1% 0 0.0%     
MI thorax and abdomen 14 0.7% 0 0.0%   
MI thorax and abdomen 
converted 3 0.2% 0 0.0%     
Unknown 17 1% 0 0%   
Reconstruction         n.a. 
No reconstruction 36 2% 1 2%   
Gastric tube 17 1% 1 2%     
Coloninterponate 2 0% 0 0%     
Jejunuminterponate 39 2.0% 0 0.0%   
Oesophagojejunostomy 776 41% 30 55%   
Gastro-enterostomy 1007 53% 22 40%   
Other 9 1% 1 2%     
Unknown 25 1% 0 0%     
Additional resections other than 
pancreatic     31 56%   
Spleen (intentional)     25 45%   
Diaphragm     1 1.8%   
Liver     4 7.2%     
Mesocolon     7 13%     
Other     10 19%     
Pathological T-stage         <0.001 
pT0-2 728 38% 3 6%     
pT3 753 39% 17 31%     
pT4 371 19% 34 62%     
pTx 29 2% 1 2%     
Unknown 30 2% 0 0%     
             
Annual volume in the hospital or 
resection         0.20 
0-19 resections 1217 64% 37 67%     
20-39 resections 481 25% 16 29%     
40 or more resections 213 11% 2 4%     
       
MI: minimally invasive, n.a.: not available 
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OPERATIONS 
Nine of 55 patients (16%) underwent pancreatoduodenectomy, 27 (49%) distal 
pancreatectomy and 19 (35%) a wedge resection (Table 3). In the vast majority 
(n=52) the indication for partial pancreatectomy was direct tumour ingrowth 
into the pancreas. Some 30 of 55 resections were performed by a surgeon with 
experience in pancreatic surgery. In 6 (11%) procedures, the surgical team was 
changed for the pancreatectomy.  
A pR0 resection was achieved in 45 of 55 patients undergoing gastrectomy with 
partial pancreatectomy (82%) (Table 4). This was not statistically significant 
different from the patients who underwent a gastrectomy without additional 
resection (1 617 of 1 911, 85%, p=0.82). 
 
 
 
 
 
Table 3. Details of the partial pancreatectomies: treatment characteristics  
 
  Total 
Pancreato-
duodenectomy 
Distal pancrea-
tectomy 
Minimal/ 
wedge 
resection 
      n % n % n % 
 55   9 16% 27 49% 19 35% 
Indication pancreas resection                 
Tumour growth in pancreas 52 95% 9 100% 25 93% 18 95% 
Intraoperative injury pancreas 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Lymph node dissection 3 5.5% 0 0.0% 2 7.4% 1 5.3% 
Other  0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Type of surgeon                 
Surgeon with expertise in 
pancreas surgery* 30 55% 7 78% 14 52% 9 47% 
Surgeon with expertise in upper 
GI surgery 25 46% 2 22% 13 48% 10 53% 
Change in surgical team                 
No 49 89% 8 89% 24 89% 17 90% 
Yes, preoperative 2 3.6% 0 0.0% 1 3.7% 1 5.3% 
Yes, intraoperative 4 7.3% 1 11% 2 7.4% 1 5.3% 
Type of reconstruction                 
No 45 82% 3 33% 24 89% 18 95% 
Pancreatico-jejunostomy, hepato-
jejunostomy and gastro-jejunostomy 8 15% 6 67% 2 7.4% 0 0.0% 
Other  2 3.6% 0 0.0% 1 3.7% 1 5.3% 
Drain in pancreatic region (intraoperative)             
Yes 16 29% 4 44% 5 19% 7 37% 
No 39 71% 5 56% 22 82% 12 63% 
Drain in pancreatic region (postoperative, percut.)           
Yes 45 83% 7 78% 23 85% 15 83% 
No 9 17% 2 22% 4 15% 3 17% 
* in the last year 
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Table 4. Short-term outcomes of patients with no additional resections versus patients 
with additional partial pancreatectomies 
       
  
Gastrectomy alone 
Gastrectomy plus 
partial  
pancreatectomy P value 
 n=1911 (97%) n=55 (2.8%)   
  Mean Median [IQR] Mean Median [IQR]   
Hospital stay (days) 14 9 [7-13] 23 14 [10-20] <0.001 
IC stay (days) 1.8 0 [0-1] 1.8 1[0-2] >0.05 
  n % n % P value 
Intra-operative complication 73 3.8% 1 1.8% 0.44 
Postoperative complication 703 37% 33 60% <0.001 
Reintervention 279 15% 20 36% <0.001 
Radiological 83   11       
Endoscopic 38   3       
Re-operation 211   10       
In-hospital and 30-day mortality 101 5.3% 4 7.3% 0.52 
Complications Clavien Dindo ³III  332 17% 21 38% <0.001 
Resection margins         0.82 
R0 Microscopic radical 1617 85% 45 82%   
R1 Microscopic irradical 202 11% 7 13%     
R2 Loco regional residual tumour 25 1.3% 1 1.8%   
Not applicable 21 1.1% 0 0.0%     
Unknown 46 2.4% 2 3.6%     
Multivariable analysis OR 95% CI   P value 
Association with complications Clavien 
Dindo ³III *         <0.001 
No additional resection 1.00       
Additional partial pancreatectomy 3.13 1.76-5.59     
* Adjusted for age, sex, Charlson comorbidity score11, ASA score, location tumour, type of resection 
(partial/total gastrectomy)  
IC: Intensive Care, R0: tumour negative resection margins, R1: microscopically tumour positive resection margins, 
R2: macroscopically tumour positive resection margins, IQR: inter quartile range, CI: confidence interval, ASA: 
American Society Anaesthesiologists 
 
COMPLICATIONS 
In the partial pancreatectomy group, there were relatively more patients with 
postoperative complications, n=33 (60%) versus n=703 (37%, p=<0.001) (Table 
4). Also, Clavien Dindo grade III and higher complications occurred more 
frequently in the partial pancreatectomy group: in 21 (38%) patients versus 332 
(17%) patients (<0.001). An additional partial pancreatectomy was 
independently associated with a complication with Clavien Dindo grade III or 
higher (OR [95% CI]: 3.28 [1.85-5.82] (Table 4). Postoperative pancreatic fistulas 
grade B and C according to the International Study Group on Pancreatic Surgery 
definition were observed in 9 (16%) and 2 (3.6%) patients, respectively12 (Table 
5). Clavien Dindo grade III or higher occurred in 42/172 (24%) patients with other 
additional (non-pancreas) resections, this was not significantly different from 
the partial pancreatectomy group (38%).  For the subgroup of patients with a 
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pT4 tumour, 332/1 911 (17%) patients in the gastrectomy only group had a 
Clavien Dindo grade III or higher complication versus 4/24 (17%) of patients in 
the partial pancreatectomy group (p=0.93). Combined in-hospital and 30-day 
mortality was 7.3% (4 of 53) in patients with partial pancreatectomy versus 5.3% 
in patients without additional resections (101 of 1 911, p=0.52) (Table 4). 
 
Table 5. Details of the partial pancreatectomies: treatment characteristics  
 
  Total 
Pancreato-
duodenectomy 
Distal 
pancrea-
tectomy 
Minimal/ 
wedge 
resection 
      n % n % n % 
 55   9 16% 27 49% 19 35% 
Postoperative complications                 
No 22 40% 2 22% 10 37% 10 53% 
Yes 33 60% 7 78% 17 63% 9 47% 
POFP *                 
No POPF, no biochemical leakage 39 71% 6 67% 18 67% 15 79% 
No POPF, but biochemical leakage  5 9.1% 1 11% 4 15% 0 0.0% 
Yes, grade B 9 16% 2 22% 5 19% 2 11% 
Yes, grade C 2 3.6% 0 0.0% 0 0.0% 2 11% 
Complications Clavien Dindo ³III                 
No 34 62% 3 33% 19 70% 12 63% 
Yes 21 38% 6 67% 8 30% 7 37% 
30-day/in-hospital mortality               
No 51 93% 8 89% 26 96% 17 90% 
Yes 4 7.3% 1 11% 1 3.7% 2 11% 
* according to the definition of Bassi&ISGPS, Surgery 2016) 
POPF: postoperative pancreatic fistula 
 
 
SURVIVAL 
Median follow up of the patients with partial pancreatectomy was 42 [95% CI: 
36.1-47.9] months. Median overall survival was 15 [6.8-23.2] months (Figure 2a), 
and median disease-free survival was 13 [7.6-18] months (Figure 2b). One-, two-
, and three-year survival rates were 56%, 38%, and 31%, respectively. In patients 
in whom an pR0 resection was obtained, median overall survival was 20 [11.8-
28.3] months and for patients with an pR1 resection 5 [2.4-7.6] months (Figure 
2c). For patients treated with perioperative systemic therapy, median overall 
survival was 20 [12.3-27.7] months versus 10 [5.7-14.3] months for patients 
without perioperative systemic therapy (Supplementary Figure 1).  
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Figure 2a. Overall survival of patients with partial pancreatectomy  
 
 
Figure 2b. Disease-free survival of patients with partial pancreatectomy  
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Figure 2c. Overall survival of patients with partial pancreatectomy (pR0 versus pR1). 
 
DISCUSS ION 
A gastrectomy with en-bloc partial pancreatectomy was rarely performed in the 
Netherlands between 2011 and 2015. The intra-operative indication for partial 
pancreatectomy for gastric cancer was usually direct tumour ingrowth in the 
pancreas. In these patients, additional partial pancreatectomy was associated 
with an R0-resection rate of 82% but an increased risk for complications.  
 
This study gives a unique overview of the national outcome of patients with 
gastric cancer for whom an additional partial pancreatectomy was performed 
during gastrectomy. Most studies on additional resections evaluated different 
multivisceral resections as one group.4,13,14 The national audit database enabled 
the identification of patients who underwent an additional partial 
pancreatectomy during a gastrectomy. Because multiple centres participated, 
we could evaluate the outcomes of a reasonable large cohort of patients treated 
5
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with gastrectomy with partial pancreatectomy in the Netherlands in the period 
2011-2015.  
 
One of the factors associated with improved survival was a radical (pR0) 
resection. Previous studies also showed a decreased survival in patients in whom 
an R0 resection could not be achieved.13-16 In the present study, the percentage 
of R0 resections was comparable between the group of patients with partial 
pancreatectomy and without additional resections (82% versus 85%, p=0.82). In 
the current literature, the percentages R0 resections after multivisceral 
resections range from 38% to 100%.17 Tran et al. reported an R0 resection rate 
of 100% in 34 patients after additional partial pancreatectomy.18  
 
In this study, only 22% of patients with an additional partial pancreatectomy had 
a cT4 tumour, and only 62% had a pT4 tumour at pathological examination. 
Ideally, a partial pancreatectomy should only be performed in actual T4 tumours. 
In other cohorts with multivisceral resections, low percentages of pT4 tumours 
have been reported as well (14-80%).17 The low percentage of patients with a 
cT4 tumour shows that there is a discrepancy in the diagnostic assessment of 
tumour stage with the intraoperative assessment. In order to distinguish a cT3 
tumour from a cT4 tumour in the preoperative phase, endoscopic ultrasound 
(EUS), multidetector row computed tomography (MDCT) and magnetic 
resonance imaging (MRI) are preferred imaging methods.19 Also, when it is not 
known whether there is ingrowth in the pancreas, it may be recommended to 
perform an EUS, MDCT or MRI. The results of the DUCA showed that in only 27% 
of patients EUS is used for diagnostics. The use of MDCT and MRI were not 
registered in the DUCA.  
The low percentage of patients with a pT4 tumour shows that there is a 
discrepancy in the intraoperative assessment of tumour stage with the actual 
tumour stage as seen in pathological examination. Intraoperatively frozen 
section biopsy could be used to assess the resection margin and to decide 
whether an additional pancreatectomy is needed. However, dissecting through 
the tumour plane violates the principle of surgical oncology i.e. en bloc 
resection.  
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In the present study, patients treated with perioperative systemic therapy had 
better survival. Selection bias might partly explain this difference. A recent study 
on the use of perioperative therapy in Dutch patients showed that older patients 
and patients with a higher ASA-score had a lower probability for initiation of 
perioperative therapy.20 In the present cohort, the patients who were not 
treated with preoperative therapy might have been frail patients who were unfit 
for undergoing preoperative therapy. These patients are probably more likely to 
die which could have influenced the survival of this group. Furthermore, 
exclusion for resection of patients that are progressive during perioperative 
therapy could have occurred. These data are not available in our surgical 
database. However, based on our results, it may be wise to take the prognosis 
of patients without perioperative systemic therapy into account. Patients who 
are not eligible for perioperative systemic therapy may also not benefit from a 
partial pancreatectomy during gastrectomy. 
Since the MAGIC trial, perioperative chemotherapy for gastric cancer gained 
importance.21 Since partial pancreatectomies are associated with high 
complication rates, it is possible that patients who undergo a partial 
pancreatectomy cannot be treated with adjuvant therapy. In the Dutch guideline 
perioperative chemotherapy is recommended for patients with stage >1 gastric 
cancer and are fit enough to undergo chemotherapy.1 This study showed that 
38% of patients in the pancreatectomy group were not treated with neoadjuvant 
therapy neither adjuvant therapy. A recent Dutch study showed that patients 
with postoperative complications had a threefold increased likelihood of not 
receiving adjuvant therapy.22 It might thus be prudent to focus on a more intense 
neoadjuvant systemic therapy to patients in whom a partial pancreatectomy is 
considered. In the future, the results of the CRITICS-II may help in choosing the 
best neoadjuvant therapy. The CRITICS-II trial aims to optimize preoperative 
treatment by comparing treatment regimens: (1) chemotherapy, (2) 
chemotherapy followed by chemoradiotherapy, and (3) chemoradiotherapy.23  
 
The performance of additional partial pancreatectomy and splenectomy in order 
to retrieve more lymph nodes abandoned in the past because of its high 
postoperative morbidity.8,9  
The current study showed high postoperative morbidity in gastrectomy patients 
with partial pancreatectomies. Complications occurred in 60% of patients, and 
5
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complications Clavien Dindo grade III and higher in 38% of patients. Tran et al. 
reported also a significantly higher percentage of complications Clavien Dindo 
grade III and higher for patients with gastric cancer undergoing a gastrectomy 
with partial pancreatectomy versus gastrectomy without multivisceral resection 
(33% versus 17%)18,24. These results are comparable to pancreatic cancer 
patients: a recent study reported the postoperative outcomes of partial 
pancreatectomies for pancreatic cancer in the Netherlands; they showed that 
30% of patients had a complication Clavien-Dindo grade III of higher.25  
 
The survival rates in our study were comparable to those reported in a recent 
study by Mita et al. evaluating additional partial pancreatectomies for gastric 
cancer. They reported a 1-year survival rate of 62% and a 3-year survival rate of 
35% (versus respectively 56% and 31% in the present cohort).26 Likewise, the 3-
year survival rates of patients with pT4 gastric cancer who underwent 
multivisceral resections are comparable with the outcomes in our cohort27. 
Compared to the 2-year survival rate of all potentially curative gastric cancer 
patients in the Netherlands the survival of this cohort is poor.28 Van Putten et al. 
reported national 2-year survival rates varying between 38% and 50%, 
depending on the variation in surgical treatment probability between hospitals.  
 
A limitation of this study was that a pancreatectomy for gastric cancer was not 
common and not all hospitals in the Netherlands participated in the data 
collection for patients with partial pancreatectomy. All hospitals have been 
contacted to participate. The hospitals that did not participate indicated that the 
reason was of a logistical nature (no time). A second limitation was that survival 
information was not available for the patients with gastrectomy only. Another 
limitation was that it was not possible to determine the independent influence 
of individual parameters on survival because the number of patients undergoing 
partial pancreatectomy was relatively limited. Because of this limited number of 
patients, no conclusions could be drawn regarding the different types of 
pancreatectomies.  
 
In conclusion, the present study showed that a gastrectomy in combination with 
a partial pancreatectomy might be considered as a valid curative treatment 
option for gastric cancer. The reported morbidity and mortality after partial 
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pancreatectomy for gastric cancer are at least comparable to rates after partial 
pancreatectomy for pancreatic cancer. Therefore, despite the high morbidity, it 
may be worthwhile to perform a partial pancreatectomy in patients with gastric 
cancer when the tumour is directly invading into the pancreas. It should 
probably be reserved for patients with a T4 tumour in whom an R0 resection is 
feasible. Preoperative and intraoperative selection of patients for additional 
partial pancreatectomy might be the key to success.  
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Supplementary figure 1. Overall survival perioperative systemic therapy versus no 
perioperative systemic therapy in patients with additional partial pancreatectomy  
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ABSTRACT  
BACKGROUND 
Clinical auditing is an emerging instrument for quality assessment and improvement. 
Moreover, clinical registries facilitate medical research as they provide ‘real world’ data. It is 
important that entered data is robust and reliable. The aim of this study was to describe the 
evolving procedure and results of data verification within the Dutch Institute for Clinical 
Auditing (DICA). 
METHODS 
Data verification performed on several (disease-specific) clinical registries between 2013-
2015 were evaluated. Sign-up, sample size and process of verification were described. For 
each procedure, hospitals were visited by external data managers to verify registered data. 
Outcomes of data verification were completeness and accuracy. An assessment of the quality 
of data was given per registry, for each participating hospital. Using descriptive statistics, 
analyses were performed for different sections within the individual registries.  
RESULTS 
Seven of the 21 registries were verified implying 174 visits to hospital departments. A step-
by-step description of the data verification process was provided. The completeness of data 
in the registries varied from 97.3-99.4 per cent. The accuracy of data varied from 86.6-97.0 
per cent. Most discrepancies were observed in postoperative complications (0.7-7.5 per cent) 
and ASA classification (7.5-11 per cent). Data quality was assessed to be ‘sufficient’ in 145 of 
174 (83 per cent) hospital departments. 
CONCLUSION 
Data verification revealed that the data entered in the observed DICA registries were rather 
complete and accurate. 
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INTRODUCTION 
Clinical auditing is a predominant instrument for quality assessment and 
improvement in healthcare which can help to improve patient outcomes1-4. 
Moreover, clinical registries facilitate evidence-based medical research as they 
provide ‘real world’ data of patients. In 2009, the nationwide Dutch ColoRectal 
Audit (DCRA) was initiated by the Association of Surgeons of the Netherlands5. 
Together with the establishment of other clinical registries, this has led to the 
foundation of the Dutch Institute for Clinical Auditing (DICA) in 20114-7. 
Nowadays, 21 clinical registries are facilitated by DICA in which already over 500 
000 patients had been registered by 20168. The clinical registries are disease-
specific. Sixteen of 21 registries are surgical registries. In the Netherlands, all 
hospitals obligatory participate in these registries. Annually, a set of hospital-
specific outcomes are published on a public website, though only after approval 
of the board of each hospital9.  These outcomes are used by policymakers, health 
insurance companies, and patient federations to assess hospital performance.  
 
A prerequisite for using this data for comparison of quality between hospitals is 
that the entered data is robust and reliable. The validity of the entered data is 
essential because it is used for medical and epidemiological outcome research. 
A recent validation study by Cundall-Curry et al.10 emphasizes the need for 
checking the uploaded data to a national registry. Another validation of data 
quality in a national registry has been described by Linder et al.11, who showed 
that the database of the registry contained reliable data. A systematic approach 
for data verification in nationwide clinical registries has not been described. This 
study aimed to describe the procedure of data verification used by DICA, as well 
as the results of each procedure of data verification and the lessons learned from 
each procedure. 
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METHODS  
This was a retrospective, descriptive study on data verification in nationwide 
registries in the Netherlands. This is a high-income country in Western-Europe 
with approximately 17 million inhabitants. Healthcare insurance is obligatory. 
Most secondary health care is provided in public hospitals. Secondary health 
care was provided in 71 hospitals in 2018. Since 2009 several nationwide 
registries have been set up by what is now known as Dutch Institute for Clinical 
Auditing (DICA). In this study data verifications performed between 2013 and 
2015 were eligible. 
 
DATA ENTRANCE IN THE REGISTRIES 
Medical professionals have been responsible for the correct registration of their 
data in the registries. At the start of DICA, the majority of surgeons recorded the 
data themselves. Today, the recording of data is performed by medical 
specialists, trainees, physician assistants, data managers, research- and 
administrative nurses. The medical specialist remains the final manager 
responsible for the quality of the data entered. Data are either uploaded in a 
web-based system or delivered by the hospitals as a badge, at least once a year 
but preferably more often to facilitate quality improvements. Hospitals adhere 
to annual deadlines to deliver all data. 
 
ORGANISATIONAL STRUCTURE OF REGISTRIES IN DICA  
Each registry is led by a clinical audit board, consisting of medical professionals 
mandated by their professional association. The registries also have a scientific 
committee, consisting of representatives of the participating centres. Together 
with the scientific bureau of DICA, this scientific committee defines valid quality 
indicators, coordinates outcomes research and is responsible for the quality of 
the data.  
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PROCEDURES TO MAINTAIN THE QUALITY OF REGISTERED DATA  
In each clinical registry, the reliability of data is improved and verified in four 
ways. Verification systems are integrated in the web-based survey. Therewith 
the registrar receives direct feedback on erroneous, missing or unlikely data 
items while entering the data.  
DICA uses a signalling list which reports the erroneous and missing data of all 
patients in a hospital. Clinical experts receive a weekly updated report with their 
outcomes for the use of clinical auditing. This report also provides the number 
of registered patients and the completeness of the data, which can help to 
identify errors early. Finally, external data verification can contribute to assess 
the reliability of the data. 
 
EXTERNAL DATA VERIFICATION 
A first pilot project on external data verification was initiated by the Association 
of Surgeons of the Netherlands in 2014. This initiation has led to the formation 
of a data verification department at DICA which coordinates the procedures of 
external verification. An independent data verification committee was assigned, 
which consists of medical experts, a biostatistician, a deputy of the Dutch Health 
Care Inspectorate (IGZ) and a deputy from the Dutch patient federation. Since 
the first procedure in 2014, the procedure of external data verification has been 
optimised based on experience gained during previous procedures.  
 
The external data verification is done by a third trusted party to guarantee the 
privacy of patients, Medical Research Data Management (MRDM, Deventer, the 
Netherlands). MRDM is NEN 7510:2011 and ISO 27001:2013 certified and 
complies to privacy regulations in the Netherlands12. 
 
PILOT VERIFICATION PROJECT 
In the pilot project the longest existing registries of DICA, the colorectal (DCRA) 
and upper gastrointestinal cancer audit (DUCA) were verified. In these 
verifications, respectively 18 and 20 variables were verified in all hospitals that 
participated in the registry. Per hospital the data of 20 patients was verified. 
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With the experiences from the pilot project the data verification procedure has 
been modified and was continued for other registries. 
REGULAR DATA VERIFICATIONS 
Patient and variable selection for verification 
The scientific committee set selection criteria for the type of patients that should 
be included in the data verification and selects the variables to be verified.  
Sign up  
Data verification was performed for each registry individually. All participating 
hospitals of the registry received an invitation to participate by e-mail. In the 
invitation letter the procedure, practical requirements, and privacy of data 
verification were explained. Participation in data verification was voluntary and 
free of costs for the hospitals, although results were reported to the National 
Health Care Institute (Zorginstituut Nederland), which was responsible for public 
transparency of hospital-specific quality information in the Netherlands.   
Sample sizes 
Since previous studies were lacking, the sample sizes were arbitrarily set in a 
consensus meeting with the data verification committee including a 
biostatistician. The preferred number of hospitals to verify for each registry was 
set at 15. The number of patients to verify in each hospital was based on a 
percentage of the annual hospital volume or a set number of patients with a 
minimum of 30 patients. 
The process 
The process of data verification in hospitals was executed manually by trained 
employees. They were all trained in both the verification procedure and the 
medical content by DICA. For each hospital, the completeness of the registration 
was evaluated, and the accuracy of data was assessed.  
Completeness of the registry 
For the verification, the dataset of a complete registration year was used. This 
dataset was used for clinical auditing, to calculate the quality indicators for each 
hospital. To verify the completeness of the registry, hospitals were asked to 
provide a patient list derived from their administrative system. A sample of the 
list was compared with the registered patients in the registry. Patients that were 
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on the patient list but who were missing in the registry were registered as 
‘absent’. 
Different types of patient lists were used. In the first verified registries, a patient 
list derived from the nationwide network and registry of histopathology and 
cytopathology in the Netherlands (PALGA, 13) or a patient list with specific 
diagnose-treatment-codes (DBC) as recorded by the hospital administration and 
insurance companies was used. These DBC codes are used in the Netherlands 
for reimbursement of all costs of delivered care and are comparable with 
International Classification of Diseases (ICD) codes.  
Not all methods mentioned above, proved to be applicable for every hospital 
since the PALGA system was not used in all hospitals and the DBC codes in some 
cases could differ between hospitals. Therefore, it was decided that in the 
studied verifications hospitals had the opportunity to choose a type of patient 
list that fit the aim of data verification and matched their system.  
 
Accuracy of the data 
To assess the accuracy of the data, the original data derived from the electronic 
patient records was compared with the data registered in the registry. For the 
hospitals, it was not possible to revise this data before data verification.  
To register the accuracy of data, a web-based survey was used. In this survey, 
the selected items to be verified were prefilled based on the registered data. 
Each variable was assessed as ‘not discrepant’, ‘discrepant’, missing data was 
assessed as ‘discrepant’. When discrepancies were observed, the correct 
information from the source data and an additional explanation of discrepancy 
had to be noted. 
At least, the variables needed to calculate two of the quality indicators were 
verified in all registries, including ‘the percentage of patients with severe 
complications’ and ‘the percentage of patients who died within 30 days after 
surgery’. For ‘severe complications’, different definitions are used among 
registries. Mostly, the definition was ‘complications leading to a prolonged 
hospital stay, a re-intervention or death’. Another reason to verify a variable was 
the use of a variable in the case-mix correction of outcome indicators i.e. ASA 
(American Society of Anesthesiologists)-score, which is a scale of the pre-
operative fitness of patients5.  
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ANALYSIS OF THE DATA VERIFICATION AND RESULTS 
In the process of analysing the data, an assessment of the observed 
discrepancies was done by an independent data manager and a medical 
researcher of DICA. Data of different hospitals were analysed separately. 
Completeness and accuracy of the data were assessed with descriptive statistics 
for different sections within the registries. Analyses were performed using IBM 
SPSS Statistics version 23.0® (Armonk, New York, United States of America). 
After the evaluation of the discrepancies of each hospital by the data manager 
and medical researcher, the results of this evaluation were reported to the 
hospitals. In a hear and rehearse procedure it was possible for each hospital to 
give a response on the detected discrepancies. The independent verification 
committee has the final say.  
 
A composite measure was defined for the conclusion of ‘sufficient quality’ or 
‘insufficient quality’. Table 1 shows the criteria for the conclusion of ‘insufficient 
quality’ in one of the procedures. For some other procedures small adjustments 
in thresholds were made due to a low number of patients or a low number of 
events.  
The conclusion about the quality of the data and an anonymous summary report 
were communicated to the hospitals, to learn from the discrepancies and to help 
them optimising their procedure of registration. The results were also reported 
to the National Health Care Institute.  
 
 
Table 1. Criteria  
 
 
 
Factors which lead to the label ‘insufficient quality’ 
• Completeness: Of all patients who met the inclusion criteria, more than 2 per cent (at least 
2 patients) has not been registered. 
• Mortality: Of all patients who met the inclusion criteria, one or more patients died but were 
not registered at all or were not registered as ‘death’.   
• Complications: Of all patients who have had a complication, the complication was not 
registered in more than 5 per cent (at least 3 patients) of the patients.  
• Reinterventions: Of all patients who have had a reintervention the reintervention was not 
registered in more than 5 per cent (at least 3 patients) of the patients.  
• Readmission: Of all patients who have had a readmission, the readmission was not 
registered in more than 5 per cent (at least 3 patients) of the patients. 
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RESULTS  
 
Since 2014, 7 of the 21 registries were verified individually. Information 
about the different verifications is shown in Table 2 and 3.  
PILOT VERIFICATION PROJECT 
In the pilot procedure, in all hospitals that signed up (n=77 and n=28), 18-20 
variables and all patients eligible in 2013 were verified. This procedure 
turned out to be very time consuming, which was logistically challenging and 
financially unfavourable. Therefore, in the following verifications, a more 
limited set of variables was used. To limit the number of hospitals, a limit of 
15 hospitals per registry was set, these hospitals were randomly selected by 
the third trusted party MRDM. 
 
Table 2. Characteristics and results of the pilot verifications in 2013  
  Pilot 
  
Dutch Colo Rectal 
Audit 
Dutch Upper GI Cancer 
Audit 
Registry year of verification 2013 2013 
Validation         
Variables verified (n) 20 18 
Hospitals that signed up (n and per cent of 
total)^ 78 (88%) 78 (88%) 
Hospitals verified (n) 77 28 
Patients verified per hospital (n) 20 20 
Completeness         
Missing patients (n and % of total patients 
following inclusion criteria)* 271 (2.8%) 10 (0.8%) 
Missed death patients (n) 24 1 
Missed patients with severe complications (n) 55 2 
Accuracy         
Total patients in sample (n) 1570 560 
Discrepant deaths (n and per cent of sample 
patients)  5 (0.3%) 0 (0%) 
Discrepant  complications (n and per cent of 
sample patients) 117 (7.5%) 17 (3.0%) 
Discrepant  reinterventions (n and per cent of 
sample patients) 29 (1.8%) 9 (1.6%) 
Discrepant  ASA score (n and per cent of 
sample patients) 134 (8.5%) 64 (11%) 
Discrepant radicality (n and per cent of 
patients in the selected sample ) 4 (1.0%) 11 (4.7%) 
Objections           
Objections (number of hospitals) 22 16 
^ The sign up of the Dutch ColoRectal Audit and Dutch Upper GI Cancer Audit was together. 
* Verification of completeness for DSCA and DUCA was done for all registered patients.  
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REGULAR VERIFICATION PROJECT 
Patient and variable selection for verification 
The verified variables that were chosen differed between registries, all 
verified variables are shown in Table 2 and 3.  
Sign up 
In the included 7 data verification procedures, an average of 71 per cent of 
hospitals signed up for verification, which varied between registries from 60 
to 88 per cent.  
In 2 verifications, some hospitals withdrew their sign-in after selection 
because they were not able to comply with the conditions for verification (no 
time and priority for preparation). In 2 other verifications, less than 15 
hospitals signed up. In 2015, an online survey was held to investigate the 
reasons to refrain from signing in. The most mentioned reasons included that 
centres would have signed-in but had forgotten, were too late or 
miscommunicated (in 8 out of 21 answers), lack of time (in 4 out of 21 
answers) and disagree or not comply with the legality of the procedure of 
verification (in 4 out of 21 answers).  
Sample size 
The number of patient records that were verified, varied per registry, from 
281 to 1570 (median: 388).  
Completeness of the registry 
The percentage of non-registered patients varied from 0.6 -2.7 per cent 
between registries. Details on these ‘absent patients’ are shown in Table 2 
and 3.  
The accuracy of the data 
Discrepancies of the verified items are shown in Table 2 and 3. Most 
discrepancies were observed in postoperative complications and ASA score. 
In 3.0 -7.5 per cent of the total number of patients in the sample, the 
postoperative complication registration was discrepant. The occurrence of a 
complication was wrongly registered or wrongly not registered, and in 8.5-
11.4 per cent of the total number of patients in the sample, an incorrect ASA 
score was registered or missing.  
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Results of the procedures 
Of 174 data verification processes performed, in 29 the quality of data was 
assessed as ‘insufficient’ according to the criteria. The number of hospitals 
which responded to the results or lodged an objection varied between 5 and 
22 per registry (Table 2 and 3).  
 
Table 3. Characteristics and results of the verifications between 2014-2015 (some 
cells are empty because this information was not available). 
  
Dutch 
Lung 
Cancer 
Audit 
Dutch Audit 
for Carotid 
Interventions 
Dutch 
Surgical 
Aneurysm 
Audit 
Dutch 
Audit for 
Treatment 
of Obesity 
Dutch 
Pancreatic 
Cancer 
Audit 
Registry year of verification 2014 2015 2015 2015 2015 
Validation           
Variables verified (n) 17 6 9 9 13 
Hospitals that signed up (n and per 
cent of total)^ 29 (67%) 36 (68%) 39 (65%) 12 (60%) 12 (63%) 
Hospitals verified (n) 15 13 14 12 12 
Completeness           
Patients verified per hospital (n) ± 26  ± 22 ± 21 35 30 
Missing patients (n and per cent of 
total patients following inclusion 
criteria)* 
5 (0.6%) 2 (0.7%) 5 (1.7%) 5 (1.2%) 2 (0.6%) 
Missed death patients (n) 0 0 0 0 0 
Missed patients with severe 
complications (n) 3 1 2 1 1 
Accuracy           
Total patients in sample (n) 388 281 298 420 358 
Discrepant deaths (n and per cent of 
sample patients)  0 (0%) 2 (0.7%) 0 (0%) 0 (0%) 0 
Discrepant  complications (n and per 
cent of sample patients) 
 13 (4.6%) 22 (7.4%)   
Discrepant severe complications (n 
and per cent of sample patients)** 216 (3.3%) 
    3 (0.7%) 18 (5.0%) 
Discrepant  reinterventions (n and 
per cent of sample patients) 
 0 (0%) 0 (0%) 3 (0.7%)   
Discrepant readmissions (n and per 
cent of sample patients) 
   6 (2.0%)   
Objections             
Objections (number of hospitals) 6   7   
* Verification of completeness for these registries was done for all patients in the sample 
** For the Dutch Lung Cancer Audit the percentage is computed as percentage of discrepant registries of the 
total complications that could be registered for sample patients. 
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LESSONS LEARNED FROM THE RESULTS OF EACH VERIFICATION 
An overview of the derived lessons is shown in Table 4. As concluded from 
discussions with the registrars, most common discrepancies in the 
verifications seemed to be caused by unclear definitions and descriptions of 
variables. This was seen in 6 out of 7 verifications. The variables with the 
most discrepancies included M-stage of the tumour, ASA score, the urgency 
of surgery, intra-operative complications, postoperative complications, 
reinterventions, and the number of days in the Intensive Care Unit. 
Moreover, incorrect inclusion and incorrect exclusion of patients in the 
registries was observed. 
 
Table 4. Lessons learned from the verifications 
  
Dutch 
Colo 
Rectal 
Audit 
(pilot) 
Dutch 
Upper 
GI 
Cancer 
Audit 
(pilot) 
Dutch 
Lung 
Cancer 
Audit 
Dutch 
Audit for 
Carotid 
Interven-
tions 
Dutch 
Surgical 
Aneurysm 
Audit 
Dutch 
Audit for 
Treatment 
of 
Obesity 
Dutch 
Pancreatic 
Cancer 
Audit 
Lessons derived for the procedure of data verification             
More extensive training for verification 
employees needed 
      x 
Patient list not suitable   x x x x x 
Selection of hospitals: too many hospitals verified x x      
Selection of variables: too many variables 
verified x x 
     
Time consuming to evaluate the completeness of 
all patients instead of a sample 
  x     
Selection of patients: too little patients verified    x x x  
Privacy of patient records at the procedure was 
complex x x 
     
Criteria for 'sufficient/insufficient' need to be set 
before start of data verification x x 
     
Criteria for 'sufficient/insufficient' need to be 
changed x x x 
    
Criteria for 'sufficient/insufficient' are without 
nuance 
  x x x x x 
Data verification has to become a continues 
process in the audit cycle x x x x x x x 
Lessons derived for registrars        
Need to fill in all variables, also when not 
required 
  x     
Complications need to be registered more precise   x x x x x 
ASA score need to be registered as described in 
the anaesthesia report x x 
     
Date of surgery has to be registered more 
precise 
   x  x  
Date of discharge has to be registered more 
precise 
      x 
Hospitals must adhere the in- and exclusion 
criteria 
    x   
Lessons derived for the audits        
Need for clear definitions of variables x x x x x x x 
Error in data structure discovered      x  
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DISCUSS ION 
This study showed that verification of completeness and accuracy of the registry 
is essential. The strength of the described process is that a dedicated team 
within the audit organisation initiates and coordinates nationwide data 
verifications of the registries. By learning from every verification, the process of 
verification was continuously improved. Data verification may help to improve 
the survey of the registries and therewith contribute to a higher quality of 
datasets. The most important lesson derived from the verification is the need 
for clear definitions of variables.  
 
In the first verification procedures a lot of missing patients had severe 
complications or died. These discrepancies may have happened because 
hospitals were afraid to be criticised if they registered all complicated patients. 
Another explanation might be that hospitals were not capable of following some 
of their complicated patients, as they are often treated on different wards (e.g. 
at the intensive care unit) or even transferred to another hospital. Because the 
registry is used to compare hospitals, it is imperative that all hospitals have a 
complete registry. Verification of data completeness may stimulate hospitals to 
adhere to the proposed rules of data entry.  
 
The verification of data accuracy is also important. One of the requirements for 
accurate data is the use of clear definitions in multi-interpretable variables. 
Many discrepancies however were seen in simple, uni-interpretable variables, 
like date of surgery and date of discharge. Because length of stay and waiting 
times are frequently used as quality indicators, these results indicate that simple 
variables should also be verified. By detecting common discrepancies, for 
example, because of unclear description of items, the survey could be improved 
by the clarification of definitions to prevent incorrect data in the future. 
Furthermore, by reporting erroneous data, registrars in hospitals can learn 
lessons and improve the registrations. A side effect of integrated data 
verification in the cycle of clinical auditing might be that it stimulates hospitals 
to register correctly because they know their data will be verified. This so-called 
‘Hawthorne’ effect describes improved results which might be caused by 
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increased awareness for an outcome, in this situation the collection of correct 
data14. All these mechanisms could benefit the quality of the datasets and may 
lead to more valid registries and more reliable data for outcome research. Valid 
registries are important because the results of quality indicators are publicly 
available for policymakers, health insurance companies and patient federations.  
 
The described process also has limitations which can be improved. Hospitals 
which might intentionally register incorrect or incomplete, were not identified 
by the current procedure because signing up for data verification was voluntary. 
Hospitals can influence their published results by intentionally registering 
incorrect or incomplete data. This might be a problem since the results are used 
for clinical auditing and comparisons between hospitals. A counter argument for 
making the verification mandatory is that some medical specialists already feel 
criticised by clinical auditing as it takes some time. Forcing them to have a data 
verification may create resistance in the field. For the integrity of verification, 
however, it is desirable that the National Health Care Institute (Zorginstituut 
Nederland) declares the process of data verification mandatory. Another 
possibility could be that details on sign-in and participation in data verification 
become publicly transparent and can be used to assess the validity of indicator 
results of individual hospitals.  
 
Another limitation in the current procedure is the struggle to verify the 
completeness of the registry. At this moment hospitals are free to choose which 
patient list they will provide. A frequently used patient list is the list extracted 
from the electronic patient record system. This strategy is unprotected for flaws 
because this list could be the same list as used to select patients for registration. 
Another disadvantage of this system is that hospitals could manipulate the 
patient list if they would like to hide patients with severe complications. The 
results of the verifications however showed that the use of the current self-
provided lists succeeded in identifying unregistered patients.  
 
To further improve registries and provide valuable, verified, benchmark data to 
all parties involved, DICA aims to develop a system in which data verification 
becomes a continuous process as part of the registry. For this purpose, data 
verification is included in the annual budget. This year will be the first time that 
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data verification is going to be repeated in two registries that have been verified 
previously, 3 years ago.  
Regarding the right sample size for verification, difficulties to find a balance 
between the cost-aspect and certainty of the verification were experienced in 
the past. In the near future pilots will be started to verify data of the clinical 
outcome registry in a more automated process. This pilot aims to select patients 
with high risk of discrepancies.15 The hypothesis is that verification of these high-
risk patients will lead to a higher sensitivity for discrepancies when the same 
sample size is used as in the current procedure. As sample size directly influences 
costs, this procedure will be more cost-effective. This pilot is funded by Stichting 
Kwaliteitsgelden Medisch Specialisten (SKMS), a Dutch foundation aiming at 
improvement of quality policy for medical specialists, which is part of the Dutch 
Federation of Medical Specialists (FMS). 
 
In most verifications, the absence of clear and uniform definitions of items led 
to the most discrepancies. DICA will make an important improvement by 
creating uniform, clear and correct definitions for items in all registries. Recently, 
a project has been launched for this purpose. SKMS also supports this project. In 
this project, as many items as possible will be defined equally in all registries, 
and it will be attempted to use existing guidelines, classifications and definitions. 
For example, definitions of SNOMED CT and the International Statistical 
Classification of Diseases and Related Health Problems (ICD-10) codes. 
It is expected that the registration of data will become increasingly automated 
in the near future. The authors envision that correct data from the electronic 
patient records are automatically uploaded to the registry without the use of 
data managers.  
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ABSTRACT  
OBJECTIVE 
The aim of this study was to investigate the association between short-term outcome 
indicators and long-term survival after oesophagogastric resections.   
SUMMARY BACKGROUND DATA 
Short-term outcome indicators are often used to compare performance between care 
providers. Some short-term outcome indicators concern the direct quality of care; i.e., 
complications, others are used because they are expected to be associated with long-term 
outcomes. 
METHOD 
For this national cohort study, all patients that underwent oesophagectomy or gastrectomy 
for cancer with curative intent between 2011-2016 and were registered in the Dutch Upper 
gastrointestinal Cancer Audit were included. Primary outcome was conditional survival (under 
the condition of surviving the first postoperative 30 days and hospital admission). Cox 
regression modelling was used to study the independent association between ‘textbook 
outcome’ with survival. ‘Textbook outcome’, a composite quality indicator, was defined as a 
pathological complete resection with at least 15 retrieved lymph nodes, an uneventful 
postoperative course, and no hospital readmission.  
RESULTS 
In total, 4414 and 2943 patients with oesophageal or gastric cancer respectively were 
included. The 1-, 2-, and 3-year overall survival rates were 76%, 62%, and 54% and 71%, 56%, 
and 49% for oesophageal and gastric cancer, respectively. Textbook outcome was achieved in 
33% and 35% of patients respectively. ‘Textbook outcome’ was independently associated with 
longer conditional survival (HR: 0.75 [95%CI: 0.68-0.84] and 0.69 [0.60-0.79]), respectively.  
CONCLUSION  
This study showed that the short-term outcome indicator textbook outcome is associated 
with long-term overall survival and therefore may accentuate the importance of using these 
indicators in clinical audits.  
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INTRODUCTION 
Society increasingly demands information on the quality of care in hospitals. One 
of the main principles of improving quality of care is monitoring and 
benchmarking performance of hospitals. To evaluate the quality of care, quality 
indicators for many diseases have been defined. These indicators can be 
subdivided into structure, process, and outcome indicators.1 
To monitor the quality of oesophageal and gastric cancer surgery, the Dutch 
Upper gastrointestinal Cancer Audit (DUCA) has developed a set of indicators. 
Benchmarked information on these indicators is weekly reported to all 
participating hospitals.2 To limit registration burden, long-term follow-up 
including survival is not registered in most clinical audits. Short-term outcomes 
are currently used for feedback to facilitate continuous quality improvement in 
the hospitals. Some of the used short-term outcome indicators concern direct 
quality of care, for example complications. Other short-term indicators are used 
because they are expected to be associated with long-term outcomes, for 
example: ‘complete resection of the tumour’. In clinical auditing, composite 
measures may help to ease the interpretation of outcomes since it is not needed 
to evaluate all separate outcomes. In the DUCA, the composite measure ‘a 
complicated postoperative course’ is used to evaluate outcomes on 
complications. This measure is defined as a postoperative complication in 
combination with a prolonged hospital stay (>21 days), reintervention, or 
death.2 Another composite measure that is used in the DUCA is ‘Textbook 
outcome’.4 ‘Textbook outcome’ consists of different parameters, all of which are 
short-term outcomes. It describes the number of patients in whom all desired 
outcomes are achieved, including a pathological complete tumour resection 
(pR0), retrieval of at least 15 lymph nodes and no complicated postoperative 
course. 
 
If outcomes on short-term quality indicators are associated with the ultimate 
goal of cancer treatment; i.e., long-term survival, this will accentuate the 
importance of using these outcome indicators in national audits. The aim of this 
study was to investigate the association of the short-term outcome indicators 
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with long-term survival in a national cohort of patients with oesophageal or 
gastric cancer who underwent resection with curative intent.  
METHODS  
For this national cohort study, data were retrieved from the DUCA. This surgical 
audit was initiated in 2011. It is mandatory for hospitals performing 
oesophagogastric cancer surgery to register all patients with oesophageal or 
gastric cancer undergoing surgery with the intent of resection. All hospitals in 
the Netherlands register data on the patient, tumour, and treatment 
characteristics, pathology, and 30-day morbidity and 30-day/in-hospital 
mortality. Surgeons have the responsibility for completeness and validity of the 
data collection and registration. To limit the registration burden, registration of 
postoperative outcomes is limited to 30 days after surgery and/or the duration 
of hospital stay. Validation of completeness and accuracy of this data 
registration in the DUCA dataset has been performed by external data 
verification. The completeness of the DUCA database is estimated at 97.8% and 
96.2% for all primary oesophageal and gastric cancer resections, respectively. 
The accuracy of data was estimated to be 94-99.8% for morbidity and 
pathological outcomes.2  
PATIENT SELECTION 
Included in this study were all patients with oesophageal or gastric cancer who 
underwent surgery with the intent of resection registered in the DUCA between 
January 2011 and December 2016. Patients were excluded if essential elements 
of the registration were unknown including the intent of surgery 
(curative/palliative/prophylactic), date of birth, survival status at 30 days after 
surgery, and date of discharge (in case of a hospital stay >30 days). Also, patients 
with a reported date of death in the Vektis dataset that lies before the date of 
surgery as reported in the DUCA dataset were excluded (n=2). To identify best 
performing hospitals and underperforming hospitals, patients operated 
between January 2015 and December 2018 were included because this 
composite measure was introduced in the DUCA in 2015. 
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COMBINED DATASETS 
To provide information regarding overall survival, the data of the DUCA were 
combined with a dataset provided by Vektis. Vektis is a national health care 
insurance database including all medical treatments paid for by Dutch insurance 
companies.5 Date of death of all deceased patients is included in this database 
since health care insurance ends when the patient dies. Health care insurance is 
obligatory in the Netherlands and therefore almost all Dutch inhabitants (99%) 
are registered in the Vektis database6.  
The combining of datasets was performed by a third trusted party to guarantee 
the privacy of patients: Medical Research Data Management (MRDM). MRDM is 
NEN 7510:2011 and ISO 27001:2013 certified and complies to privacy 
regulations in the Netherlands.7 The combining of data was done in September 
2017. As the Vektis dataset contains only deceased patients, it had to be 
assumed that all patients in the DUCA without a match were alive at the time 
that data were extracted from the Vektis database (date of the last follow-up: 
1st of September 2017). For all patients, the interval (in months) from the date 
of surgery to the date of death or date of the last follow-up was calculated. The 
actual date-of-death-variable was deleted in the dataset to guarantee the 
privacy of all patients. It was not possible to differentiate between patients that 
did not match because they were not deceased and those that did not match 
because the matching was technically not possible. Therefore, validation tests 
of the survival information in the combined dataset were performed. 
VALIDATION OF THE COMBINED DATASET 
The validation was performed with two patient cohorts. Validation cohort 1: 30-
day mortality data: In the DUCA the 30-day mortality status is registered, 
including date of death if a patient died within 30 days or during hospital 
admission. All patients that had deceased within 30 days or during hospital 
admission were included in the primary validation cohort. A comparison was 
made between the date of death as registered by DUCA and by Vektis.  
Validation cohort 2: Snapshot study: From a recent snapshot study with DUCA 
data, long-term outcomes of patients with additional pancreatic resection for 
gastric cancer were added to the DUCA dataset.8 In this study, participating 
hospitals provided follow-up information regarding recurrence and survival of 
54 patients. These data were compared with data registered by Vektis.  
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The main outcome in the validation was the percentage of patients with a 
discrepancy in survival status, i.e., patients assumed to be alive in the combined 
dataset, while those have been registered deceased in the data of the validation 
cohort.  
 
PRIMARY OUTCOMES AND SUBGROUPS 
The primary outcomes were overall survival and conditional survival (under the 
condition of surviving the first postoperative 30 days). To examine whether 
short-term outcomes were associated with long-term outcomes, stratified 
survival analyses were performed according to outcomes used in the DUCA: 
‘textbook outcome’, ‘complicated postoperative course’ and ‘pR0’. For all 
survival analyses, only patients with curative intent of surgery, as preoperatively 
defined by the surgeon, were included.  
To evaluate variation in hospital outcomes on ‘textbook outcome’, subgroups of 
patients treated in hospitals with different annual volumes were compared (0-
19, 20-39, and 40 or more resections/year). Also, variation between individual 
hospitals was evaluated; to identify best performing hospitals and 
underperforming hospitals, the percentage ‘textbook outcome’ in every hospital 
was compared to the national mean. A hospital with a significantly higher 
percentage on textbook outcome was classified as ‘best performer,’ and a 
hospital with a significantly lower percentage on textbook outcome was 
classified as ‘underperformer’. 
 
DEFINITIONS 
‘Textbook outcome’ in the DUCA is defined as a radical resection according to 
the surgeon at the end of the operation, no intraoperative complications, a pR0 
resection with at least 15 lymph nodes retrieved and examined, no severe 
postoperative complication, no reintervention, no readmission to the intensive 
care unit or medium-care unit, no prolonged hospital stay (21 days or less), no 
postoperative mortality and no hospital readmission.4 A ‘complicated 
postoperative course’ in the DUCA is defined as a complication in combination 
with a hospital stay >21 days, any reintervention or death during hospitalization 
or within 30 days postoperative.2 Pathological complete tumour resection (pR0) 
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was defined as microscopic tumour-negative resection margins as reported by 
the pathologist. Incomplete resection was defined as tumour-positive resection 
margins as reported by the pathologist (pR1 or pR2).9  
 
STATISTICAL ANALYSIS 
In all analyses, patients with oesophageal cancer (including gastroesophageal 
junction tumours) or gastric cancer were analysed separately. Patient, tumour, 
and treatment characteristics were analysed using descriptive statistics. Overall 
survival was reported using 1, 2, and 3-year survival rates and evaluated using 
the Kaplan Meier method. To evaluate the independent association of ‘textbook 
outcome’, ‘complicated postoperative course’, ‘pR0’ with overall survival and 
conditional survival, a multivariable Cox regression model was compiled. To 
assess confounding, the following factors were analysed (based on the 
literature): sex, age, pre-operative weight loss, body mass index (BMI), location 
of the tumour, American Society of Anesthesiologists (ASA) score, Charlson 
comorbidity score,10 pathological tumour stage according to the TNM-7 
classifications, pathological T- and N-stage, clinical M-category, histological 
subtype of the tumour, differentiation grade, and, surgical procedure. All factors 
with a p-value <0.10 in the univariable Cox regression analyses were included in 
the multivariable model to adjust for confounding.  
Missing items were analysed in a separate group if exceeding 5%. For all 
analyses, statistical significance was defined as P<0.05. All analyses were 
performed with SPSS version 24 (for Mac, IBM, Armonk, New York, USA) and R 
studio version 1.1.456 (for Mac, RStudio, Inc). 
RESULTS  
A total of 7357 patients were included, 4414 patients with oesophageal cancer 
and 2943 patients with gastric cancer (Figure 1). 
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VALIDATION OF THE DATASET 
In the first validation cohort, in 15 of 249 patients (6.0%) a discrepancy in survival 
status was found between the combined dataset and data of the validation 
cohort (Figure 1). In the second validation cohort in 2 of 39 patients (5.1%) a 
discrepancy was found.  
 
 
 
Figure 1. Flowchart inclusion and results validation tests 
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Table 1. Basic characteristics 
   
Oesophageal 
cancer  
Gastric cancer 
    n % n % 
Total    4414   2943   
Gender Male 3422 78% 1838 63% 
  Female 991 22% 1102 37% 
  Unknown 1 0% 3 0% 
Age (in years) 40 or less 35 1% 69 2% 
  41-50 264 6% 171 6% 
  51-60 968 22% 418 14% 
  61-70 1927 44% 822 28% 
  71-80 1114 25% 1050 36% 
  more than 80 106 2% 413 14% 
Body Mass Index <18.5 124 3% 116 4% 
  18.5-25 1848 42% 1367 46% 
  25-30 1695 38% 992 34% 
  30+ 697 16% 371 13% 
  Unknown 50 1% 97 3% 
ASA score I 737 17% 399 14% 
  II 2633 60% 1616 55% 
  III 994 23% 863 29% 
  IV 20 1% 39 1% 
  V 0 0% 1 0% 
  Unknown 23 1% 18 1% 
Charlson Comorbidity score 0 2098 48% 1282 44% 
  1 1124 26% 677 23% 
  2+ 1192 27% 984 33% 
Comorbidities Myocardial infarction 287 7% 231 8% 
  Congestive heart failure 47 1% 70 2% 
  Chronic Pulmonary Disease 820 19% 495 17% 
  Peripheral Vascular Disease 177 4% 130 4% 
  
Diabetes Mellitus 
(uncomplicated) 647 15% 474 16% 
  
Diabetes Mellitus (end-organ 
damage) 28 4% 14 3% 
  
Moderate to Severe Renal 
Disease 50 1% 103 4% 
Timing of surgery Elective 4388 100% 2789 95% 
  Urgent 11 0% 111 4% 
  Emergency 9 0% 41 1% 
  Unknown 2 0% 1 0% 
Neoadjuvant therapy No 419 10% 1368 47% 
  Chemotherapy 359 8% 1509 52% 
  Chemoradiotherapy 3612 82% 47 2% 
  Radiotherapy 11 0% 2 0% 
  Unknown 1 0% 2 0% 
Location tumour: Oesophagus Cervical (C15.0) 9 0% 0 0% 
  Proximal (C15.3) 45 1% 0 0% 
  Mid (C15.4) 529 12% 0 0% 
  Distal (C15.5) 2681 61% 0 0% 
  
Gastro-oesophageal 
junction(C16.0) 1120 25% 0 0% 
Location tumour: Stomach  Fundus (C16.1) 0 0% 248 8% 
  Corpus (C16.2) 0 0% 870 30% 
  Antrum (C16.3) 0 0% 1133 39% 
  Pylorus (C16.4) 0 0% 260 9% 
  Total stomach 0 0% 184 6% 
  Rest stomach / anastomosis 0 0% 133 5% 
  Unknown (stomach) 28 1% 55 2% 
  Missing 2 0% 60 2% 
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Table 2. Treatment characteristics  
   
Oesophageal 
cancer  
Gastric cancer 
  
    n % n % 
Total    4414   2943   
 
Pathological Tumour stage  pT0-2 2452 56% 937 32% 
  pT3 1561 35% 1005 34% 
  pT4 59 1% 608 21% 
  Missing 342 8% 393 13% 
Pathological Node stage pN- 2481 56% 1126 38% 
  pN+ 1607 36% 1403 48% 
  pNx 16 0% 57 2% 
  Missing 310 7% 357 12% 
Pathological Metastases stage pM- 4071 97% 2248 88% 
  pM+ 58 1% 183 7% 
  Not applicable 12 0% 46 2% 
  pMx 62 2% 66 3% 
Surgical approach Open 1814 41% 1901 65% 
  MI 2595 59% 1037 35% 
Type of procedure Transhiatal oesophagectomy 1349 31% 21 1% 
  Transthoracic oesophagectomy 2780 63% 19 1% 
  Total gastric resection 98 2% 1072 37% 
  Partial gastric resection 7 0% 1490 51% 
  Bypass (gastro-enterostomy) 2 0% 110 4% 
  Exploratory only open 122 3% 192 7% 
  Exploratory only MI 38 1% 2 0% 
  Other  11 0% 33 1% 
Site of anastomosis Intrathoracic 1401 32% 183 6% 
  Neck 2703 61% 23 1% 
  Abdomen 57 1% 2294 78% 
  Other/none 253 6% 443 15% 
Conduit/reconstruction Stomach 4055 96% 54 2% 
  Colon 24 1% 4 0% 
  Small bowel 5 0% 40 2% 
  Oesophagojejunostomy (Roux-Y) 90 2% 1054 41% 
  Gastroenterostomy (BII or Roux-Y) 12 0% 1365 53% 
  Other/none 24 1% 76 3% 
Intent of resection preoperative Palliative 5 0% 120 4% 
  Prophylactic 5 0% 14 1% 
 Unknown 3 0% 39 1% 
  Curative 4399 100% 2769 94% 
Intent end-of-surgery No resection 163   246   
  Curative, macroscopic radical 4222   2445   
  Palliative, tumour left behind 12   74   
  Prophylactic 2   4   
            
 
PATIENT COHORT 
A curative intent of resection was registered for 4399 (99.7%) oesophageal 
cancer patients and 2769 (94%) gastric cancer patients. Basic and treatment 
characteristics are shown in Tables 1 and 2. Of all patients with oesophageal 
cancer who underwent resection with curative intent, 33% had a textbook 
outcome, 30% had a complicated postoperative course, and 93% had a pR0 
resection. Of all patients with gastric cancer who underwent resection with 
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curative intent, 35% had a textbook outcome, 19% had a complicated 
postoperative course, and 87% had a pR0 resection (Table 3).  
 
SURVIVAL OF OESOPHAGEAL CANCER PATIENTS 
The 1-, 2-, and 3-year overall survival of patients who underwent a curative 
resection was 76%, 62%, and 54%, respectively (Figure 2a). Patients with a 
textbook outcome had 1-, 2-, and 3-year overall survival rates of 85%, 70%, and 
62%, respectively, versus 72%, 58%, and 50% for patients with no textbook 
outcome, respectively. The conditional survival curves are shown in Figure 2b. A 
textbook outcome was independently associated with longer overall survival 
(hazard ratio (HR): 0.68 [95% confidence interval (CI): 0.61-0.76]) and longer 
conditional survival (HR: 0.72 [95% CI: 0.65-0.81])(Table 3). The conditional 
survival curves of patients with a pR0 versus pR1/pR2 resection are shown in 
Supplementary figure 1a. The association of a complicated postoperative course 
and pR0 resection with survival are shown in Table 3. A sensitivity analysis 
including only patients treated with neoadjuvant chemo radio therapy did not 
significantly change results.  
 
 
Figure 2a. Overall survival of oesophageal and gastric cancer of patients who 
underwent curative surgery. 
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Figure 2b and 2c. (b) Conditional survival (under the condition of surviving the first 
postoperative 30 days) of patients who underwent curative surgery for oesophageal 
cancer and whether or not had a ‘textbook outcome’ and (c) Conditional survival (under 
the condition of surviving the first postoperative 30 days) of patients who underwent 
curative surgery for gastric cancer and whether or not had a ‘textbook outcome’. 
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Table 3. Multivariable Cox regression analyses, multiple models evaluating the 
independent association of short-term outcomes with overall survival and conditional 
survival (under the condition of surviving the first postoperative 30 days).  
Oesophageal cancer   
  
        
Each outcome is adjusted for: sex, age, Charlson comorbidity score, American Society of Anesthesiologists 
(ASA), Body Mass Index, weight loss preoperatively, location tumour, pTNM stage, pT-stage, pN-stage, cM-
category, histological subtype, differentiation of the tumour and surgical procedure.   
    n P value HR CI 95% 
Association short-term outcomes with overall 
survival  4110         
              
Textbook outcome   1443 (33%) <0.001 0.68 0.61 0.76 
Complicated postoperative course 1310 (30%) <0.001 1.54 1.39 1.70 
pR0   3933 (93%) <0.001 0.75 0.63 0.89 
Association short-term outcomes with conditional 
survival  4110         
              
Textbook outcome    <0.001 0.72 0.65 0.81 
Complicated postoperative course  <0.001 1.36 1.22 1.51 
pR0    0.003 0.77 0.64 0.92 
 
Gastric cancer   
  
        
Each outcome is adjusted for: sex, age, Charlson comorbidity score, American Society of Anesthesiologists 
(ASA), Body Mass Index, weight loss preoperatively, location tumour, pTNM stage, pT-stage, pN-stage, cM-
category, histological subtype and differentiation of the tumour.   
    n P value HR CI 95% 
Association short-term outcomes with overall 
survival  2382     
              
Textbook outcome   975 (35%) <0.001 0.62 0.54 0.71 
Complicated postoperative course 533 (19%) <0.001 1.91 1.67 2.20 
pR0   2169 (87%) <0.001 0.69 0.58 0.82 
Association short-term outcomes with conditional 
survival  2276     
              
Textbook outcome    <0.001 0.67 0.59 0.77 
Complicated postoperative course  <0.001 1.51 1.29 1.77 
pR0    <0.001 0.67 0.56 0.80 
       
 
 
SURVIVAL OF GASTRIC CANCER PATIENTS 
The 1-, 2-, and 3-year overall survival of the patients who underwent a curative 
resection was 71%, 56%, and 49%, respectively (Figure 2a). Patients with a 
textbook outcome had 1-, 2-, and 3-year overall survival rates of 85%, 70%, and 
64%, respectively, versus 64%, 49%, and 42% for patients with no textbook 
outcome, respectively. The conditional survival curves are shown in Figure 2c. A 
textbook outcome was independently associated with longer overall survival 
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(HR: 0.62 [95% CI: 0.54-0.71]) and longer conditional survival (HR: 0.69 [95% CI: 
0.60-0.79])(Table 3). The conditional survival curves of patients with pR0 versus 
pR1/pR2 are shown in Supplementary figure 1b. The association of a complicated 
postoperative course and pR0 resection with survival are shown in Table 3. A 
sensitivity analysis including only patients not treated with neoadjuvant therapy 
did not significantly change results. 
 
HOSPITAL VARIATION 
‘Textbook outcome’ was achieved in 15% of patients who underwent surgery in 
hospitals performing 0-19 oesophagectomies per year (total number of patients 
(n)=102), in 21% of patients in hospitals performing 20-39 oesophagectomies 
per year (n=938), and 37% of patients in hospitals performing >40 
oesophagectomies per year (n=3374)(p=<0.001). For gastric cancer, ‘textbook 
outcome’ was achieved in 23% of patients who underwent surgery in hospitals 
performing 0-19 gastrectomies per year (n=483), 29% in hospitals performing 
20-39 gastrectomies per year (n=567), and 27% in hospitals performing >40 
gastrectomies per year (n=1896)(p=<0.001). In the time period 2015-2018, for 
oesophagectomies, 4 hospitals could be identified as best performers and 4 
hospitals as underperformers. Textbook outcome was achieved in 44% and 26% 
of patients in the best-performing and underperforming hospitals, respectively. 
For gastrectomies, 3 hospitals could be identified as best performers and 3 
hospitals as underperformers. Textbook outcome was achieved in 48% and 32% 
of patients in the best-performing and underperforming hospitals, respectively.  
DISCUSS ION 
This study was performed to assess the association between short-term 
outcomes and long-term survival in a national cohort of patients with 
oesophageal or gastric cancer who underwent resection with curative intent. It 
was shown that the composite measure ‘textbook outcome’ was associated with 
longer overall survival and conditional survival. Separately, an ‘uncomplicated 
postoperative course’ and ‘complete tumour resection (pR0)’ were also 
associated with longer overall and conditional survival. This study showed that 
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it was possible to identify best-performing hospitals and underperforming 
hospitals based on ‘textbook outcome’.  
 
The results of this national cohort study are in line with findings of previous 
research. It is generally known that complete tumour resection (pR0) is 
associated with longer survival,11-17 and recently, in a single centre cohort study, 
‘textbook outcome’ was found to be associated with longer survival.18 This single 
centre was a tertiary hospital, which might not represent the ‘real world’ 
situation. In the current study, the association with long-term outcomes is 
confirmed with data of a ‘real world’ cohort.  
For patients with postoperative complications it is known that these have worse 
short-term outcomes; i.e., lower postoperative quality of life and higher 
costs.19,20 However, there is inconclusive evidence that postoperative 
complications are associated with long-term survival. In the current study, the 
composite measure: ‘a postoperative complicated course’ was associated with 
worse long-term outcomes, even after adjustment for several confounding 
factors.  
 
In the Netherlands, the quality indicators evaluated in this study are currently 
used in the DUCA. 'Textbook outcome', ‘complicated postoperative course', and 
‘pR0’ were already considered valuable by patient federations, healthcare 
insurance companies, and the scientific committee of the DUCA. The results of 
this study might accentuate the value of these indicators for use in clinical 
auditing.  
The outcome indicators of the DUCA contain only information on the 
postoperative period until 30 days and during the initial hospital admission. 
There are two major reasons not to include long-term outcome indicators in the 
DUCA. A first reason for not using long-term outcomes in the DUCA is to limit 
the registration burden. The second reason for not using long-term outcomes 
may be even more important. For control and continuous improvement of 
processes, the Plan-Do-Check-Act cycle is often used.21 For efficient quality 
improvement, a short feedback loop is essential. For long-term outcomes, the 
Plan-Do-Check-Act method is less effective and efficient as it may take up to one 
to two years to evaluate these long term outcomes. For example, when the 
percentage of patients that experience anastomotic leakage is used as a quality 
7
 
Chapter 7 158 
indicator, a short feedback loop may help surgical teams noticing a high 
percentage of anastomotic leakage on time. Appropriate measures can be taken 
(e.g., team evaluation, surgical training, or proctoring). Subsequently, the results 
of this intervention can then also be analysed in the short term. When using 
long-term outcomes, deviating outcomes might be noticed too late, 
interventions might be started too late, and the results after an intervention 
might be announced too late. The present study provides additional evidence 
that short-term outcome indicators may be a proxy for long-term outcomes and 
this result may highlight the importance of the use of these outcomes. 
Hospital outcomes on percentage ‘complicated postoperative course' and 
‘complete tumour resection’ are open to the public. The primary goal of 
transparency is to stimulate quality improvement initiatives in underperforming 
hospitals. Secondly, patients can use this information to choose between 
hospitals. Selecting good-performing hospitals by patients may improve 
outcomes on a nationwide basis. The national outcomes on the DUCA indicators 
suggest that performance on short-term indicators could be improved. This 
study showed that in patients that are operated on with curative intent, the 
percentage of patients with a ‘textbook outcome’ in the DUCA cohort was only 
33% for oesophageal cancer and 35% for gastric cancer, respectively. A 
‘complicated postoperative course’ occurred in 30% of oesophageal cancer 
patients and 19% of gastric cancer patients. Complete tumour resection was 
achieved in 93% of oesophageal cancer patients and 87% of gastric cancer 
patients. 
Because of the transparency of DUCA indicators, it was already known that the 
outcomes of ‘complicated postoperative course’ and ‘complete tumour 
resection’ varied between individual hospitals.22 In this study also variety in 
hospital outcomes on ‘textbook outcome’ was shown. High annual volume 
hospitals had higher percentages of ‘textbook outcome’ after both 
oesophagectomy and gastrectomy, and best-performing hospitals and 
underperforming hospitals could be identified. Taken together the variation 
between hospitals and the association of these outcomes with survival may 
underline the importance of the use of these indicators in national audits. These 
indicators might be an important instrument to improve the quality of care on a 
national level.  
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In previous studies, it has been suggested that the relationship between 
complications and survival may not be causal. Patients with comorbidities or 
more severe disease may be at higher risk for complications but may also die 
sooner because of comorbidities or more severe disease. However, some other 
studies suggest that secondary disturbance of the immune system due to the 
presence of perioperative complications may lead to an early recurrence.23-26 In 
this study, it was attempted to adjust for confounding with multivariable 
analysis. However, residual confounding could have been present. For more 
accurate assessment of causality, data on disease-specific survival are needed. 
Unfortunately, those were lacking in the used datasets.  
 
A limitation of this study was the validity of the combined dataset. The survival 
information of a nationwide database was combined with the data of the DUCA. 
Based on the validation tests with two cohorts in this study, the accuracy of 
survival status in the combined dataset is estimated to be 94-95% based on 
discrepancies in 5.1-6.0% of patients in the test cohorts. The most likely reason 
for the discrepancy between test cohort data and the combined dataset is that 
matching of patients from both datasets failed. The citizen's service number 
(BSN) was used to match patients. However, when by accident an incorrect BSN 
was registered in the DUCA dataset, matching was not possible. Another reason 
for the discrepancy could be that patients were missing in the Vektis dataset, for 
example because they had no health care insurance or because they have been 
migrated. In this study, it was assumed that patients with a discrepancy in 
survival status were randomly divided between the stratified analyses on 
outcomes executed in this study. However, registration of incorrect BSN might 
not be randomly divided between hospitals, and therefore it is not excluded that 
this dataset has influenced the analysis on association of hospital performance 
and survival.  
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FUTURE  PERSPECTIVES  AND CONCLUSIONS  
This study showed an association of the composite measure ‘a complicated 
postoperative course’ with long-term survival. Further research is needed to 
assess the association of different kinds of complications with long-term survival 
and to assess the association of complications with disease-specific survival. The 
DUCA group aims to create a dataset with fair survival information to also 
support hospital comparisons and more reliable survival rates.  
With these findings, it can be concluded that the achievement of good short-
term outcomes such as ‘textbook outcome’ is valuable for long-term survival 
after surgery for both oesophageal and gastric cancer. These outcomes should 
be used in clinical auditing to improve outcomes of clinical care in these patients. 
With the Plan-Do-Check-Act cycle, the outcomes of every hospital need to be 
evaluated on a continuous base to improve the quality of care.  
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Supplementary figure 1a and 1b. Conditional survival (under the condition of surviving 
the first postoperative 30 days) of patients who underwent curative surgery for 
oesophageal (a) and gastric (b) cancer and had a pR0 versus pR1/2 resection  
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Supplementary figure 2a and 2b. Overall survival of patients who underwent curative 
surgery for oesophageal (a) and gastric (b) cancer in best performing hospitals versus 
underperforming hospitals, identified based on ‘textbook outcome’.  
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INTRODUCTION 
A surgical resection remains the most important treatment modality for the cure 
of non- metastasized oesophageal cancer. For many years, open 
oesophagectomy was performed worldwide through two approaches: the 
transhiatal oesophagectomy (THO) and transthoracic oesophagectomy (TTO). 
Pertaining in-hospital mortality rates were between 3 and 10%, and the 5-year 
survival rate after surgery was 20–30%. Resulting contributions to improved 
patient-care and selection were the improvement of perioperative care, the 
introduction of neoadjuvant treatments, the centralization of surgery in high 
volume centres and the better imaging modalities. Hence, short and long-term 
outcomes of surgical resection have improved substantially. 
Minimally invasive oesophagectomy (MIE) was pioneered in the early nineties 
and popularized in the last decades by many surgeons. Three meta-analyses 
support the concept that MIE may be associated with less respiratory 
complications, a reduction of morbidity and a faster postoperative recovery.1–3 
At the same time, the procedure is technically demanding and programs to 
safely introduce these techniques are warranted. Two randomized trials 
compared open oesophagectomy with MIE: the total (thoraco-laparoscopic) MIE 
in the TIME-trial and the hybrid (laparoscopy and thoracotomy) 
oesophagectomy in the MIRO-trial. Both studies show the short-term 
advantages of MIE: less blood loss, a lower rate of respiratory infection, a shorter 
hospital stay and a better quality of life in favour of the MIE. The quality of the 
specimen resected is similar to the open technique (radicality and number of 
lymph nodes). Long-term oncological outcome of the TIME trial at 1-year and 3-
year showed no differences between the two groups concerning overall and 
disease-free survival.4 
In this chapter we review the transhiatal and transthoracic oesophagectomy and 
discuss the comparison of the outcomes of these two open approaches by a 
randomized controlled study, the HIVEX trial. 
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COMPARING THO WITH  TTO:  THE  HIVEX TRIAL  
TRANSHIATAL OESOPHAGECTOMY 
Via an upper abdominal incision, the distal oesophagus and locoregional lymph 
nodes in the posterior mediastinum are dissected en bloc through a widened 
hiatus. The upper abdominal lymph nodes are dissected including the 
paracardial lymph nodes, the nodes along the lesser curvature and the nodes at 
the left gastric artery. A standard D1 plus or D2 lymphadenectomy of the celiac 
trunk is performed. The cervical oesophagus is dissected via a left (or right) 
cervical incision and the intrathoracic oesophagus dissected bluntly and stripped 
with the aid of a vein stripper. Creation of gastric tube and resection of the 
specimen is then followed by positioning the gastric tube in the prevertebral 
plane to the neck where the anastomosis is made.5 
 
TRANSTHORACIC OESOPHAGEAL RESECTION 
Several techniques are used: Ivor Lewis procedure (right thoracotomy and 
laparotomy), Mc Keown (three-stage with neck incision) and the Sweet 
procedure (left thoraco-abdominal incision). The three-stage and the two-stage 
open oesophagectomy involves an oesophageal resection, creation of a gastric 
tube, a two-field lymphadenectomy (celiac trunk and mediastinal 
lymphadenectomy) followed by a cervical anastomosis in the three-stage 
procedure and an intra- thoracic anastomosis in the case of an Ivor Lewis 
procedure. The extent of the mediastinal lymphadenectomy is still debated, but 
the majority of the patients undergoes a total mediastinal lymphadenectomy. 
 
DIFFERENCES BETWEEN OPEN TTO AND THO 
In 2001, Hulscher et al. published a meta- analysis on transthoracic and 
transhiatal oesophagectomy.6 Six prospective comparative studies including 
three control-randomized studies (RCT) and 18 retrospective comparative 
studies were included (all published between 1990 and 1999). The three RCTs in 
this meta-analysis were all underpowered and focused on squamous cell 
carcinoma.7–9 In 2002, Hulscher et al. published the Dutch HIVEX trial, an RCT 
8
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comparing TTO with THO.10 In 2007, Omloo et al. published a long- term follow-
up of this trial (5 years).11 
The HIVEX trial included 220 patients with adenocarcinoma type I of the distal 
oesophagus or adenocarcinoma type II of the gastric cardia involving the distal 
oesophagus. Patients were randomized to THO or TTO with extended en bloc 
lymphadenectomy. Primary endpoints of this study were overall survival and 
disease-free survival. Secondary endpoints were the perioperative data and 
other parameters such as postoperative morbidity and mortality, the quality of 
the resected specimen, the number of lymph nodes involved and the number of 
quality-adjusted life-years gained. 
Perioperative morbidity was higher after TTO, but there was no statistically 
significant difference between the groups THO and TTO regarding in-hospital 
mortality (2% in the transhiatal group and 4% in the transthoracic group, p = 
0.45). In the TTO group, 57% of patients had pulmonary complications vs. 27% 
in the THO group (p <0.001). Chyle leakage occurred more in the TTO group, 10% 
vs. 2% (p = 0.02). In the THO group, vocal-cord paralysis was more common but 
this difference was not significant (21% vs. 13%, p = 0.15). Mechanical ventilation 
time, ICU stay and hospital stay were significantly higher in the TTO group 
(postoperative ventilation time: 2 days vs. 1 day, p <0.001; ICU stay: 6 days vs. 2 
days, p <0.001; and postoperative hospital stay: 19 days vs. 15 days, p <0.001). 
After a median follow-up of 4.7 years, 142 patients had died: 74 (70%) after THO 
and 68 (60%) after TTO (p = 0.12). Although the difference in survival was not 
statistically significant, there was at 5 years a trend toward a survival benefit 
holding for the extended approach. Disease- free survival was 27% in the THO 
group, as compared with 39% in the TTO group, whereas overall survival was 
29% as compared with 39%. 
The conclusion of this HIVEX trial was that THO was associated with a lower 
morbidity rate than TTO with its extended en bloc lymphadenectomy. Although 
median overall, disease-free, and quality-adjusted survival did not differ 
statistically between the groups, there was at 5 years a trend toward improved 
long-term survival holding for the extended transthoracic approach. 
The long-term follow-up of this randomized trial was published in 2007. Omloo 
et al., analysed a total of 95 patients who underwent a THO and 110 patients 
who underwent a TTO. After transhiatal and transthoracic resection, 5-years 
survival was 34% and 36%, respectively (p = 0.71). 
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WHO MAY BENEFIT FROM TTO OR THO? 
In a subgroup analysis, based on the location of the primary tumour (classified 
after pathological examination of the resection specimen), no over- all survival 
benefit for either surgical approach was seen in 115 patients with a type II 
tumour (p = 0.81). In 90 patients with a type I tumour, an absolute survival 
benefit of 14% was observed with the transthoracic approach (51% vs. 37%, p = 
0.33). Moreover, there was evidence that depending on the number of positive 
lymph nodes in the resection specimen, the effect of treatment differed. In 
patients (n = 55) without positive nodes, the locoregional disease-free survival 
after THO was comparable to that of TTO (86% and 89%, respectively). A poor 
outcome was found for patients (n = 46) with more than eight positive lymph 
nodes in the resection specimen: the survival was 0% in both groups. Regarding 
patients (n = 104) with one to eight positive lymph nodes in the resection 
specimen, a 5-year locoregional disease-free survival advantage was seen for 
those patients operated via the transthoracic approach (64% vs. 23%, p = 0.02). 
The authors concluded that there is no significant overall survival benefit for 
either approach. However, when compared with THO, a TTO for type I 
oesophageal cancer shows an ongoing trend towards a better 5-year survival 
rate. Moreover, patients with a limited number of positive lymph nodes 
(between one and eight) in their resection specimen also seem to benefit from 
TTO. In patients with a limited nodal burden, a more extensive nodal dissection 
may indeed cure the patient. However, when the number of positive nodes is 
very high, this reflects systemic disease and then more extensive surgery can not 
cure the 
patient. Moreover, in patients with a very limited nodal spread, the locoregional 
nodes can be removed by a THO as well as a TTO. 
 
POST-OPERATIVE MORBIDITY 
Most studies showed more complications for the TTO as compared to the THO. 
The meta-analysis of Hulscher et al.2 showed more perioperative blood loss, 
pulmonary complications, chyle leakage, and wound infections in the 
transthoracic group. More anastomotic leakage and vocal cord paralysis were 
found in the transhiatal group. The in-hospital mortality rates for transthoracic 
resection in comparison with transhiatal were higher (9.2% vs. 5.7%, RR: 1.60, 
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95% confidence interval: 1.89–1.35). The question arises whether these 
differences still are representative because in recent years we see better patient 
selection, improvement of perioperative care and refinement of surgical 
techniques. Lacking recent RCTs we note a cohort study in 2014 by Davies et al. 
including 680 patients operated between 2000 and 2010, showing a shorter 
median hospital stay for transhiatal surgery (14 days vs. 17 days, p < 0.001). The 
in-hospital mortality rate also favoured THO (1.1% vs. 3.2% for THO and TTO 
respectively, p = 0.110). The results show a median of 20 nodes in the 
transthoracic group vs. 13 in the transhiatal group (p < 0.001).12 
 
MINIMALLY  INVAS IVE  OESOPHAGECTOMY 
(MIE)  
Over the last decades, the safe and oncological- proficient operation termed MIE 
emerged. Ideally, minimally invasive techniques should be as radical as open 
approaches and not compromise oncological outcome.13 It may be fair to say 
that during the early developmental phase of MIE a somewhat different 
oncological operation was performed—attributable to the enormous technical 
challenges and search for optimal techniques. More recent studies show, 
however, that indices of the number of lymph nodes dissected and surgical 
margins for MIE are similar or perhaps superior to open approaches. Two RCTs 
have been performed, one total MIE (TIME trial) and the other hybrid, in which 
laparoscopy and right posterolateral thoracotomy are performed with 
intrathoracic anastomosis (MIRO trial).14, 15 The long-term follow-up of the TIME 
trial up to 3 years posits similar survival outcomes for the open and the MIE 
groups.16 
Minimally invasive oesophagectomy may harbour several advantages for the 
surgeons as well. The developments of high definition and 3D cameras with 
robotic platforms offer an excellent and detailed view of the operation field. This 
facilitates a careful dissection along the tissue planes enabling an increased 
radical nodal dis- section with less blood loss. Also, ergonomics of the 
instruments has improved and the surgeon may feel more comfortable during 
MIE than at open surgery. The possible advantages of robotic surgery including 
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oesophageal cancer resections seems clear but this has yet to be evidenced by 
the ROBOT trial, which compares the open oesophageal resection vs. the 
laparoscopy and thoracoscopy as assisted by robot.17 
Minimally invasive surgery—especially in prone position—is technically 
challenging and needs careful introduction using a structured program. 
 
INFLUENCE  OF  NEOADJUVANT THERAPY 
The extended use of neoadjuvant therapy changed the prognosis of the 
resectable oesophageal cancer cure. According to the long-term outcome of the 
CROSS trial, a better survival after neoadjuvant chemoradiotherapy is seen for 
both adenocarcinoma and squamous cell cancer (Carboplatin and Paclitaxel for 
5 weeks with concurrent radiotherapy, 41.4 Gy given in 23 fractions, 5 days a 
week). Five-year overall and progression-free survival rates were 47 and 44% in 
the neo-adjuvant chemoradiotherapy-plus- surgery group while in the surgery-
alone group 33% and 27%, respectively. Holding for the squamous cell cancer, it 
was 61% vs. 30% and 58% vs. 28%; whereas in the adenocarcinomas case it was 
43% vs. 33% and 41% vs. 27%, respectively.18, 19 
The dissection of lymph nodes is important for the staging of oesophageal cancer 
and the number of dissected lymph nodes is an important predictor of survival 
in patients with oesophageal cancer. 
Based on data from the CROSS study, Talsma et al. found that in the group of 
patients treated by surgery alone, the number of resected lymph nodes indeed 
had a prognostic impact on the survival rate.20 But the therapeutic value of 
lymphadenectomy is still controversial in this study after CRT because the 
number of resected nodes was not associated with survival. Also, a cohort study 
by Lagergren et al. showed no significant influence of the number of resected 
nodes on the 5-year survival rates (disease specific and overall) in patients with 
the surgery-alone group.21 
As described above, an important distinction between the outcomes of 
transthoracic and of transhiatal oesophagectomies concerns the differences in 
lymph-node yield and the possible influence on locoregional recurrent disease. 
Moreover, given the data on the association between the number of nodes 
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dissected after neoadjuvant chemoradiotherapy, the question arises what the 
best surgical approach is for Gastro- oesophageal junction tumours: either the 
transhiatal approach with limiting morbidity and inability to dissect the nodes 
from the middle and upper mediastinum, or the transthoracic MIE with 
extended mediastinal nodal dissection. The trend in the Netherlands is to 
operate distal oesophageal tumours (type I) totally minimally invasive by use of 
thoracoscopy and laparoscopy after neoadjuvant therapy. For type II tumours 
(cardia cancers) many Dutch surgeons prefer a thoracoscopic or transhiatal 
approach by laparoscopy after neoadjuvant therapy. 
Discussions concern whether to organize a new trial, one comparable with the 
HIVEX trial, in which patients will be treated by neoadjuvant therapy and by 
minimally invasive surgery. This trial is yet to be accomplished. 
 
CONCLUSION 
Evidence concerning which approach is the best for distal oesophageal and GEJ 
cancers was produced by the HIVEX trial that compared the Transhiatal vs. 
Transthoracic approach without neoadjuvant therapy. Given the current use of 
neoadjuvant therapy, there is no comparison of cohorts or of randomized 
studies that compare MIE THO with MIE TTO for distal or GEJ types 1 and 2 
tumours after neoadjuvant therapy. Such a study is crucial for improving the 
treatment of the distal and GEJ cancers. 
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ABSTRACT  
BACKGROUND 
For oesophageal cancer, the number of retrieved lymph nodes (LNs) is often used as a quality 
indicator. The aim of this study was to analyse the number of retrieved LNs in the Netherlands, 
to assess factors associated with LN yield and to explore the association with short-term 
outcomes.  
STUDY DESIGN 
For this retrospective national cohort study, patients with an oesophageal carcinoma who 
underwent oesophagectomy between 2011-2016 were included. Primary outcome was the 
number of retrieved LNs. Associations were tested with univariable and multivariable 
regression analysis for the association with ≥15 LNs.  
RESULTS 
3970 patients were included. Between 2011-2016 the median number of LNs increased from 
15 to 20. Factors independently associated with ≥15 LNs were: 0-10 kg preoperative weight 
loss (versus: unknown weight loss, odds ratio [95% confidence interval]: 0.71[0.57-0.88]), 
Charlson-score 0 (versus: Charlson-score 2: 0.76[0.63-0.92]), cN2-category (reference: cN0, 
1.32[1.05 – 1.65]), no neoadjuvant therapy and neoadjuvant chemotherapy (reference: 
neoadjuvant chemoradiotherapy, 1.73[1.29-2.32], 2.15[1.54-3.01]), minimally invasive 
transthoracic (reference: open transthoracic, 1.46[1.15-1.85]), open transthoracic (versus 
open and minimally invasive transhiatal, 0.29[0.23-0.36] and 0.43[0.32-0.59], hospital volume 
of 26-50 or >50 resections/year (reference: 0-25, 1.94[1.55-2.42], 3.01[2.36-3.83]) and year 
of surgery (reference: 2011, ORs: 1.48, 1.53, 2.28, 2.44, 2.54). There was no association of ≥15 
LNs with short-term outcomes.  
CONCLUSION 
The number of LNs retrieved increased between 2011 and 2016. Weight loss, Charlson score, 
cN-category, neoadjuvant therapy, surgical approach, year of resection and hospital volume 
were all associated with increased LN yield. The retrieval of ≥15 LNs was not associated with 
increased postoperative morbidity/mortality. 
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INTRODUCTION 
Since a relationship between the number of retrieved LNs and survival has been 
shown, the number of retrieved lymph nodes (LNs) is often used as a quality 
indicator for oesophageal cancer surgery.1-5  
In 2013, the total number of retrieved LNs has been introduced as one of the 
quality indicators in the Dutch Upper gastrointestinal Cancer Audit (DUCA).6 This 
nationwide audit is to provide insight in the quality of delivered care by reporting 
reliable and benchmarked information on process and outcome parameters, 
defined as ‘quality indicators’. The 7th edition of the Union for International 
Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) 
classification recommended removal of at least 15 LNs for reliable staging of 
gastric cancer.7 Hence, the number of 15 nodes was introduced as a quality 
indicator for oesophageal cancer.  
It is unclear whether or not the introduction of this indicator has resulted in a 
higher LN yield. Furthermore, it is unknown which factors are associated with 
the number of LNs retrieved and whether or not a higher LN yield is associated 
with a higher postoperative morbidity or mortality. 
 
The aim of this study was to evaluate trends in the number of retrieved lymph 
nodes and the proportion of patients with ≥15 LNs in the resection specimen. 
The second aim was to identify patient, tumour, and treatment factors 
associated with the number of retrieved LNs, LN yield and thirdly, to evaluate if 
a higher LN yield is associated with increased morbidity and/or 30-day/in-
hospital mortality.  
METHODS  
STUDY DESIGN 
Data were retrieved from the DUCA. This surgical audit was initiated in 2011 and 
is part of the Dutch Institute for Clinical Auditing (DICA). All patients with 
oesophageal or gastric cancer undergoing with the intent of resection should be 
registered. Results on quality indicators are reported to the participating 
9
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hospitals. Every year, external quality indicators are transparent for the public, 
policy makers, insurance companies and patient federations. Validation of 
completeness and accuracy of data registration is performed.6 For this study, 
patient -, tumour -, and treatment characteristics, pathological information, and 
postoperative outcome (until 30 days after the operation) were retrieved from 
the DUCA. Because patient- and hospital identity are anonymous in the 
database, it was not possible to retrieve missing data and additional variables in 
retrospect. 
PATIENT SELECTION 
All patients undergoing surgery for oesophageal cancer with curative intention 
between 2011 and 2016 were included. Patients with an unknown date of birth, 
unknown survival status at 30 days after surgery or discharge (in case of a 
hospital stay of >30 days), or with an unknown number of retrieved LNs were 
excluded.  
Since 2010, nCRT followed by surgery has been the standard treatment 
according to the Dutch guideline for oesophageal carcinoma (with the exception 
for T1N0 tumours).8  
OUTCOMES 
Primary outcomes were the number of retrieved LNs (as documented by the 
pathologist based on examination of the resection specimen) and the 
percentage of patients with ≥15 LNs retrieved (as defined by the number of 
patients with at least 15 retrieved LNs relative to the total number of patients 
who underwent a resection).  
No informed consent or ethical approval was required under Dutch law.  
STATISTICAL ANALYSIS 
To compare patient-, tumour-, and treatment characteristics and surgical 
outcomes between the groups with ≥15 LNs and with <15 LNs, the χ2 test was 
used. To identify associated factors, univariable and multivariable logistic 
regression analyses was performed. Factors with a P value < 0.10 in univariable 
analyses or clinically relevant were included in the multivariable analyses. For all 
analyses, statistical significance was defined as P < 0.05. All analyses were 
performed with SPSS® version 24 (IBM, Armonk, New York, USA) and R (R Studio, 
version 0.99.903, Inc., with package ‘ggplot2’).  
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Possible factors associated with LN yield were selected by the scientific 
committee of the DUCA based on the literature. Consensus was reached for the 
factors age, pre-operative weight loss, body mass index (BMI), location of the 
tumour, American Society of Anesthesiologists (ASA) score, Charlson 
comorbidity score9, clinical T-, N- and M-category of the tumour, neoadjuvant 
chemo(radio)therapy, surgical approach (minimally invasive or open, and 
transhiatal or transthoracic), annual hospital volume, and year of surgery. For 
evaluation of minimally invasive approaches, a stratified multivariable analysis 
for transhiatal and transthoracic were used. To assess the relationship between 
≥15 LNs and surgical outcomes, a yield of ≥15 LNs was analysed in relation to 
irradicality of the resections (resection margins not free of tumour cells), 
intraoperative complications, postoperative complications and 30-day and/or 
in-hospital mortality was tested. A severe complication was defined as a 
complication leading to a hospital stay of >21 days, reintervention or death.  
RESULTS  
A total of 4 076 patients who underwent oesophagectomy for oesophageal 
carcinoma were registered in the DUCA between 2011 and 2016. Some patients 
were excluded because date of birth was missing (n=12), survival status after 30 
days/at discharge was missing (n=80) or the number of LNs was not documented 
(n=14). Hence, a total of 3970 patients was included in the study analyses 
(Supplementary Figure 1).  
NUMBER OF RETRIEVED LNS 
Since 2011, the median number of retrieved LNs increased from 15 LNs 
(interquartile range, IQR: 10-21) in 2011 to 20 (IQR: 16-27) in 2016 (Figure 1). 
Overall, the percentage of patients with ≥15 LNs was 69%. Among patients with 
≥15 LNs, the median number of retrieved LNs was 22 (IQR: 18-28), and in the 
group of patients with <15 LNs, this number was 11 (IQR: 8-13). The percentage 
of patients with ≥15 retrieved LNs increased from 51% in 2011 to 81% in 2016. 
In 2011, the percentage of patients with ≥15 retrieved LNs ranged between 0% 
and 77% among hospitals. In 2016, this hospital variation decreased (Figure 2).  
 
9
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Figure 1. Distribution of the absolute number of LNs retrieved from 2011-2016.    
 
 
 
Figure 2. Variation in hospital score on the indicator ‘a minimal number of 15 retrieved 
LNs’. 
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FACTORS ASSOCIATED WITH ≥15 LNS 
Patient, tumour, treatment and hospital characteristics are shown in Table 1. 
Factors associated with <15 LNs were a Charlson score of 2 (reference: Charlson 
score 0, 0.76[0.63-0.92]) and unknown preoperative weight loss (reference: 0-
10 kg weight loss, odds ratio [95% confidence interval]: 0.71[0.57-0.88]) (Table 
2).  
Factors associated with ≥15 LNs were clinical N2-category (reference: clinical N0, 
1.32[1.05 – 1.65]), no neoadjuvant therapy and neoadjuvant chemotherapy 
(reference neoadjuvant chemoradiotherapy, 1.73[1.29-2.32] and 2.15[1.54-
3.01]), resection in a hospital with 26-50 or >50 resections per year (reference: 
0-25 resections, 1.94[1.55-2.42] and 3.01[2.36-3.83]) and resection between 
2012-2016 (reference: 2011, ORs: 1.48[1.13-1.94], 1.53[1.17-2.00], 2.28[1.73-
3.00], 2.44[1.85-3.21], 2.54[1.91-3.39] for the years 2012 through 2016). 
A transthoracic (open or minimal invasive) approach was associated with a 
higher percentage of patients with ≥15 LNs (versus an open or minimally invasive 
transhiatal approach, 0.29[0.23-0.36] and 0.43[0.32-0.59]).  
A stratified multivariable analysis for transthoracic resections showed a 
statistically significant association of the minimally invasive approach with a LN 
yield of ≥15 LNs (reference: open transthoracic approach, 1.46[1.15-1.85]). 
There was no such association for minimally invasive transhiatal resection with 
≥15 LNs (reference: open transhiatal resection, 1.31 [0.97-1.75]). 
 
Table 1. Basic characteristics of study population, including score of percentage of 
patients with <15 or ≥15 retrieved lymph nodes for each subgroup 
Patient characteristics Total Results on the quality indicator 
      <15 LNs ≥15 LNs   
        P value* 
    n (%)    % %    
Total   3970 31% 69%   
Gender Male 3077 (78%) 31% 69% 0.83 
  Female 892 (23%) 31% 69%   
  Unknown 1 (0.0%) 0% 100%   
Age (in years) 0-64  1787 (45%) 29% 71% 0.002 
  65-74  1650 (42%) 31% 69%   
  75+  533 (13%) 37% 63%   
Weight loss pre-
operative  0-5 kg 2154 (54%) 29% 71% <0.001 
  6-10 kg 835 (21%) 31% 69%   
  10+ kg 443 (11%) 33% 67%   
  Unknown 538 (14%) 38% 62%   
Body mass index <20 257 (6.5%) 34% 66% 0.48 
  20-24 1512 (38%) 31% 70%   
  25-29 1522 (38%) 30% 70%   
  30+ 635 (16%) 33% 67%   
  Unknown 44 (1.1%) 41% 59%   
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Table 1. Continued 
 
    
Patient characteristics Total Results on the quality indicator 
      <15 LNs ≥15 LNs   
           P value 
    n (%)     % %      
Location tumour in 
oesophagus 
Cervical  4 (0.1%) 50% 50%   
Proximal  40 (1.0%) 15% 85% <0.001 
  Mid  486 (12%) 25% 76%   
  Distal  2504 (63%) 31% 69%   
  Gastro-oesophageal junction 936 (24%) 36% 65%   
ASA score I-II 3070 (77%) 30% 70% 0.08 
  III+ 880 (22%) 33% 67%   
  Unknown 20 (0.5%) 50% 50%   
Charlson score 0 1939 (49%) 29% 71% 0.002 
  1 1012 (26%) 31% 69%   
  2+ 1019 (26%) 35% 65%   
Clinical T-category cT0-1 209 (5.3%) 29% 71% 0.63 
  cT2 736 (19%) 33% 67%   
  cT3 2731 (69%) 31% 69%   
  cT4 135 (3.4%) 29% 71%   
  Unknown 159 (4.0%) 31% 69%   
Clinical N-category cN0 1407 (35%) 33% 67% 0.001 
  cN1 1591 (40%) 31% 69%   
  cN2 716 (18%) 26% 74%   
  cN3 100 (2.5%) 25% 75%   
  cN+ (count unknown) 42 (1.1%) 29% 71%   
  Unknown 114 (2.9%) 45% 55%   
Clinical M-category cM0 3837 (97%) 31% 69% 0.85 
  cM1 34 (0.9%) 29% 71%   
  Unknown 99 (2.5%) 34% 66%   
Neoadjuvant therapy No 324 (8.2%) 28% 73% 0.05 
  Chemotherapy 253 (6.4%) 26% 74%   
  Chemoradiotherapy 3373 (85%) 32% 68%   
Surgical approach TTO thoracic part open  694 (18%) 27% 73% <0.001 
  TTO thoracic part MI 1984 (50%) 18% 82%   
  THO open 935 (24%) 56% 44%   
  THO MI 344 (8.7%) 45% 55%   
  Unknown 13 (0.3%) 69% 31%   
Salvage resection No 3870 (98%) 31% 69% 0.75 
  Yes 55 (1.4%) 29% 71%   
  Unknown 45 (1.1%) 29% 71%   
Hospital volume (in 
average number of 
resections/year) 
0-25  522 (13%) 53% 47% <0.001 
26-50  2194 (55%) 29% 71%   
  50+  1229 (31%) 24% 76%   
  Stopped before 2014 25 (0.6%) 76% 24%   
Year of resection 2011 491 (12%) 50% 50% <0.001 
  2012 613 (15%) 39% 62%   
  2013 641 (16%) 37% 63%   
  2014 702 (18%) 26% 74%   
  2015 778 (20%) 24% 76%   
  2016 745 (19%) 20% 80%   
* Chi square analysis, in case of <5% 'unknown' this category is not added in the statistical analysis (exception: cN-
category) ASA= American Society of Anesthesiologists, TTO= transthoracic oesophagectomy, THO= transhiatal 
oesophagectomy, MI= minimally invasive, LNs= Lymph nodes 
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Table 2. Multivariable logistic regression analysis for factors associated with ≥15 LNs 
      Multivariable analysis 
Characteristics n            
Total    3970 P value OR CI 95% 
Age (in years)   0.29       
  0-64  1756   ref     
  65-74  1615 0.67 0.96 0.82 1.14 
  75+  521 0.12 0.83 0.66 1.05 
Weight loss pre-operative  0.01       
  0-10 kg 2938   ref     
  10.1-15 kg 261 0.12 0.79 0.59 1.06 
  >15 kg 174 0.19 0.78 0.54 1.13 
  Unknown 519 <0.001 0.71 0.57 0.88 
Location tumour in oesophagus 0.59       
  Cervical  4 0.41 0.4 0.05 3.46 
  Proximal  39 0.22 1.8 0.71 4.54 
  Mid 480 0.68 0.95 0.74 1.22 
  Distal 2451   ref     
  Gastro-oesophageal junction 918 0.59 1.05 0.87 1.27 
ASA score   0.77       
  I-II 3020   ref     
  III+ 872   1.03 0.85 1.24 
Charlson score   0.02       
  0 1897   ref     
  1 998 0.68 0.96 0.8 1.16 
  2+ 997 0.01 0.76 0.63 0.92 
Clinical N-category   0.02       
  cN0 1383   ref     
  cN1 1553 0.37 1.08 0.91 1.29 
  cN2 707 0.02 1.32 1.05 1.65 
  cN3 99 0.15 1.47 0.87 2.48 
  cN+ (count unknown) 41 0.3 1.5 0.7 3.19 
  Unknown 109 0.07 0.67 0.43 1.03 
Neoadjuvant therapy <0.001       
  No 322 <0.001 1.73 1.29 2.32 
  Chemotherapy 249 <0.001 2.15 1.54 3.01 
  Chemoradiotherapy 3321   ref     
Surgical approach   <0.001       
  TTO thoracic part open (incl. MI abdomen) 686   ref     
  TTO thoracic part MI 1968 0.004 1.38 1.11 1.73 
  THO open 912 <0.001 0.29 0.23 0.36 
  THO MI 326 <0.001 0.43 0.32 0.59 
Hospital volume (in 
average number of 
resections/year) 
    <0.001       
  0-25  506   ref     
  26-50  2174 <0.001 1.94 1.55 2.42 
  50+  1212 <0.001 3.01 2.36 3.83 
Year of resection   <0.001       
  2011 462   ref     
  2012 599 0.01 1.48 1.13 1.94 
  2013 616 0 1.53 1.17 2 
  2014 699 <0.001 2.28 1.73 3 
  2015 774 <0.001 2.44 1.85 3.21 
  2016 742 <0.001 2.54 1.91 3.39 
ASA= American Society of Anesthesiologists, TTO= transthoracic oesophagectomy, THO= transhiatal 
oesophagectomy, MI= minimally invasive, OR= Odds Ratio, CI= confidence interval 
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LN YIELD IN RELATING TO SHORT TERM SURGICAL OUTCOMES 
In Table 3 the association of ≥15 LNs with short term outcomes (with <15 LNs as 
reference group) are shown. A LN yield with ≥15 LNs was independently 
associated with fewer intraoperative complications (4.5% versus 6.8%, OR: 
0.69[0.50-0.95]). Postoperative complications were more frequent in patients 
with ≥15 LNs than in patients with <15 LN, but in multivariable analysis there 
was no statistically significant association (Table 3). 
 
Table 3. Surgical outcomes associated with ≥15 LNs 
     Univariable analysis Multivariable analysis 
    (with outcomes as dependent variable) 
Outcomes <15 LNs ≥15 LNs         
  % (n) % (n) OR [95% CI] ≥15 LNs 
P 
value 
OR [95% CI] ≥15 
LNs 
P 
value 
Positive resection margins  5.6% (68) 4.9% (132) 1.16 [0.86-1.57] 0.33    
Intraoperative complications 6.8% (83) 4.5% (122) 0.64 [0.48-0.86] 0.003 0.69 [ 0.50-0.95] ^ 0.02 
   Bleeding (with transfusion) 22% (18) 16% (20)         
   Intestinal injury 9.6% (8) 5.8% (7)         
   Spleen injury 13% (11) 17% (20)         
   Other 55% (46) 61% (75)         
Postoperative complications 57% (702) 61% (1667) 1.17 [1.02-1.34] 0.02 1.01 [0.93-1.27] * 0.28 
   Pulmonary 29% (356) 32% (879)         
   Cardiac 12% (150) 15% (401)         
   Anastomosis leakage/local 
necrosis conduit 20% (241) 18% (503)         
   Chyle leakage 5% (58) 8% (240)         
Severe postoperative 
complications 28% (339) 31% (847) 1.18 [1.01-1.37] 0.03 1.00 [0.85-1.19] * 0.98 
30-day/in-hospital mortality 4.2% (52) 3.5% (95) 0.82 [0.58-1.15] 0.24     
^ Adjusted for: body mass index, ASA score, surgical approach, year of resection. * Adjusted for: age, body mass 
index, Charlson score, ASA score, histological type, tumour location, surgical approach, hospital volume. ASA= 
American Surgical Association, LNs= Lymph nodes, OR= Odds Ratio, CI= Confidence Interval 
 
DISCUSS ION 
Between 2011-2016, the percentage of patients with at least 15 retrieved LNs in 
oesophageal cancer surgery increased on a national level as well as for the 
individual hospitals. Our results show an association of ≥15 LNs with a higher 
clinical N-category. It may be possible that in patients with clinical suspicious 
positive lymph nodes the surgeon is particularly focused on a more complete LN 
dissection. Also, tumour positive LNs are often increased in size and therefore 
easier to identify during the operation and during pathological examination of 
the resection specimen. This could result in a higher number of retrieved LNs. 
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Another explanation is that the immune response against the tumour influences 
the number of retrieved LNs. It has been suggested that larger tumours may 
cause a more intense immune response, leading to hyperplasia of local LNs, 
which could increase the LN detectability.10 However, this hypothesis is not 
proven yet. 
 
It is well known that the type of surgical approach in oesophageal resection 
influences the number of retrieved LNs; i.e., a transthoracic as compared to a 
transhiatal approach is associated with a higher number of LNs retrieved, as was 
also seen in the current study.11,12 Regarding the impact of a minimally invasive 
approach on LN yield, conflicting results have been published. A systematic 
review showed no differences between open and minimally invasive surgery 
while another meta-analysis showed a significant higher LN retrieval in 
minimally invasive surgery (16 vs. 10, P = 0.03).13,14 In the present study, a higher 
LN retrieval was seen especially in minimally invasive transthoracic procedures, 
which is in accordance with a recent propensity score matched analysis also with 
the data of the DUCA (20 LNs (2-59) versus 18 (0-53); p<0.001).15 It is possible 
that minimally invasive surgery offers benefits in terms of magnification and 
visibility of surgical structures and planes which may translate into a higher LN 
yield.  
 
Busweiler et al. recently showed that in patients undergoing gastrectomy, the 
percentage of patients with ≥15 retrieved LNs was higher in hospitals with a 
higher composite hospital volume (gastrectomies, oesophagectomies and 
pancreatectomies).16 In our study, a similar association was noticed for 
oesophageal cancer surgery. It is suggested that hospitals performing this type 
of surgery, may benefit from the in-hospital experience.16 More intensive 
cooperation of a multidisciplinary team could be important for quality 
improvement initiatives.  
This study showed an increase in the number of LNs every year. It is expected 
that since the introduction of quality indicators in the DUCA, quality 
improvement initiatives in all hospitals have been initiated because the results 
of these indicators are transparent for all individual hospitals each year. The 
national health care inspectorate, the health insurance authorities, and different 
federations use the outcomes of this indicator to assess the quality of upper 
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gastrointestinal surgical care in the hospitals in the Netherlands. The increased 
numbers of retrieved LNs over the years could be the result of an increased 
awareness for the importance of LN dissection by the surgeon. On the other 
hand, back table dissection of the specimen and more extensive pathological 
assessment as a result of dedication of the pathologist, could be major 
explanations as well. All explanations have likely contributed to improving 
quality of care. The role of the pathologists in identifying the nodes in the 
resection specimen is very important as the time spent doing this makes a great 
difference.17 In this study the role of the pathologist could not be studied but 
dedicated pathologists or technicians are associated with increased number of 
nodes detected.18,19 
 
A more extensive LN dissection may lead to better loco-regional tumour control. 
However, the importance of LN dissection for loco-regional tumour control is 
debated since the introduction of neoadjuvant chemoradiotherapy. It is known 
that neoadjuvant chemoradiotherapy leads to tumour and lymph node down 
staging, resulting in more resections with negative margins and lymph nodes.20 
The study of Talsma et al. showed that the number of retrieved LNs had a 
prognostic impact for patients who underwent surgery without neoadjuvant 
chemoradiotherapy, but not in the group of patients who underwent 
neoadjuvant chemoradiotherapy.21 For patients treated with neoadjuvant 
chemotherapy, Markar et al. also showed for patients with a higher lymph node 
yield, a lower recurrence rate and improved survival. Similarly, the effects of a 
higher lymph node yield on survival or recurrence was not observed in patients 
treated with neoadjuvant chemoradiotherapy.22 In the current study, we 
observed an inverse correlation between neoadjuvant chemoradiotherapy and 
retrieved LNs which has been reported before.11,21,23,24 An explanation for this 
phenomenon could be that the use of neoadjuvant chemoradiotherapy leads to 
less priority for an extended LN dissection by Dutch surgeons, or that 
neoadjuvant treatment, especially neoadjuvant chemoradiotherapy may induce 
regression of LNs as reported before.10 So, despite a radical resection, fewer LNs 
are retrieved or detected by the pathologist. Unfortunately, the DUCA registry 
has no long-term follow-up. Hence, from the results of this study it cannot be 
concluded whether or not the number of retrieved LNs is a valid indicator for the 
quality of loco regional tumour treatment. Nonetheless, this indicator may be 
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meaningful as an indicator for overall quality of oesophageal cancer care. A 
higher number of retrieved LNs may lead to an improved tumour staging and 
complete pathological staging is essential to predict the prognosis of patients. 
Furthermore, in patients treated with neoadjuvant chemoradiotherapy, signs of 
tumour regression in LNs (instead of positive LNs) are a better predictor of 
prognosis than clinical N-category which is not always easy to assess 
preoperatively.  
 
CONCLUSION 
Pro and contra arguments can be provided for the use of a minimal number of 
retrieved LNs as a quality indicator in clinical auditing. An argument to use this 
indicator in clinical auditing is that the use of this indicator shows relevant 
variation in outcomes of hospitals, which seems to distinguish hospitals. Another 
advantage could be that this indicator may lead to better quality of oesophageal 
cancer because of quality improvement initiatives. However, the validity of this 
indicator as a direct measure for the quality of LN dissection is questionable, and 
the effect of more retrieved LNs on tumour control is debatable since the 
introduction of neoadjuvant chemoradiotherapy. Nevertheless, a higher lymph 
node retrieval does not seem to lead to higher morbidity or mortality, so the 
number of retrieved LNs could be used safely as an indicator for quality of care.  
  
9
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Supplementary figure 1. Flowchart for inclusion   
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ABSTRACT  
OBJECTIVE 
This study aimed to evaluate whether the quality indicator ‘retrieval of at least 15 lymph 
nodes (LNs)’ is associated with better long-term survival and more accurate pathological 
staging in patients with oesophageal cancer treated with neoadjuvant chemoradiotherapy 
and resection.  
SUMMARY BACKGROUND DATA 
Previous studies evaluating the association of LN yield and survival presented conflicting 
results and many may be influenced by confounding and stage migration.  
METHODS 
Data of oesophageal cancer patients who underwent neoadjuvant chemoradiotherapy and 
surgery between 2011-2016 was retrieved from the Dutch Upper Gastrointestinal Cancer 
Audit. Patients with <15 LNs and ≥15 LNs were compared after propensity score matching 
based on patient and tumour characteristics. The primary endpoint was 3-year survival. To 
evaluate the effect of LN yield on the accuracy of pathological staging, pathological N-stage 
was evaluated and 3-year survival was analysed in a subgroup of patients with node-negative 
disease.  
RESULTS 
In 2260 of 3281 patients (67%) ≥15 LNs were retrieved. In total, 992 patients with ≥15 LNs 
were matched to 992 patients with <15 LNs. The 3-year survival did not differ between the 
two groups (57% versus 54%, p=0.28). pN+ was scored in 41% of patients with ≥15 LNs versus 
35% of patients with <15 LNs. For node-negative patients, the 3-year survival was significantly 
better for patients with ≥15 LNs (69% versus 61%, p=0.01).  
CONCLUSIONS 
In this propensity score matched cohort, 3-year survival was comparable for patients with ≥15 
LNs, although increasing nodal yield was associated with more accurate staging. In node-
negative patients, 3-year survival was higher for patients with ≥15 LNs. 
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ABSTRACT  
BACKGROUND 
Radical gastrectomy is the cornerstone of the treatment of locally advanced gastric cancer. 
This study aimed to evaluate factors associated with a tumour-positive resection margin after 
gastrectomy and to evaluate the influence of hospital volume. 
METHODS 
In this Dutch cohort study, patients with junctional or gastric cancer who underwent curative 
gastrectomy between 2011-2017 were included. The primary outcome was incomplete 
tumour removal after the operation defined as the microscopic presence of tumour cells at 
the resection margin. The association of patient and disease characteristics with incomplete 
tumour removal was tested with multivariable regression analysis. The association of annual 
hospital volume with incomplete tumour removal was tested and adjusted for the patient- 
and disease characteristics.  
RESULTS 
In total, 2 799 patients were included. Incomplete tumour removal was seen in 265 (9.5%) 
patients. Factors associated with incomplete tumour removal were: tumour located in the 
entire stomach (OR[95%CI]: 3.38[1.91-5.96] reference: gastro-oesophageal junction), cT3, 
cT4, cTx (1.75[1.20-2.56], 2.63[1.47-4.70], 1.60[1.03-2.48], reference: cT0-2), pN+ (2.73[1.96-
3.80], reference: pN-), and diffuse and unknown histological subtype (3.15[2.14-4.46] and 
2.05[1.34-3.13], reference: intestinal). Unknown differentiation grade was associated with 
complete tumour removal (0.50[0.30-0.83], reference: poor/undifferentiated). Compared to 
a hospital volume of <20 resections/year, 20-39 and >39 resections were associated with 
lower probability for incomplete tumour removal (OR 0.56[0.42-0.76] and 0.34[0.18-0.64]).  
CONCLUSIONS 
Tumour location, cT, pN, histological subtype and tumour differentiation are associated with 
incomplete tumour removal. The association of incomplete tumour removal with an annual 
hospital volume of <20 resections may underline the need for further centralization of gastric 
cancer care in the Netherlands.  
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INTRODUCTION 
A radical gastrectomy is one of the most important predictors of survival in 
patients with gastric cancer.1 An non-radical resection, i.e. gastrectomy with a 
tumour-positive resection margin (incomplete tumour removal), is seen in 
approximately 1.8-8.4% of patients.2 In the Netherlands, the percentage of 
incomplete tumour removal is used as one of the quality indicators of 
gastrectomies. Between 2011 and 2016, of all gastrectomies for gastric cancer 
with curative intent, in 9 to 13% the tumours were incompletely removed.3 This 
number corresponds with other European outcome registries.4,5 The British 
National Oesophago-Gastric Cancer Audit (NOGCA) reported that up to 29% of 
the gastrectomies performed in individual hospitals had tumour-positive 
margins.5 In the Swedish Register for Oesophageal and Gastric Cancer (NREV) 
the percentage of incomplete tumour removal/unknown resection status was 
17%.4 
Gastric cancer surgery might involve tumour-positive margins on the distal side 
(duodenum), proximal (gastric remnant or oesophagus) or circumferential. With 
the current literature, it is unknown which side is most involved. The Dutch 
national guideline, nevertheless, recommends a proximal and distal resection 
margin of 60 millimeter.6  
 
Awareness of increased risk for incomplete tumour removal may prevent this 
undesirable outcome. However, data on factors associated with incomplete 
tumour removal, including preoperative risk assessment models, are scarce. So 
far, retrospective studies have reported on cohorts from single centres and only 
few patients were included.2,7 Also, surgical expertise and quality assurance may 
play an important role. As individual surgical volume data are difficult to retrieve, 
annual hospital volume is a widely accepted proxy for surgical experience. For 
complex surgery including upper gastrointestinal surgery, there is evidence that 
higher hospital volume and individual surgeon volume are associated with 
improved surgical quality and outcome.8-11 However, the relation between 
hospital volume and incomplete tumour removal has never been investigated. 
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This study aimed to evaluate the factors associated with incomplete tumour 
removal in a Dutch cohort. Furthermore, we sought the association between 
hospital volume and incomplete tumour removal. 
METHODS  
STUDY DESIGN 
Patient data were retrieved from the Dutch Upper Gastrointestinal Cancer Audit. 
This surgical audit was initiated in 2011. Hospitals are mandated to register all 
patients with oesophageal or gastric cancer undergoing surgery with curative 
intent. The DUCA provides insight into the quality of care by reporting validated 
process and outcome parameters, defined as ‘quality indicators’.  
Because the radicality of an operation is used as one of the quality indicators, 
the resection status (R0, R1, R2, not applicable, or unknown), as well as the site 
of the resection margin (proximal, distal, circumferential) in millimeters is 
registered. For the reporting of the pathological examination of oesophageal 
and gastric cancer, a standardized report is used.12 For this study, data on 
pathology of the resection specimen, patient -, tumour -, and treatment 
characteristics were used. Validation of completeness and accuracy of data 
registration in the DUCA dataset has been performed.13 Patient- and hospital 
identity is anonymous in this database. The study protocol was approved by the 
DUCA scientific committee.  
PATIENT SELECTION 
Included were all patients with gastric cancer or cancer of the oesophagogastric 
junction (Siewert type I-III) 14 who underwent gastrectomy between 2011 and 
2017 defined as curative by the surgeon at the end of the operation. Patients 
were excluded if the resection status or essential elements of the registration 
were unknown including date of birth, survival status at 30 days after surgery or 
date of discharge (in case of a hospital stay of >30 days).  
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OUTCOMES 
The primary outcome was complete tumour removal as documented by the 
pathologist based on examination of the resection specimen. The definition of 
the College of American Pathologists is used in the DUCA to define the 
completeness of the tumour removal.15 Removal of the tumour is considered 
complete (R0) if no microscopical tumour cells are visible in the margin and 
incomplete (R1 or R2) if microscopically or macroscopically tumour cells are 
visible in the margin (Patients of who the surgeon defined the resection as 
complete and curative at the end of the operation, but where the pathological 
examination showed an R2 resection, were included because this study focuses 
on the surgeon’s estimation of the resection margins.)   
STATISTICAL ANALYSIS 
To compare patient, and tumour characteristics between the groups with an R0 
and R1/R2 resection, the χ2 test was used. Univariable and multivariable logistic 
regression analyses were performed to identify factors associated with 
incomplete tumour removal. Factors with a P value <0.10 in univariable analyses 
or with clinical relevance were included in the multivariable analyses. To test 
whether the explanatory variables are useful in predicting the outcome, the 
Nagelkerke R2 and an area under the receiver operating characteristic curve 
(ROC) was used. By expert opinion, possible factors for the preoperative 
associated risk model were selected. At the selection of factors for this model, it 
was decided to choose only patient- and tumour characteristics. Treatment 
characteristics such as neo-adjuvant chemotherapy and surgical approach were 
not selected because this could potentially lead to bias, these factors were 
analysed with descriptive statistics. The factors age, Charlson comorbidity 
score16, American Society of Anesthesiologists (ASA) score, tumour location, 
TNM stage, histological subtype, differentiation grade, and year of surgery were 
used. To determine factors which can be used preoperatively to identify patients 
who are at risk for incomplete tumour removal, the clinical TNM-category was 
preferred for this analysis. However, for N-status of the tumour it was chosen to 
use pN-stage. The first reason was because an unknown clinical N-stage (cNx) 
was registered in 13% of patients.1. Also, cN-stage and pN-stage do often not 
correspond and pN-stage is more reliable.   
11
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To test the association of annual hospital volume with the resection status, 
logistic regression models were used with and without adjustment for case-mix 
variety. Because centralization has taken place in the Netherlands, analyses 
were executed in the total cohort of 2011-2017 and stratified for the most 
recent years 2014-2017. Between 2014-2017 hospital volumes were more 
constant. To address possible confounding caused by differences in treatment 
strategy between high and low volume hospitals, stratified analyses for patients 
treated with or without neoadjuvant therapy was performed.  
The annual hospital volume in the year of surgery was assigned to each patient. 
Because the minimum annual hospital volume in the Netherlands is 20 
resections per year, and to draw clinically relevant conclusions, subsequently, 
the volume was grouped into three groups: <20, 20-39 and ≥40 resections per 
year. Missing items were analysed in a separate group if exceeding 5 per cent. 
For all analyses, statistical significance was defined as P<0.05. All analyses were 
performed with SPSS® version 24 (IBM, Armonk, New York, USA). 
 
RESULTS  
A total of 2 799 patients had undergone a curative gastrectomy according to the 
surgeon at the end of the operation and met the inclusion criteria (Figure 1). The 
majority of patients were male (63%), and the median age was 70 years 
[interquartile range: 62-77]. In 265 patients (9.5%) the tumour was not 
completely removed. Patient- and tumour characteristics according to resection 
status are shown in Table 1.  
Tumour location, histological subtype, and, differentiation grade were 
statistically significant different between patient with complete or incomplete 
tumour removal. Clinical and pathological T-, N-, and M- stage was more 
advanced in patients with incomplete tumour removal.  
 
RISK FACTORS FOR INCOMPLETE TUMOR REMOVAL 
A tumour located in the entire stomach (versus gastroesophageal 
junction/fundus), higher cT-categories (cT3, cT4 and cTx category versus cT0-2), 
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a pN+-category and pNx-category (versus pN-), and diffuse or unknown type 
adenocarcinoma (versus intestinal type) were associated with incomplete 
tumour removal (Table 2). Unknown differentiation grade was associated with a 
complete tumour removal (in comparison with poor differentiation 
grade/undifferentiated). The area under the ROC of the multivariate model was 
0.76. 
 
 
Figure 1. Flowchart inclusion 
 
HOSPITAL VOLUME 
In Figure 2, the centralization of gastric surgery in the Netherlands is shown. 
Compared to 2011, the hospital volumes were higher in 2017, and the number 
of hospitals performing gastric surgery decreased.  
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In all logistic regression models, annual hospital volume of <20 was associated 
with a higher percentage of incomplete tumour removal compared to annual 
hospital volumes of 20-39 and ≥40 resections per year (Table 3). There was no 
statistically significant difference between 20-39 and ≥40 resections per year. In 
a sensitivity analysis including data from the period 2014-2017, similar results 
were found (data not shown). In stratified analyses according to neoadjuvant 
therapy, similar results were found. Patients not treated with neoadjuvant 
therapy, with a volume of <20 resections/year had a higher probability for 
incomplete tumour resection compared to 20-39 resections/year and 40 or 
more resections/year ((OR: 0.60 [0.37-0.98] and 0.19 [0.05-0.69], respectively). 
In patients treated with neoadjuvant therapy, the probability for incomplete 
tumour resection was also higher for low hospital volume (<20 resections/year) 
compared to 20-39 resections/year (OR: 0.65 [0.43-0.98]) and for 40 or more 
resections/year (OR: 0.50 [0.23-1.09]).  
 
Figure 2. Centralization gastric cancer surgery  
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Table 1. Patient and tumour characteristics  
        
  Total 
Complete tumour 
removal 
Incomplete tumour 
removal P value 
Patient characteristics n=2799 n=2534 (90.5%) n=265 (9.5%)   
  n % n % n %     
Gender       0.044 
Man 1754 63% 1603 63% 151 57%   
Women 1045 37% 931 37% 114 43%   
Age (in groups)       0.142 
<65 years 888 32% 791 31% 97 37%   
65-74 years 959 34% 880 35% 79 30%   
>75 years 952 34% 863 34% 89 34%   
Charlson score       0.119 
0 1243 44% 1121 44% 122 46%   
1 634 23% 587 23% 47 18%   
2+ 922 33% 826 33% 96 36%   
ASA score       0.17 
I-II 1942 70% 1768 70% 174 66%   
III+ 838 30% 749 30% 89 34%   
Unknown         
Location of tumour       <0.001 
Oesophageal-Gastric 
junction/Fundus  313 12% 286 12% 27 11%     
Corpus 833 31% 775 31% 58 23%   
Antrum/Pylorus 1330 49% 1214 49% 116 45%   
Entire stomach 141 5% 94 4% 47 18%   
Pouch/anastomosis 109 4% 99 4% 10 4%   
Unknown 0 0% 0 0% 0 0%   
Clinical Tumour category        <0.001 
cT0-2 825 30% 781 31% 44 17%   
cT3 1177 43% 1041 42% 136 52%   
cT4 152 6% 128 5% 24 9%     
cTx 602 22% 542 22% 60 23%   
Missing 0 0% 0 0% 0 0%   
Clinical Node category       0.007 
cN0 1433 52% 1319 53% 114 43%   
cN+ 1038 38% 925 37% 113 43%   
cNx 288 10% 251 10% 37 14%   
Missing 0 0% 0 0% 0 0%   
Clinical Metastases category       0.043 
cM-0 2618 94% 2375 94% 243 92%     
cM+ 44 2% 35 1% 9 3%   
cMx 137 5% 124 5% 13 5%   
Tumour histology       0.092 
Adenocarcinoma 2633 95% 2379 95% 254 97%   
Squamous carcinoma 5 0% 5 0% 0 0%   
Other 133 5% 127 5% 6 2%   
Not applicable 3 0% 2 0% 1 0%   
Unknown 0 0% 0 0% 0 0%   
Histological subtype       <0.001 
Intestinal adenocarcinoma 1149 41% 1097 43% 52 20%   
Diffuse adenocarcinoma 823 29% 676 27% 147 56%   
Mixed type 164 6% 153 6% 11 4%   
Unknown 663 24% 608 24% 55 21%   
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Table 1. Continued 
 
  Total 
Complete tumour 
removal 
Incomplete tumour 
removal P value 
Patient characteristics n=2799 n=2534 (90.5%) n=265 (9.5%)   
 n % n % n %  
Differentiation grade       <0.001 
Well/moderate 881 32% 835 33% 46 17%   
Poor/undifferentiated 1471 53% 1273 50% 198 75%   
not available  93 3% 91 4% 2 1%   
Unknown 354 13% 335 13% 19 7%   
Pathological Tumour stage        <0.001 
pT0-2 1030 37% 1010 40% 20 8%   
pT3 1094 40% 977 39% 117 45%   
pT4 614 22% 490 20% 124 47%   
pTx 32 1% 30 1% 2 1%   
Missing 0 0% 0 0% 0 0%   
Pathological Node stage        <0.001 
pN0 1254 45% 1198 48% 56 21%   
pN+ 1481 53% 1277 51% 204 78%   
pNx 36 1% 33 1% 3 1%   
Missing 0 0% 0 0% 0 0%   
Pathological Metastases stage        <0.001 
pM0 2490 89% 2272 90% 218 82%   
pM1 118 4% 89 4% 29 11%   
pMx 54 2% 47 2% 7 3%   
Not applicable  137 5% 126 5% 11 4%     
cT vs. pT staging       0.019 
Correct estimated 549 20% 509 20% 40 15%     
Underestimated T stage 256 9% 218 9% 38 14%   
Overestimated T stage 72 3% 68 3% 4 2%   
cTx 283 10% 256 10% 27 10%   
pTx 21 1% 20 1% 1 0%   
cT or pT missing 0 0% 0 0% 0 0%     
Not applicable (neo-adjuvant 
therapy) 1585 57% 1431 57% 154 58%   
ASA: American Society of Anesthesiologists 
 
SITE OF TUMOR-POSITIVE MARGIN 
In 175 of 265 patients with incomplete tumour removal, the site of the tumour-
positive resection margin was reported in the DUCA (Supplementary table 1). 
When the resection of the tumour was incomplete, the proximal resection 
margin was mostly involved in patients with proximal gastric cancer 
(junctional/fundus 86% and corpus 80%). Gastrectomy for distal tumours 
(antrum/pylorus) was most often incomplete at the distal margin (68%). When 
the tumour was located in the entire stomach, the resection was incomplete at 
the distal margin in 17%, the proximal margin in 42%, and involvement of both 
margins was seen in 42% of patients (Supplementary table 2). 
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Table 2. Probability for incomplete tumour removal, results of uni- and multivariable 
analyses 
Probability for incomplete 
tumour removal Univariable analysis  Multivariable analysis  
Variables n OR [95% CI] P-value n OR [95% CI] P-value 
Total 2799     2671     
Age (in years)     0.143       
0-64 888 1         
65-74  959 0.73 [0.54-1]  0.050       
75+  952 0.84 [0.62-1.14]  0.263       
Charlson score     0.121       
0 1243 1         
1 634 0.74 [0.52-1.05]  0.087       
2+ 922 1.07 [0.81-1.42]  0.648       
ASA score     0.170       
I/II 1942 1         
III+ 838 1.21 [0.92-1.58]          
Tumour location     <0.001     <0.001 
GEJ/Fundus 313 1   304 1   
Corpus  833 0.79 [0.49-1.28]  0.339 813 0.70 [0.43-1.16]  0.167 
Antrum/Pylorus 1330 1.01 [0.65-1.57]  0.957 1308 0.95 [0.60-1.50]  0.828 
Entire stomach 141 5.30 [3.13-8.98]  <0.001 138 3.38 [1.91-5.96]  <0.001 
Pouch/residual stomach 109 5.30 [3.13-8.98]  0.862 108 1.14 [0.51-2.57]  0.749 
Clinical Tumour category      <0.001     0.005 
cT0-2 825 1   808 1   
cT3 1177 2.32 [1.63-3.30]  <0.001 1137 1.75 [1.20-2.56]  0.004 
cT4 152 3.33 [1.96-5.66]  <0.001 146 2.63 [1.47-4.70]  0.001 
cTx 602 1.97 [1.31-2.94]  0.001 580 1.60 [1.03-2.48]  0.036 
Pathological Node category     <0.001     <0.001 
pN- 1254 1   1207 1   
pN+ 1481 3.42 [2.52-4.64]  <0.001 1433 2.73 [1.96-3.80]  <0.001 
pNx 36 1.95 [0.58-6.53]  0.282 31 
3.17 [0.86-
11.61]  0.082 
Clinical Metastases category     0.053     0.984 
cM0 2618 1   2517 1   
cM1 44 2.51 [1.19-5.29]  0.015 43 1.08 [0.46-2.51]  0.867 
cMx 137 1.03 [0.57-1.84]  0.935 111 1.02 [0.53-1.99]  0.948 
Histological subtype     <0.001     <0.001 
Intestinal adenocarcinoma 1149 1   1112 1   
Diffuse adenocarcinoma 823 4.59 [3.30-6.38]  <0.001 797 3.15 [2.14-4.64]  <0.001 
Mixed type 164 1.52 [0.77-2.97]  0.224 160 1.02 [0.50-2.06]  0.963 
Unknown 663 1.91 [1.29-2.82]  0.001 602 2.05 [1.34-3.13]  0.001 
Differentiation grade     <0.001     0.017 
Well/moderate 881 0.35 [0.25-0.49]    839 0.72 [0.48-1.06]    
Poor/undifferentiated 1471 1 <0.001 1417 1 0.096 
Not applicable 93 0.14 [0.04-0.58]  0.006 89 0.33 [0.08-1.38]  0.129 
Unknown 354 0.37 [0.22-0.59]  <0.001 326 0.50 [0.30-0.83]  0.008 
Year of resection     0.562       
2011 250 1         
2012 319 0.71 [0.42-1.20]  0.199       
2013 448 0.71 [0.43-1.15]  0.160       
2014 498 0.78 [0.49-1.25]  0.294       
2015 419 0.66 [0.40-1.09]  0.104       
2016 475 0.64 [0.39-1.05]  0.078       
2017 390 0.61 [0.36-1.02]  0.061       
ASA = American Society of Anesthesiologists 
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Table 3. Multiple regression models to test the association of hospital volume with 
incomplete tumour removal 
 
Probability for incomplete tumour removal Association with hospital volume     
2011-2017   n OR 95% CI P-value 
Nagelkerke 
R2 ROC 
Probability model based 
on patient and tumour 
characteristics   
2671   
      0.17 0.76 
*Added to the model: 
location tumour, cT 
category, pN stage, cM 
category, histological 
subtype, differentiation 
grade   
    
          
Hospital volume           0.001     
*Not adjusted <20 resections/year 1388 1           
20-39 resections/year 1155 0.68 [0.52-0.89] 0.004     
40 or more 
resections/year 256 0.41 [0.23-0.74] 0.003     
Hospital volume           <0.001     
*Adjusted for: location 
tumour, cT category, pN 
stage, cM category, 
histological subtype, 
differentiation grade 
<20 resections/year 1308 1           
20-39 resections/year 1134 0.56 [0.42-0.76] <0.001     
40 or more 
resections/year 
229 0.34 [0.18-0.64] 0.001     
Hospital volume (OTHER REFERENCE)         <0.001     
*Adjusted for: location 
tumour, cT category, pN 
stage, cM category, 
histological subtype, 
differentiation grade 
<20 resections/year 1308 2.95 [1.57-5.55] 0.001     
20-39 resections/year 1134 1.66 [0.88-3.13] 0.120     
40 or more 
resections/year 
229 1           
 
DISCUSS ION 
This Dutch cohort study shows that patients with advanced gastric cancers (i.e. 
involving the entire stomach, advanced TNM-stage and diffuse-type gastric 
cancer) are at risk for incomplete tumour removal. Furthermore, low annual 
hospital volume (<20 resections per year) is also associated with a higher risk for 
incomplete tumour removal than middle and high-volume hospitals. The present 
study is the first population-based study reporting patient-related and tumour-
related factors associated with incomplete tumour removal for gastric cancer. 
The risk factors that were identified in this national cohort study are similar to 
earlier studies: Songun et al. reported the association between incomplete 
tumour removal with tumour location and size of the tumor.18 Other studies 
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reported the association between incomplete tumour removal and diffuse type 
carcinoma.19,20  The risk factors identified in the present study appear to be 
related to more advanced stomach cancer, and this in itself might be a risk factor 
for an incomplete tumour removal.  
In addition to patient and tumour factors, Bissolati et al. studied the association 
between the distance from the tumour to the margin of resection and 
incomplete tumour removal. They showed that resection margins of <20 
millimeters in T1 tumours resection and resection margins of <30 millimeters in 
and T2-4 tumours were associated with incomplete tumour removal.7 In the 
present study, the association of resection margin with incomplete tumour 
removal could not be assessed. Based on the study by Bissolati et al., it could be 
argued that an extra wide resection margin may prevent incomplete tumour 
removal. The Dutch guideline recommends a minimum resection margin of 60 
milimeters.6 The German guideline recommends a resection margin of 50 
millimeters for intestinal type and 80 millimeters for diffuse-type gastric 
cancer.21  
 
Choosing an appropriate surgical margin can be challenging. The margin should 
be wide enough to prevent incomplete tumour removal but at the same time a 
technically feasible and reliable reconstruction should be created. To achieve a 
safe proximal resection margin for middle gastric tumours, a total gastrectomy 
may be indicated. Although postoperative mortality and 5-year survival after 
total and subtotal gastrectomy is comparably,22 a subtotal gastrectomy is 
associated with less nutritional side effects and a better quality of life.  
For proximal gastric tumours that invade the oesophagus, a more technically 
challenging anastomosis in the lower mediastinum or a total gastrectomy with 
subtotal oesophagectomy and colonic interposition may be indicated. This 
procedures have a higher risk for anastomotic leakage or other postoperative 
complications.23,24 
Bissolati et al. also showed that there was an association between incomplete 
tumour removal at the oesophagogastric junction. However, the surgeon may 
be confronted intra-operatively with a difficult decision as how to deal with 
suspicious extension of the tumour beyond what was anticipated. Proximal 
gastric cancers may invade the oesophagus and the proximal resection margin is 
at risk.  
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In the present study, tumour location was not associated with incomplete 
tumour removal. Distal gastric cancers may invade the duodenum and a 
Whipple’s operation for patients who can tolerate this should be considered. 
Hence, in the Netherlands the foundation for oncological cooperation (SONCOS) 
recommends that gastric and oesophageal resections should be performed in 
the same hospital.25 However, there are no recommendations regarding the 
combination of gastric and hepatobiliary surgery.26 Therefore, when it is 
anticipated that the proximal margin at the oesophagus or the duodenum is at 
risk, it is probably advisable to refer patients to hospitals where oesophageal 
and/or hepatobiliary surgery is performed.  
 
To facilitate a radical resection without unnecessarily wide resection margins, 
intraoperative frozen section analysis could be used. However, this technique is 
time-consuming, and the clinical value can be dubious since results can be false 
negative.27,28 Squires et al. evaluated outcomes of patients with gastric cancer 
with a positive intraoperative proximal frozen section converted to an R0 
resection in the same procedure. The local recurrence was significantly lower in 
the converted-to-R0-group than in patients with a positive final frozen section. 
This study showed that overall survival and progression-free survival was not 
improved.29 If time is a concern of hospitals, a frozen section could be considered 
to achieve a R0 resection in high-risk patients as identified in this study rather 
than in all patients.  
Additionally, intraoperative endoscopic ultrasonography may help in 
determining the extent of infiltration in the oesophagus or duodenum.30 
Kawakatsu et al. described the combination of preoperative placement of 
marking clips and intraoperative endoscopy as being helpful in determining a 
surgical margin in patients who undergo laparoscopic gastrectomy. However, 
this is the only study that describes the systematically use of endoscopy during 
gastrectomy. Further studies are therefore needed to evaluate the benefits of 
this technique. 
 
Besides tumour-related factors, the surgeon’s experience with oesophageal and 
gastric cancer surgery and the number of operations per year performed 
(hospital volume) may be important to reduce the number of incomplete 
resections. In the present study, a hospital volume of <20 gastric resections per 
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year was associated with a higher chance of incomplete tumour removal 
compared to 20-50, and >50 resections per year. In the past, the association 
between hospital volume and postoperative morbidity/mortality and overall 
survival has been studied.8-10,31-34 For overall survival, conflicting results were 
published. However, for postoperative morbidity and mortality, several studies 
reported improved outcomes in high-volume centres. More recently, low 
hospital volume (<25 resections per year) was associated with fewer retrieved 
lymph nodes.35 Between 2012 and 2014, the Association of Surgeons of the 
Netherlands introduced volume standards for complex surgery. In particular for 
gastric surgery, a minimum volume of 10 gastric cancer resections in 2012, and 
from 2013 onwards a minimum of 20 resections per year was required. 
Currently, some Dutch hospitals have not met this standard yet, and 
centralization in gastric surgery is still ongoing (Figure 2). It may be possible that 
hospitals with a relatively low number of patients with gastric cancer use more 
liberal criteria to select patients for gastrectomy to comply with the minimum 
required target. This may result in worse outcomes; e.g. higher rates of 
incomplete tumour removal. At present, we are performing a more in-depth 
examination in several hospitals to identify if organizational, human or technical 
factors contribute to unfavourable outcomes after gastrectomy. Nevertheless, 
the current study endorses the need for centralization of gastric cancer surgery. 
Another strategy could involve discussing complex patients in a multicentre 
multidisciplinary team.36  
In the case of postoperative determination of tumour-positive resection 
margins, some studies describe that adjuvant chemoradiotherapy is associated 
with improved survival,37,38 especially for patients who had no neoadjuvant 
therapy.39 Another option which may of benefit is to perform a reoperation with 
resection of the tumour-positive resection margins.40,41 The largest cohort of 
reoperations was 122 patients and a reoperation was successfully performed in 
41% of these patients. The authors of the study describe a survival benefit 
especially for stage N2 or lower tumors.42 However, evidence for an optimal 
treatment after an incomplete tumour removal is based on non-randomized 
studies with small patient groups.  
 
The main strength of this study is the nationwide coverage of the dataset 
allowing national performance to be assessed. Outcomes of studies using 
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population-based data reflect daily clinical practice. Prospective (randomized) 
trials are usually conducted under strict quality control and only with selected 
patients and thus may not reflect the real world. A national registry might do 
reflect the real world. However, a database from a national registry may also 
have its disadvantages; the accuracy and completeness of data may be 
questioned. Nevertheless, we believe that the DUCA database is accurate to 
answer our research question. The case ascertainment of the DUCA database is 
estimated at 97.8%13 and the resection status is reported with high 
completeness (1.6% missing, Figure 1). Because in the Netherlands, the 
information regarding resection margins must be reported according to a 
standardized pathology report, we assume that the accuracy of the registered 
resection status is also high.12  
Another limitation is the retrospective nature of this study. In this study, we 
could not evaluate the influence of treatment-related factors on resection status 
such as neoadjuvant chemotherapy and the surgical approach. The reason for 
this is that bias in the selection of patients for specific treatments may have 
occurred (treatment by indication bias). Therefore, this study could not evaluate 
much-discussed treatment-related factors such as the approach of surgery. 
However, recently, a study with data of the DUCA compared minimally invasive 
gastrectomy with open gastrectomy in a propensity-matched cohort. This study 
showed no differences in resection status between the two groups (R0 in 88% 
versus 85%, p=0.189).17 Another potential treatment-related factor that could 
not be evaluated in this study is inadequate diagnostic staging. From the present 
dataset it was not possible to compare the diagnostic work up between patients 
that underwent a complete and incomplete tumour removal, because both 
patient identity and hospital identity are anonymous.  
Finally, data on survival were not available. Therefore, evaluation of the 
(independent) association of complete resection with survival was not possible. 
A gastrectomy with tumour-positive margins may reflect an aggressive biology 
of the tumour and as a consequence have a poor prognosis. Even after 
gastrectomy with negative resection margins, large poorly differentiated 
tumours will likely spread beyond the surgical field and surgery can not cure 
these patients. Future studies may be needed to evaluate the independent 
association of incomplete resections with survival.  
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Supplementary table 1. Location tumor-positive resection margin 
Location tumor-positive resection margin     
  n % 
Distal 68 26% 
Proximal 78 29% 
Circumferential  1 0.4% 
Distal and proximal 29 11% 
Unknown 90 34% 
Reported 'unknown' 37 41% 
Both margins reported >0mm 43 48% 
Missing 6 6.7% 
Reported 'not applicable' 3 0.3% 
Total 265   
 
 
 
 
Supplementary table 2. Location tumor-positive resection margin for each tumor 
location 
   
Location tumor-positive resection 
margin 
  
  Total 
No 
information Distal  Proximal  
Distal and 
proximal  Circumferential 
  n n  n % n % n %   
Location of tumor                   
GEJ 14 6 0 0% 7 88% 0 0% 1 13% 
Fundus  13 6 1 14% 5 71% 1 14%   
Corpus 58 18 6 15% 32 80% 2 5%   
Antrum/Pylorus 116 38 53 68% 16 21% 9 12%   
Entire stomach 47 11 6 17% 15 42% 15 42%   
Pouch/anastomosis 10 5 2 40% 2 40% 1 20%   
                    
GEJ: Gastro-esophageal junction                 
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ENGLISH  SUMMARY 
Since the introduction of the Dutch Upper Gastrointestinal Cancer Audit, some outcomes in 
oesophagogastric cancer surgery has been improved (30-day mortality, lymph node retrieval). 
However, outcomes on a complicated postoperative course (a complication in combination 
with reintervention, prolonged hospital stay or death) are stable. Therefore, a nationwide 
improvement project was initiated. In this project, two meetings were organized. In these 
meetings, all Dutch upper gastrointestinal surgeons participated, and all presented their 
results regarding anastomotic leakage and lymph node retrieval. All results were compared 
and discussed. Also, experiences with different anastomosis techniques were shared. During 
these meetings, the atmosphere was safe, which seem to be essential for sharing results and 
experiences. One of the conclusions during these meetings was that the Dutch upper 
gastrointestinal surgeons feel joint responsibility for national outcomes and are willing to 
work together for the improvement of these national outcomes. Future data is needed to 
show whether these meetings are effective in improving quality of oesophagogastric cancer 
surgery.    
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GENERAL  DISCUSSION  
Quality of care can be monitored in clinical audits and can be improved with 
improvement initiatives. Both are of absolute necessity in the current health 
care system. To define the quality of care, reliable and valid quality indicators 
are essential. In this thesis, the reliability and validity of different quality 
indicators in the Dutch Upper Gastrointestinal Cancer Audit (DUCA) were 
evaluated. Additionally, the value of the use of different indicators for 
oesophagogastric cancer care was evaluated. 
 
RELIABILITY OF THE DUCA INDICATORS 
Quality indicators can be considered reliable if the indicator would produce 
similar outcomes in the same conditions if used again. When doctors themselves 
register data in a national audit, it is important that this registered data is 
verified to check whether it is complete and accurate. Therefore, in Chapter 6, 
the procedure for data verification was described,1 as well as the results of this 
data verification in the DUCA, showing that the data are highly complete and 
accurate (Chapter 2).2 The use of an outcomes set with uniform definitions is 
essential for fair comparisons between different hospitals and different 
countries. In 2016, the international uniform standardized outcomes set of the 
Oesophagectomy Complication Consensus Group (ECCG) Platform was 
successfully implemented in the DUCA (Chapter 2).2  
With the outcomes of data verification and the recent implementation of the 
international uniform standardized outcomes set, it can be concluded that the 
data and results in the DUCA are reliable.  
 
VALIDITY OF THE DUCA INDICATORS 
Indicators can be considered valid to monitor the quality of care if they actually 
measure aspects of the quality of care. The quality of care for oesophagogastric 
cancer patients can be determined by two pillars; quality of life and long-term 
survival outcomes.  
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Quality of life 
To evaluate quality of life, patient-reported outcomes are essential. In this 
thesis, it was not possible to evaluate indicators with data on Patient-Reported 
Outcome Measures (PROMs) because data on PROMs were not yet available in 
the DUCA. However, it is described that postoperative morbidity has a significant 
effect on the quality of life postoperatively,3 and some quality indicators on 
postoperative morbidity were evaluated on validity. In the DUCA, one of the 
existing quality indicators regarding postoperative morbidity is a complicated 
postoperative course, defined as the percentage of patients with a complication 
in combination with a prolonged hospital stay, reintervention or death.4 Another 
existing quality indicator regarding postoperative morbidity is the percentage of 
patients with ‘a complication Clavien Dindo grade III or higher’.  
In recent literature, a new parameter on postoperative morbidity was described; 
the Comprehensive Complication Index (CCI). Because the CCI is the first 
morbidity outcome that is partly based on patients’ opinion, it was evaluated in 
Chapter 5 whether the CCI could be applied in a clinical audit. ‘The percentage 
of patients in the 75th percentile of the CCI’ was defined as a new quality 
indicator. With this new quality indicator, it was possible to identify hospitals 
with significantly better performance or significantly worse performance. It was 
also shown that hospital outcomes on this new quality indicator were highly 
correlated to hospital outcomes on the existing indicator ‘a complicated 
postoperative course’ but not to hospital outcomes on ‘a complication Clavien 
Dindo grade III or higher’. Although future studies are needed to determine 
whether CCI is associated with quality of life, results of this study suggest that 
the new indicator on CCI and the existing indicator ‘a complicated postoperative 
course’ are valid to measure the quality of care.   
 
Long-term survival 
The validity of quality indicators regarding association with long-term survival 
outcome was evaluated in the second part of this thesis.  
Because monitoring long-term outcomes is important, in the DUCA some short-
term outcome indicators are used as a proxy for long-term outcomes. In this 
thesis, four DUCA outcomes were evaluated on the association with long-term 
survival. In Chapter 7, it was found that three of these outcomes; ‘Textbook 
outcome’, ‘Complicated postoperative course’, and ‘Complete tumour 
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resection’, were associated with long-term survival.5 In Chapter 10, a fourth 
indicator was evaluated on the association with long-term survival; ‘retrieval of 
at least 15 lymph nodes’. The importance of lymph node retrieval has been re-
discussed since the introduction of neoadjuvant chemo- and radiotherapy 
(Chapter 8). In these studies, it was found that there was no association of 
retrieval of at least 15 lymph nodes with survival, however, in patients with at 
least 15 retrieved lymph nodes, the pathological staging appeared to be more 
accurate. 
 
VALUE OF THE DUCA INDICATORS 
Variation  
The value of the use of indicators in a national audit can be determined by 
analysing whether these indicators demonstrate variation between hospitals or 
international cohorts. The comparison of the DUCA outcomes with outcomes of 
an international cohort of the Oesophagectomy Complication Consensus Group 
(ECCG) Platform, showed that significantly more complications and anastomotic 
leakage exist in the DUCA (Chapter 2). These differences underlined the value of 
indicators on morbidity outcomes.  
For other outcomes, significant differences were found between different types 
of hospitals. Low volume hospitals failed more often in the retrieval of at least 
15 lymph nodes in the treatment of patients with oesophageal cancer (Chapter 
9). In patients with gastric cancer, low volume hospitals failed more often in 
achieving a complete tumour resection (Chapter 11).  
 
Trends 
Not only differences between hospitals or international cohorts are important 
to determine the value of indicators, but also the ability to demonstrate trends 
in outcomes after introduction of an indicator may emphasize the value of 
indicators. In Chapter 9, a significant improvement of national outcomes on 
lymph node retrieval was shown since the introduction of the DUCA. This 
improvement may be an effect of the use of the indicator regarding lymph node 
retrieval and therefore, may strengthen the value of the DUCA and its indicators.  
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FUTURE  PERSPECTIVE  
BEST QUALITY INDICATORS FOR OESOPHAGOGASTRIC CANCER 
SURGERY 
Short-term outcomes 
All indicators of the DUCA contain only information on short-term outcomes. 
There are two reasons for this. Firstly, because limiting the number of outcomes 
and the follow-up period reduces the registration burden. Secondly, because the 
use of short-term outcomes facilitates a short feedback loop. For continuous 
control and improvement of processes, the Plan-Do-Check-Act cycle is often 
used.6 For efficient quality improvement, a short feedback loop in this cycle is 
essential and therefore, the use of short-term outcomes in a clinical audit such 
as the DUCA is recommended. Since it has been shown that the short-term 
outcomes ‘Textbook outcome’, ‘a complicated postoperative course’ and 
‘complete tumour resection’ are a proxy for long-term survival, these specific 
short-term indicators seem valid (Chapter 7).5 
 
Composite measures 
Another type of indicators that may be important for quality monitoring are 
composite measures. Because composite measures simplify the interpretation 
of outcomes, these are preferable for use by external parties including patient 
organisations and health insurance companies. An example is the composite 
measure ‘Textbook outcome’. It should be noted that outcomes on the 
individual elements/parameters are essential for health care providers to 
monitor and improve quality of care. Future studies are needed to evaluate 
which method is the best to improve outcomes on these specified parameters. 
 
 
Morbidity 
Postoperative morbidity after oesophagogastric surgery has a serious impact on 
the quality of life and costs and may be associated with long-term survival. 
Therefore, it can be argued to use morbidity as a main outcome in a clinical 
audit.3, 5, 7 The CCI may reflect the most complete outcome on complications 
because it considers all complications and the outcome is partly based on 
13
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patients’ opinion. In this thesis, it was shown that the CCI and a complicated 
postoperative course are highly correlated. Therefore, both outcomes can be 
recommended to use in the DUCA (Chapter 3).  
 
Patient-reported outcomes and patient-reported experience 
For the future, it might be of great value to include patient-reported outcomes 
and patient-reported experience in the DUCA.  
In the Netherlands, patient-reported outcomes are collected on a national base 
in the Prospective Observational Cohort Study of Oesophageal-gastric cancer 
Patients (POCOP) project. Because it is not desirable to target the patient with 
overlapping questionnaires, the DUCA is working on a link between the POCOP 
database and the DUCA database to give hospitals benchmarked information 
regarding the quality of life of patients treated in their hospital. Patient-reported 
outcomes can be used to validate currently used clinical outcomes by evaluating 
the association of these factors with quality of life. Also, a quality indicator 
regarding the percentage of patients that completed a patient-reported 
outcome questionnaire may help to increase the use of these questionnaires in 
clinical contact.   
Patient-reported experience questionnaires are not yet included in the DUCA. 
Because patient-reported experience may be a promising outcome to use as a 
quality measure for hospital performance, implementation of this outcome in 
the DUCA should be considered in the future.  
 
ULTIMATE GOAL OF CLINICAL AUDITING: QUALITY IMPROVEMENT 
Quality improvement based on monitoring of outcomes has been described in 
the past.8 Also, making outcomes transparent may help to improve outcomes.9-
11 In the first 8 years after initiation of the DUCA, some of the outcomes have 
improved over time including the number of retrieved lymph nodes,9 and the 
30-day mortality after gastrectomy.4  
On the other hand, some other important outcomes in the DUCA did not 
improve; especially morbidity remained stable.12 This in itself is not a problem 
as these outcomes might be just the best that is achievable at the moment. 
However, for morbidity, it was shown that morbidity reported by the DUCA was 
significantly worse than that in an international cohort containing data of several 
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high-volume hospitals.2 These results emphasize the need for critical evaluation 
of morbidity outcomes after 8 years of clinical auditing. Moreover, it underlined 
the need for an alternative method of outcome evaluation in addition to the 
standard method of evaluation.13 (see below) 
 
In the standard method, outcomes on quality indicators are reported online to 
the hospital. In this report, the outcome of a particular hospital is shown among 
the outcomes of all other hospitals that remain anonymous. Hospital outcomes 
are compared to the national mean and 95% confidence intervals are used to 
identify outliers, defined as hospitals performing significantly better or 
significantly worse than the national mean. To improve quality of care, this 
method falls short on some points. First, hospitals with outcomes that are at the 
same level of the national mean may not be stimulated to start improvement 
initiatives. This may lead to a lack of improvement over time. Secondly, in the 
Netherlands, oesophagogastric cancer surgery is still performed in rather low 
volumes (20-40 resections per year). A small number of patients leads to broad 
confidence intervals. With broad confidence intervals, a type II error may occur; 
underperforming or overperforming hospitals may not be identified as a 
significant outlier. Thirdly, most quality indicators are composite quality 
indicators.4, 14 For example, the quality indicators regarding morbidity evaluate 
all complications together. With these indicators, hospitals obtain no insight in 
specific complications while focusing on specific complications is needed for 
effective improvement initiatives. Lastly, outcomes are reported anonymously. 
Individual hospitals are notified, but cannot be helped by offering quality 
improvement programs as long as they remain anonymous. The initiative to do 
so completely lies within the hospital itself.  
In this thesis, it was shown that outcomes on morbidity and especially 
anastomotic leakage within the DUCA cohort were significantly worse compared 
with an international cohort.2 Since introduction of the DUCA these outcomes 
were stable.12 To improve the outcomes after oesophagogastric cancer surgery, 
an alternative evaluation of national outcomes was introduced in the DUCA 
(Chapter 12). In 2018, a two-day meeting was organized for upper 
gastrointestinal surgeons of all hospitals performing oesophagogastric cancer 
surgery in the Netherlands. This meeting was repeated in 2019. The purpose of 
this meeting was to evaluate outcomes, and with an expert group to discuss how 
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national outcomes might be improved. All hospitals were asked to present their 
results and to discuss why they thought these outcomes were better or worse 
than other outcomes (no matter if they were an outlier or not). Since the goal of 
these meetings was to improve outcomes, the choice was to focus on two 
specific outcomes; anastomotic leakage and lymph node retrieval.  
In the future, more of these meetings are needed to bring joint responsibility for 
outcomes after oesophagogastric surgery in the Netherlands. Future evaluation 
of outcomes in the DUCA cohort are needed to evaluate whether these meetings 
lead to an improvement in outcomes.  
 
THE SAFETY-I VERSUS THE SAFETY-II APPROACH 
Another idea that has penetrated into the world of clinical auditing is focusing 
on a desired outcome rather than an undesired outcome. The first indicators for 
oesophagogastric cancer surgery mainly reflected undesired outcomes including 
a complicated postoperative course. To improve this outcome, hospitals must 
ensure that as little as possible goes wrong. In the example of a complicated 
postoperative course, to prevent a high score on complicated postoperative 
course, physicians have to ensure that complications will not lead to a 
reintervention, prolonged hospital stay or death. This reactive management is 
described in the literature as the ‘Safety-I’ approach.15 In contrast, the newer 
indicator ‘Textbook outcome’ focusses on a desired outcome. ‘Textbook 
outcome’ is defined as a perioperative process following the textbook; a curative 
treatment with no undesired events. To improve this outcome, hospitals have 
to ensure that many key attributes in the care for the patient are well performed. 
For ‘Textbook outcome’, this means that hospitals are motivated to monitor and 
improve the whole perioperative pathway. This proactive management is 
described as the ‘Safety-II’ approach.15 It has been described that Safety-I is 
inadequate in the long run, while the Safety-II approach provides flexible 
solutions to many potential problems.16  
Another application of the Safety-II approach in the DUCA would be to identify 
the three best performing hospitals and to explore if and where these hospitals 
differ in the perioperative management of the patient and to set a blueprint for 
all other hospitals. It has been suggested that in clinical practice, the way ahead 
lies in the combination of the Safety-I and Safety-II approach.16 
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BETTER INSIGHT IN RESULTS 
Another development which may lead to quality improvement is a new dynamic 
dashboard (CODMAN dashboard) that shows trends in hospital’s outcomes at a 
glance. This dashboard may help to monitor hospital’s quality and may stimulate 
improvement projects. In 2019, this new dynamic dashboard was introduced for 
all hospitals participating in the DUCA. Besides the fact that it is easier to gain 
insight into trends with this new dashboard, it enables doctors also to focus on 
subgroups of patients, which allows in-depth evaluation of outcomes. This 
information may facilitate the evaluation of results during morbidity and 
mortality conferences held in individual hospitals.  
 
CENTRALISATION 
With the currently used annual volume standard of at least 20 resections per 
year, centralisation has taken place in the past years. Several studies in this 
thesis underlined the need for better organization of oesophagogastric cancer 
surgery in the Netherlands. Further centralization may be needed, but also 
setting up networks with multicentre multidisciplinary team meetings may help. 
However, an annual volume of 20 may be still be considered as ‘low volume’. 
Additionally, a higher number of patients per year in the individual hospitals 
enable short-cycle auditing with higher distinctiveness.  
Another consideration in the organization of oesophagogastric cancer surgery is 
the introduction of a composite volume-outcome. The current guideline 
describes that oesophageal and gastric cancer surgery is preferably performed 
in the same hospitals because it shares many similarities. However, this is not 
yet set as a standard. In addition, also quality of oesophagogastric cancer surgery 
may benefit from shared experience with other complex upper gastrointestinal 
cancer resections such as pancreatectomies.  
 
MULTIDISCIPLINARY AUDIT 
In previous studies with national data on patients with oesophagogastric cancer, 
considerable variation between hospitals was shown in the percentage of 
patients treated with curative intent.17, 18 This underlines the need for a 
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multidisciplinary clinical audit. At this moment, full data on all oesophagogastric 
cancer patients are collected in the Dutch Cancer Registry. In the DUCA, only 
information regarding the (peri)operative treatment in patients that underwent 
surgery is registered. The DUCA is working on a link between the Dutch Cancer 
Registry database and the DUCA database to create a multidisciplinary audit 
without extra registration burden. In the future, it is essential to monitor the 
entire treatment process and the outcomes of all multimodality treatments to 
give a complete overview of the quality of care between hospitals. This will be 
of imminent importance for the quality of care of all oesophagogastric cancer 
patients in the Netherlands 
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QUAL ITY  MEASUREMENT  IN  
OESOPHAGOGASTRIC CANCER SURGERY 
 
The research described in this thesis focuses on the reliability and validity of 
different quality indicators in the Dutch Upper Gastrointestinal Cancer Audit 
(DUCA). Additionally, the value of the use of different indicators for 
oesophagogastric cancer care was evaluated. 
 
PART  I .  NAT IONAL  OUTCOMES  ON 
POSTOPERAT IVE  MORBIDITY  QUALITY  
INDICATORS  
 
CHAPTER 2. INTERNATIONAL STANDARDISED OUTCOMES SET  
In this national cohort study, morbidity and mortality after oesophagogastric 
cancer in the Netherlands is reported. The outcomes are reported according to 
the definitions of an international standardised outcomes set. The results 
showed that the data of the DUCA are complete and accurate. In the 
Netherlands, the most common complications were pneumonia and 
anastomotic leakage. The DUCA outcomes were compared to previously 
reported outcomes of an international cohort. Complications occurred more 
often in the DUCA and the percentage of anastomotic leakage was higher. The 
conclusion of this study was that using an international standardised outcomes 
set facilitates international comparison.  
 
CHAPTER 3. COMPREHENSIVE COMPLICATION INDEX 
Because oesophageal and gastric surgery is associated with high morbidity, 
monitoring complications is important. The purpose of this study was to 
investigate whether a new measure of morbidity can be applied in a national 
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audit. This new measure was the Comprehensive Complication Index (CCI). In 
this measure, recorded complications are combined and weighted by the 
severity of each complication. In the study was seen that the CCI outcomes 
varied between hospitals in the Netherlands. In addition, it was seen that the 
CCI outcomes per hospital were strongly correlated with an existing DUCA 
quality indicator that describes the percentage of patients with a complicated 
course. From this study it was concluded that the CCI can be applied in a national 
audit. In the future, the CCI outcome can possibly contribute to accurate trend 
monitoring of outcomes per hospital. 
 
CHAPTER 4. TIME INTERVAL BETWEEN NEOADJUVANTE 
CHEMORADIOTHERAPY AND SURGERY 
Because the optimal time interval between neoadjuvant chemoradiotherapy 
and surgery for oesophageal cancer is unknown, in this study the difference in 
pathological outcomes and complications between patients operated on after 
varying time intervals was evaluated. The research showed that a longer time 
interval (>10-13 weeks) was associated with a higher percentage pathologically 
complete response. For the different time intervals, the lymph node yield and 
the percentage of intraoperative and postoperative complications were 
comparable. From these results it can be concluded that postponed surgery 
after neoadjuvant chemoradiation does not appear to be associated with 
morbidity and may have a positive effect on the response to neoadjuvant 
therapy. 
 
CHAPTER 5. GASTRIC RESECTIONS WITH ADDITIONAL PANCREAS 
RESECTION 
In this study the outcomes of patients undergoing gastric resection with 
additional pancreatic resection were investigated. The purpose of this additional 
resection usually is to achieve a complete resection in case the tumour has 
grown into the pancreas. A complete resection was shown to be achieved in 82% 
of patients. However, it was seen that there were more serious complications in 
these patients compared to those without an additional resection. These results 
emphasize that a gastric resection with additional pancreatic resection may be 
14
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a curative treatment strategy, but that it should only be done when it is expected 
that the tumour can be completely removed. 
 
CHAPTER 6. DATA VERIFICATION 
When using national data for hospital comparison, it is important that the 
entered data are robust and reliable. The Dutch Institute for Clinical Auditing has 
developed a data verification procedure for the national audits in the 
Netherlands. This chapter describes the procedure of the data verification. The 
results of different data verification procedures are described together with the 
lessons learned from these different procedures. 
 
 
PART  I I .  QUALITY  INDICATORS AS A  PROXY 
FOR LONG-TERM OUTCOMES   
 
To monitor and improve outcomes in a short-cycle, it is important that outcomes 
can be determined in the short term. However, in cancer operations, survival is 
often seen as the ultimate outcome measure. 
 
CHAPTER 7. ASSOCIATION SHORT-TERM OUTCOMES WITH LONG-TERM 
OUTCOMES 
This study investigated whether different short-term outcomes used in the 
DUCA were associated with long-term outcomes. A significant association was 
found with three short-term outcomes. It concerned "Textbook outcome", a 
composite outcome measure which describes a postoperative period "as 
described in the textbook", "complicated course" and "complete resection of the 
tumour". The use of these outcomes facilitates monitoring and improvement of 
outcomes in the short term, whereby this study showed that these short term 
outcomes also function as a proxy for long-term outcomes as overall survival. 
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CHAPTER 8. TRANSHIATAL RESECTION OR TRANSTHORACAL RESECTION 
In this chapter the differences between a transhiatal or transthoracic resection 
for oesophageal cancer were described based on existing literature. In an early 
study, less morbidity after open transhiatal resections was described. In 
contrast, a trend towards better survival after open transthoracic resections was 
described. It is suggested that more extensive lymph node dissection with 
transthoracic resections had a part in this. It is also described that, since the 
introduction of neoadjuvant chemoradiotherapy, the value of lymph node 
dissection is re-discussed. The differences between the two approaches in 
minimally invasive surgery are unclear. 
 
CHAPTER 9. QUALITY INDICATOR LYMPH NODE RETRIEVAL 
Another short-term outcome indicator concerns the "percentage of patients in 
whom at least 15 lymph nodes have been examined in the resection 
preparation". In this study, the results on this quality indicator in the first years 
of DUCA were evaluated. The results showed that the lymph node retrieval has 
been increased in recent years but that there is still variation between hospitals. 
Hospitals with a high annual hospital volume achieved the quality indicator more 
often. These findings may indicate that using a quality indicator can lead to an 
improvement of outcomes. 
 
CHAPTER 10. EFFECT OF LYMPH NODE RETRIEVAL ON SURVIVAL AFTER 
OESOPHAGEAL CANCER 
As described in Chapter 8, the value of lymph node dissection after neoadjuvant 
chemoradiation has been discussed which also questions the value of the quality 
indicator regarding lymph node retrieval. Therefore, in this study the association 
of this quality indicator with survival was evaluated for oesophageal cancer. It 
was found that oesophageal cancer patients with <15 lymph nodes and ≥15 
lymph nodes had a similar survival. However, it was found that patients with <15 
lymph nodes may have had positive lymph nodes left behind (in the resection 
specimen or in the body), resulting in a lower tumour stage. The conclusion of 
this study is that patients in which ≥15 lymph nodes have been examined are 
14
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better staged and that this quality indicator is therefore important for measuring 
quality of care. 
 
CHAPTER 11. RISK FACTORS FOR INCOMPLETE RESECTIONS FOR GASTRIC 
CANCER 
In this study, risk factors for incomplete resections for gastric cancer have been 
identified. An incomplete resection is associated with poor survival and 
therefore the percentage of complete resections is one of the quality indicators 
within the DUCA. In this chapter, it was seen that various tumour-specific factors 
are associated with incomplete resections, but also that in high volume 
hospitals, incomplete resections are less common. The results of this study show 
that re-organization of gastric cancer surgery in the Netherlands may help to 
improve outcomes. High-risk patients might be better off in a hospital with a 
higher annual hospital volume. 
 
CHAPTER 12. NATIONAL IMPROVEMENT PROJECT WITH DUCA DATA 
Because morbidity outcomes in the DUCA are stable in the first 8 years after the 
introduction of the DUCA and because there is a wide variation between 
hospitals on specific outcomes, a national improvement project has been 
started. National meetings were organized. In these meetings the results were 
compared and discussed. Joint plans were made to improve outcomes on 
national level. In this chapter, the complete process of this project was 
described. 
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KWAL ITEITSMET ING B INNEN DE  SLOKDARM- 
EN MAAGKANKERCHIRURGIE  
INTRODUCTIE  
In Nederland stijgt de incidentie van slokdarmkanker terwijl de incidentie van 
maagkanker stabiel is.1 In 2018 was de incidentie van slokdarmkanker 2.500 en 
van maagkanker 1.300. Het percentage patiënten dat in aanmerking komt voor 
een curatieve behandeling is 60% voor slokdarmkanker en 50% voor 
maagkanker.23  
Multimodale therapie wordt in de behandeling van slokdarm- en maagkanker 
steeds belangrijker.3-6 Voor slokdarmkanker wordt het overgrote merendeel van 
de patiënten behandeld met neoadjuvante chemoradiatie gevolgd door een 
operatie. Ook niet-chirurgische behandelingen zoals endoscopische resectie en 
definitieve chemoradiatie worden tegenwoordig als curatieve behandeling 
gezien.7-9 De meest recente ontwikkeling is de potentiele toepassing van actieve 
surveillance na neoadjuvante chemoradiatie in plaats van een operatie.10 
Voor maagkanker is de combinatie van chemotherapie met een operatie de 
standaardbehandeling als patiënten fit genoeg zijn om chemotherapie te 
ondergaan.  
 
Bij de operatieve behandeling staat het verkrijgen van een complete resectie van 
de tumor, een lymfeklier dissectie en een reconstructie van het maag-darm 
kanaal centraal. Slokdarm- en maagresecties zijn complexe operaties welke 
gepaard gaan met een hoge morbiditeit en mortaliteit.14 Om te zorgen voor 
voldoende ervaring in de operatie en de postoperatieve zorg is er een 
volumenorm ingesteld. In Nederland is een minimumaantal van 20 resecties per 
jaar per ziekenhuis verplicht voor zowel slokdarmresecties als maagresecties.14 
In 2016 werden in 25 ziekenhuizen slokdarm- en maagresecties uitgevoerd, dit 
is gedaald naar 20 ziekenhuizen in 2018.17 De kwaliteit van slokdarm- en 
maagresecties wordt gemonitord met behulp van een clinical audit: de Dutch 
Upper gastrointestinal Cancer Audit (DUCA).14 Door middel van 
kwaliteitsindicatoren wordt de kwaliteit van de slokdarm- en maagchirurgie in 
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Nederland in kaart gebracht. De uitkomsten op deze indicatoren worden 
teruggekoppeld aan de ziekenhuizen en eens per jaar transparant gemaakt 
zodat iedereen (patiënten, zorgverzekeraars en overheidsinstellingen) deze 
kunnen inzien. Met inzicht in deze uitkomsten kunnen ziekenhuizen volgens de 
plan-do-check-act methode streven naar het verbeteren van uitkomsten.  
In dit proefschrift ligt de focus op het vaststellen van de betrouwbaarheid, 
validiteit en waarde van kwaliteitsindicatoren binnen de slokdarm- en 
maagchirurgie.  
 
DEEL  I .  LANDELIJKE UITKOMSTEN VAN 
POSTOPERAT IEVE MORBID ITEIT  
KWAL ITEITS INDICATOREN 
HOOFDSTUK 2. INTERNATIONALE GESTANDAARDISEERDE UITKOMST SET 
In dit landelijke cohortonderzoek is gerapporteerd wat de morbiditeit en 
mortaliteit na slokdarm- en maagresecties in Nederland was. De uitkomsten zijn 
gerapporteerd volgens de definities van een eerder beschreven internationale 
gestandaardiseerde uitkomst set. Er bleek in dit onderzoek dat de data in de 
DUCA zeer compleet en accuraat geregistreerd zijn. In Nederland bleken 
pneumonie en naadlekkage de meest voorkomende complicaties te zijn. De 
Nederlandse uitkomsten werden vergeleken met eerder gepubliceerde 
uitkomsten van een internationaal cohort. In de DUCA kwamen vaker 
complicaties voor en het percentage naadlekkage was hoger. Een van de 
conclusies uit dit onderzoek was dat er gemakkelijk een goede internationale 
vergelijking plaats kan vinden wanneer uitkomsten volgens een 
gestandaardiseerde uitkomst set geregistreerd zijn.    
 
HOOFDSTUK 3. COMPREHENSIVE COMPLICATION INDEX 
Doordat slokdarm- en maagoperaties gepaard gaan met een hoge morbiditeit is 
het monitoren van complicaties belangrijk. Het doel van deze studie was om te 
onderzoeken of een nieuwe maat betreffende morbiditeit toegepast kan 
worden in een landelijke audit. Het betreft de nieuwe samengestelde 15
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complicatie maat: de Comprehensive Complication Index (CCI). Bij deze maat 
worden eventueel meerdere geregistreerde complicaties gecombineerd en 
gewogen aan de hand van de ernst van iedere complicatie. In het onderzoek 
werd gezien dat de CCI-uitkomsten tussen ziekenhuizen in Nederland varieerde. 
Daarnaast werd gezien dat de CCI-uitkomsten per ziekenhuis sterk gecorreleerd 
waren aan een bestaande DUCA-kwaliteitsindicator welke het percentage 
patiënten beschrijft met een gecompliceerd beloop. De conclusie van dit 
onderzoek was dat het haalbaar is om de CCI toe te passen in een landelijke 
audit. Mogelijk kan de CCI in de toekomst bijdragen aan nauwkeurige trend-
monitoring van uitkomsten per ziekenhuis. 
 
HOOFDSTUK 4. TIJDSINTERVAL TUSSEN NEOADJUVANTE 
CHEMORADIOTHERAPIE EN CHIRURGIE  
Omdat het optimale tijdsinterval tussen neoadjuvante chemoradiotherapie en 
chirurgie bij slokdarmkanker onbekend is, is in dit onderzoek gekeken naar het 
verschil in pathologische uitkomsten en complicaties tussen patiënten 
geopereerd na variërende tijdsintervallen. Het onderzoek liet zien dat er vaker 
sprake was van een pathologisch complete respons bij een langer tijdsinterval 
(>10-13 weken). De lymfeklier opbrengst en het percentage intra-operatieve en 
postoperatieve complicaties waren vergelijkbaar voor de verschillende 
tijdsintervallen. Uit deze resultaten is te concluderen dat langer wachten na 
neoadjuvante chemoradiatie niet geassocieerd te zijn met meer complicaties en 
mogelijk zelfs een positief effect kan hebben door een hogere kans op een 
pathologisch complete respons.   
 
HOOFDSTUK 5. MAAGRESECTIES MET AANVULLENDE PANCREASRESECTIE 
In deze studie is onderzocht wat de uitkomsten zijn van patiënten die een 
maagresectie met aanvullende pancreasresectie hebben ondergaan. Het doel 
van deze aanvullende resectie is meestal om een complete resectie van de 
tumor te verkrijgen wanneer deze is doorgegroeid in het pancreas. Er werd 
aangetoond dat in 82% van de patiënten een complete resectie werd behaald. 
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Wel werd er gezien dat er vaker sprake was van ernstige complicaties in 
vergelijking met patiënten zonder een aanvullende resectie. Deze resultaten 
benadrukken dat een maagresectie met aanvullende pancreasresectie mogelijk 
een curatieve behandeling kan zijn, maar dat het alleen moet worden gedaan 
wanneer er wordt verwacht dat de tumor compleet kan worden verwijderd.  
 
HOOFDSTUK 6. DATA VERIFICATIE 
Om op een goede en eerlijke manier uitkomsten te vergelijken in een landelijke 
registratie is het van belang dat data compleet en accuraat worden ingevoerd. 
Bij het Dutch Institute for Clincial Auditing is een dataverificatie procedure 
ontwikkeld. Met deze dataverificatie wordt de data van landelijke audits extern 
geverifieerd. In dit hoofdstuk wordt in detail beschreven hoe deze procedure in 
zijn werk gaat. De resultaten van verschillende data verificatie procedures 
worden beschreven samen met de lessen die geleerd zijn uit deze verschillende 
procedures.  
 
 
DEEL  2 .  KWAL ITEITS INDICATOREN ALS  PROXY 
VOOR LANGE TERMIJNSUITKOMSTEN  
Om kort-cyclisch uitkomsten te monitoren en verbeteren is het van belang dat 
uitkomsten op korte termijn kunnen worden vastgesteld. Bij oncologische 
operaties is het echter zo dat overleving vaak wordt gezien als ultieme 
uitkomstmaat. 
 
HOOFDSTUK 7. ASSOCIATIE KORTE TERMIJNSUITKOMSTEN MET LANGE 
TERMIJNSUITKOMSTEN 
In deze studie werd onderzocht in hoeverre verschillende korte-termijn 
uitkomsten welke worden gebruikt in de DUCA geassocieerd waren met lange-
termijn uitkomsten. Er werd een significante associatie gevonden bij drie korte-
termijn uitkomsten. Het ging om ‘Textbook outcome’, een samengestelde 
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uitkomstmaat waarbij alles ‘volgens het boekje’ verloopt, ‘gecompliceerd 
beloop’ en ‘complete resectie van de tumor’. Het gebruik van deze uitkomsten 
zorgt voor monitoring en verbetering van uitkomsten op korte termijn, waarbij 
dit ook effect heeft op de kwaliteit van zorg op lange termijn; namelijk betere 
lange termijn overleving.  
 
HOOFDSTUK 8. TRANSHIATALE RESECTIE OF TRANSTHORACALE RESECTIE 
In dit hoofdstuk zijn de verschillen tussen een transhiatale of transthoracale 
resectie voor slokdarmkanker beschreven op basis van bestaande literatuur. In 
de gerandomiseerde HIVEX-trial werd minder morbiditeit beschreven bij open 
transhiatale resecties. Daarentegen werd een trend naar betere overleving bij 
open transthoracale resecties beschreven. Er wordt beschreven dat het idee 
bestaat dat uitgebreidere lymfeklierdissectie bij transthoracale resecties hierin 
een aandeel heeft gehad. Daarbij wordt ook beschreven dat sinds de introductie 
van neoadjuvante chemoradiotherapie, de waarde van lymfeklierdissectie in 
twijfel wordt getrokken. Daarnaast zijn de verschillen tussen beide 
benaderingen bij minimaal invasieve chirurgie onduidelijk.  
 
HOOFDSTUK 9. KWALITEITSINDICATOR LYMEKLIERENOPBRENGST 
SLOKDARMKANKER 
Een andere korte-termijn uitkomst indicator betreft het ‘percentage patiënten 
waarbij tenminste 15 lymfeklieren zijn aangetoond in het resectiepreparaat’. In 
deze studie is onderzocht wat de uitkomsten waren van deze kwaliteitsindicator 
in de Nederlandse ziekenhuizen in de eerste jaren van de DUCA. Er werd gezien 
dat de uitkomsten toegenomen zijn in de afgelopen jaren maar dat er nog steeds 
variatie bestaat tussen ziekenhuizen. Ziekenhuizen met een hoog aantal 
slokdarmoperaties per jaar behaalden vaker deze kwaliteitsindicator. Deze 
bevindingen wijzen er mogelijk op dat het gebruiken van een kwaliteitsindicator 
kan leiden tot een toename van uitkomsten.  
 
 
Chapter 15 279 
HOOFDSTUK 10. EFFECT VAN LYMFEKLIEROPBRENGT OP OVERLEVING NA 
SLOKDARMKANKER 
Zoals beschreven in Hoofdstuk 9 bestaat er twijfel over de waarde van 
lymfeklierdissectie na neoadjuvante chemoradiatie waardoor ook de waarde 
van de kwaliteitsindicator betreffende lymfeklieropbrengt in twijfel getrokken 
wordt. Dat was de reden waarom in deze studie is onderzocht of het behalen 
van deze kwaliteitsindicator geassocieerd was met een betere overleving. Er 
werd in deze studie gevonden dat slokdarmkankerpatiënten met <15 
lymfeklieren en ≥15 lymfeklieren een vergelijkbare overleving hadden. Wel 
werden er aanwijzingen gevonden dat bij patiënten met <15 lymfeklieren 
mogelijk positieve lymfeklieren zijn achtergebleven (in het resectie preparaat of 
in het lichaam) waardoor een te laag tumor stadium is afgegeven. De conclusie 
van deze studie is dat patiënten waarbij ≥15 lymfeklieren zijn onderzocht betere 
gestadieerd zijn en dat deze kwaliteitsindicator daardoor valide is voor het 
meten van kwaliteit van zorg.  
 
HOOFDSTUK 11. RISICOFACTOREN VOOR IRRADICALE MAAGRESECTIES 
Deze studie beschrijft een analyse waarbij risico factoren voor irradicale 
maagresecties zijn geïdentificeerd. Een irradicale maagresectie is geassocieerd 
met een slechte overleving en daarom is het percentage radicale maagresecties 
ook een van de kwaliteitsindicatoren binnen de DUCA. In dit hoofdstuk werd 
gezien dat er verschillende tumor-specifieke factoren geassocieerd zijn met 
irradicale maagresecties, maar ook dat in hoog volume ziekenhuizen minder 
vaak irradicale maagresecties voorkomen. De resultaten van deze studie laten 
zien dat de organisatie van maagchirurgie in Nederland mogelijk kan helpen om 
uitkomsten te verbeteren. Hoog-risicopatiënten zijn daarom wellicht beter af 
zijn in een ziekenhuis met een hoger volume. 
 
HOOFDSTUK 12. LANDELIJK VERBETERPROJECT MET DATA UIT DE DUCA 
Omdat de morbiditeit uitkomsten in de DUCA in de eerste 8 jaar na de 
introductie van de DUCA stabiel zijn en er grote variatie in sommige uitkomsten 
is tussen ziekenhuizen, is een landelijk verbeterproject gestart. Er zijn landelijke 
meetings georganiseerd. In deze meetings zijn uitkomsten vergeleken en 
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bediscussieerd. Gezamenlijk werden er plannen gemaakt om de landelijke 
uitkomsten te verbeteren. In dit hoofdstuk is het complete proces van dit project 
beschreven. 
 
CONCLUSIE   
In dit proefschrift zijn verschillende kwaliteitsindicatoren voor de slokdarm- en 
maagchirurgie geëvalueerd op betrouwbaarheid, validiteit en waarde.  
Allereerst is aangetoond dat de data en resultaten in de DUCA betrouwbaar zijn. 
Wat betreft de validiteit is er gevonden dat de indicatoren over ‘gecompliceerd 
beloop’ en ‘CCI’ mogelijk iets zeggen over de postoperatieve kwaliteit van leven. 
Er kon geconcludeerd worden dat de indicatoren ‘Textbook outcome’, 
‘gecompliceerd beloop’ en ‘complete resectie van de tumor’ valide waren omdat 
zij geassocieerd zijn met lange termijn uitkomsten. De waarde van de 
verschillende indicatoren werd onderschreven doordat er in verschillende 
studies variatie aangetoond werd. Er werd gevonden dat de uitkomsten in de 
DUCA significant afwijken van internationale uitkomsten. Ook werd er variatie 
gevonden tussen laag- en hoog volume ziekenhuizen. Daarnaast werd de waarde 
van de DUCA-indicatoren bevestigd doordat er een toename van lymfeklier 
opbrengst werd gezien na introductie van een indicator betreffende het aantal 
lymfeklieren.  
 
DISCUSS IE  EN TOEKOMSTPERSPECTIEF  
Met de verschillende onderzoeken in dit proefschrift is te concluderen dat de 
geteste uitkomstindicatoren welke worden gebruikt in de DUCA bijna allemaal 
als betrouwbaar, valide en waardevol kunnen worden beschouwd.  
Het doel van de DUCA is monitoren en verbeteren van de kwaliteit van de 
slokdarm- en maag oncologische zorg. In de eerste 8 jaar van de DUCA zijn 
sommige uitkomsten verbeterd. Echter, de uitkomsten betreffende morbiditeit 
stabiel gebleven. In de toekomst is het van belang dat resultaten van de DUCA 
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naast de gebruikelijke manier ook op een alternatieve manier worden 
geëvalueerd. Een voorbeeld hiervan kan zijn het bespreken van specifieke 
complicatie uitkomsten in een georganiseerde bijeenkomst. Daarnaast is het 
belangrijk dat in de toekomst door de patiënt gerapporteerde uitkomsten over 
kwaliteit van leven worden geïmplementeerd in de DUCA. Als laatste is het van 
belang dat ook de niet-chirurgische zorg voor slokdarm- en maagkanker 
patiënten in kaart wordt gebracht door de audit multidisciplinair te maken. 
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